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DTT   Dithiothreitol 
EC50    Half maximum effective concentration 
EDT   Ethane dithiol 
EDX   Energy-Dispersive X-ray 
Eq   Equivalence 
F2FlAsH  Difluro-FlAsH 
F4FlAsH  Tetrafluro-FlAsH 
FA-HSA   Folate-labelled Human-Serum-Albumin  
FBS   Fetal bovine serum 
FDA   Food and drug administration 
FlAsH   Fluorescein arsenical hairpin binder 
FRβ    Folate receptor-β  
FRET   Forster resonance energy transfer 
FRP   Free radical polymerisation 
FT   Fourier transform 
G’   Storage modulus 
G’’   Loss modulus 
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GFP   Green fluorescent protein 
GPC   Gel Permeation Chromatography 
GSAO   4-(N-(S-Glutathionylacetyl)amino) phenylarsonous acid 
GSH   Glutathione 
HDT    Hexa(ethylene glycol) dithiol 
HEAm   2-Hydroxyethyl acrylamide 
HeLaS3  Human cervix carcinoma 
HepG2   Human liver cancer cell line 
HMPA   N-(2-Hydroxypropyl)methacrylamide 
HL60   Human leukemia cell line 
HPLC   High Performance Liquid Chromatography 
HSA   Human-Serum-Albumin 
Hsp90   90 kDa Heat shock protein 
HUVEC  Human umbilical vein endothelial cells 
IC50   Half maximum inhibitory concentration 
ICP-OES  Inductively coupled plasma optical emission spectroscopy 
K562   Myelogenous leukemia cell line 
Kd   Dissociation constant 
KI   Potassium iodide 
MALS   Multi-angle light scattering  
MDA-231  Human breast adenocarcinoma cell line 
MDA-MB-435 Human melanoma cell line 
Me   Methyl 
MMA   Methyl methacrylate 
Mn,Theory  Theoretical Number average molar mass 
Mn,SEC    Experimental Number average molar mass 
MPTP   Mitochondrial permeability transition pore 
MRI   Magnetic resonance Imaging 
Mw   Weight Average molecular weight. 
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Nd-YAG  Neodymium doped yttrium aluminum garnet 
NEM   N-ethyl maleimide  
NIH/3T3  Mouse embryo fibroblasts  
NIPAm  N-isopropylacrylamide 
NLO    Non-linear optical 
NMP    Nitroxide-mediated polymerization  
NMR   Nuclear Magnetic Resonance  
NP   Nanoparticle 
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p   para 
PABTC  2-(((Butylthio)-carbonothioyl)thio)propanoic acid 
PANC-1   Epithelioid carcinoma pancreatic cell lines 
PAO    Phenylarsine oxide 
PAzPAO  p-Azidophenyl arsenoxide  
PBS   Phosphate buffer solution 
PC    Phosphatidylcholine 
PC3   Human Prostate adenocarcinoma 
PCCL   Poly(α-carboxylate-ε-caprolactone) 
PCCLSH  Mercaptohexylamine functionalised PCCL 
PDi   Polydispersity index 
PDI    Protein disulfide isomerase 
PEG   Poly(ethylene glycol) 
PEGA Poly(ethylene glycol) methyl ether acrylate (average Mn = 480 
gmol-1) 
PENAO 4-(N-(S-Penicillaminylacetyl)amino) phenylarsonous acid  
PENAOMAm  4-N-(S-Penicillaminylacetyl)amino phenylarsonous acid 
Methacrylamide 
PET Positron emission tomography 




pin   Pinacol 
PMMA  Poly(methyl methacrylate) 
ppm   Parts per million 
PTM    Pentaerythritol tetrakis(3-mercaptopropionate) 
RAFT   Reversible addition Fragmentation Chain Transfer 
RAME   Rat adrenal medullary endothelial cells 
rBSA    Reduced Bovine serum albumin 
RCRAC  Ring Collapse Radical Alternating copolymerization 
RDRP   Reversible Deactivation Radical Polymerisation 
ReAsH   Resorufin arsenical hairpin binder 
Rh   Hydrodynamic Radius 
ROP   Ring Opening Polymerisation 
RPMI-1640  Roswell Park Memorial Institute 1640 cell Medium 
RpoA    RNA polymerase 
SAMs    Self-assembled monolayers 
sCT    Salmon calcitonin 
SEC   Size Exclusion Chromatography 
SET-LRP  Single Electron Transfer Living Radical Polymerisation 
SD   Standard deviation 
SH   Thiol 
SLS   Static Light scattering 
SPECT/CT Single-Photon Emission Computed Tomography / Computed 
Tomography 
SPR   Surface Plasmon resonance 
STORM  Stochastic Optical Reconstruction Microscopy 
Sty   Styrene 
TC   Tetracysteine 
TEM   Transmission Electron Microscopy 
Tg   Glass transition temperature 
THF   Tetrahydrofuran 
TFE   2,2,2-Trifluoroethanol 
TTM   Trimethylolpropane tris(3-mercaptopropionate)  
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w.r.t   With respect to 
XTT   Triphenyl tetrazolium chloride 







I would like to take this opportunity to thank all the people who has provided help during 
my PhD and has helped to develop to be a better person. 
 
First and foremost, I thank Paul Wilson for being the best mentor and PhD supervisor I 
could ever have. I would’ve never got this far without him. I really appreciated every help 
I got from him even when I lacked focus due to life crisis. I hope that in the future I will 
be able to give back to him all the time he gave to me.  
 
I thank Seb for letting me join his group. It would’ve not been possible to obtain the same 
level of knowledge and experience had I have been in other group. I greatly appreciate 
his advice and scientific wisdom. The regular biweekly team meetings was paramount 
importance for learning during my PhD. 
 
I thank Dave for funding me for 6 months during my PhD and letting me involved in his 
group too. I really appreciated his wise advice across the years, all the way back from 
2012.  
 
I thank Guilleaume Moriceau who has been emotional support and best friend during my 
PhD. Living together was definitely one of the best decision made during my time. I thank 
George, Dan L, Sam Lawton and Marie who added more colours in my life outside work.  
I thank, Rachel Hodgson, for helping me when I was in desperate need and providing me 
stability during most part of my PhD.  
 
I thank original members of the Seb’s group at warwick: Ming, Johannes, Gody, Tammie, 
Sophie, Junliang and Liam. I thank Liam and Junliang, both who helped me transcended 
me from copper mediated polymerisation to RAFT polymerisation!! I especially thank 
Junliang who worked together on many of my crazy ideas and being a mentor in life and 




I thank the people in the bionano team, Alex and Pratik who I both respect for their 
science. We shared many great ideas and discussions, which contributed to much of the 
work carried out during my PhD. I also thank the people who joined our team in the 
expansion pack: Mathias, Agnes, Fannie, Tom, Andy K., Andy L., Carlos, Ed and all the 
summer students and Master students for contributing towards scientific discussions in 
the meeting. 
 
I thank all the other members of Perrier group: Ximo, Jie, Qiao, Robert, Sean, Julia, 
Majda, Raoul, Caroline and Sylvain. I especially thank Satu, who I worked closely with 
towards the end of my PhD, and for helping me move to USA post PhD.  
 
I thank all the members of Haddleton group too: Atty, George, Evelina, Athina, Vasilik i, 
Alex Simula, Rachel Hand, Sam Lowe, Qiang, Jenny and Patrick. I especially thank Glen 










Arsenic exhibits diverse chemical reactivity depending upon its oxidation state. This 
distinctive reactivity has been largely overlooked in the field of polymer and biomateria ls 
science, owing to concerns about the toxicity of arsenic. However, a recent clinica l 
renaissance in the use of arsenicals suggests the possibility of broader acceptance and 
application. The aim of this work is to stimulate interest in and highlight the potential of 
polymeric arsenicals as a novel platform for functional and responsive biomateria ls 
(Literature review discussed in Chapter 1). 
 
Cross-linking of polymers through pendent organic arsenic functional groups is 
demonstrated using three different chemistries: 1) reductive coupling forming arsine 
oligomers, As(I)n (Chapter 2) 2) forming arsenic-thiolate bonds with poly-thiol cross-
linkers (Chapter 3) 3) polymerizing As(I) via the addition of acetylenes to form vinylene-
acetylene bonds (Chapter 4). All three methods of cross-linking were able to cross-link 
thermally self-assembled NIPAm-PEG diblock copolymers with an arsenical acrylamide 
(AsAm) monomer incorporated in the NIPAm core. The first two were found to be 
responsive towards GSH and H2O2 under model physiological conditions. The stability 
of the particles can be finely tuned through varying the amounts of arsenic or varying the 
nature of the thiol-functional external cross-linker. The last form of cross-linking was 
found to be non-responsive towards the given stimuli however it enabled incorporation 
of further functionality to the nanoparticle, such as Rhodamine B, which helped determine 
the co-localization of the nanoparticle. Notably, in all three chemistries, the nanopartic les 
produced were not found to be toxic at 2 mg/ml by cell viability assays. 
 
Finally using the As(I)n cross-linking strategy, the formation of hydrogels (with DMA-
AsAm copolymers made by FRP), was demonstrated which were responsive towards 
oxidation with H2O2. Synthesised hydrogels were responsive towards oxidation. 3D cell 
culturing of these gels were carried out by rehydration of dialyzed/lyophilized gels with 
trypsinized solution of cells. (Chapter 5).  
 
In addition to the investigation of polymeric arsenicals, synthesis of microscale 
 
xxxiv 
multiblock copolymers are described (Appendix A). This enabled generation and 
characterisation of polymers at 2 μL scale, and procedure to synthesise Multi-block 






Chapter 1 : Organic arsenicals as functional motifs in 
polymer and biomaterials science 
 
 
The materials presented in this chapter is directly reproduced with permission from the 
publishers, a review (with the exceptions of pages 11-12) where I was the first Author: 
Macromol. Rapid Commun. 2018, 1800205. This was published together with Thomas P. 
Davis and Paul Wilson (supervisor) who are both corresponding authors and princip le 
investigators. 
Abstract 
Arsenic (As) exhibits diverse (bio)chemical reactivity and biological activity depending 
upon its oxidation state. However, this distinctive reactivity has been largely overlooked 
across many fields owing to concerns regarding the toxicity of arsenic. Recently, a clinica l 
renaissance in the use of arsenicals, including organic arsenicals that are known to be less 
toxic than inorganic arsenicals, alludes to the possibility of broader acceptance and 
application in the field of polymer and biomateria ls science. Here the present examples 
of polymeric/macromolecular arsenicals are reported to stimulate interest and highlight 




1.1 Introduction  
Arsenic exists as a dichotomous enigma between toxicity and therapy in (bio)chemis try 
and medicine. It is ubiquitously distributed in the Earth’s crust and despite being a well-
known contaminant of base water supplies, it is an essential dietary element and has 
historically been employed to treat malignancies, most notably in the form of 
Arsphenamine/Salvarsan, Paul Ehrlich’s first ‘magic bullet’ chemotherapeutic.1 More 
recently, following a demise in use due to concerns over formulation and toxicity, arsenic 
trioxide (Trisenox, As2O3) has revitalised the therapeutic potential of (in)organic 
arsenicals in the treatment of blood born malignancies such as acute promyelocytic 
leukaemia (APL).2 This has stimulated the development of a number of new (in)organic 
arsenicals which have been shown to exhibit improved efficacy and reduced toxicity 
compared to As2O3 in pre-clinical and early-stage clinical trials against both 
haematological and solid malignancies, highlighting their potential as future 
chemotherapies.3, 4 
Arsenic can adopt two biologically relevant oxidation states, trivalent arsonous acid 
(As(III)) and pentavalent arsonic acid (As(V)) which are chemically distinct. An example 
of the interesting reactivity of arsenicals is the synthesis of Salvarsan which was prepared 
by reductive coupling of 3-amino-4-hydroxyphenylarsenic(V) to form a mixture of 
homocyclic 3-amino-4-hydroxyphenylarsenic(I) species.5 The ensuing core of cyclic As-
As single bonds can act as a reservoir for biologically relevant As(III).  Inorganic arsonic 
acid, or arsenate (As(V)), exhibits chemical similarities to phosphate (P(V)).6  
Biochemically, arsenate is purported to enter the cell through phosphate transporters 
where it is either metabolised, via reduction and methylation processes, or can interfere 
with phosphate dependent biosynthetic pathways.7 Chemically, phenylarsonic acids 
(As(V)) can undergo condensation with chelating 1,2- and 1,3-diols to form spiro-
arsoranes in both organic and aqueous media. The spiro-arsoranes derived from vicina l 
1,2-diols are favoured and hydrolytically stable at neutral and acidic pH.8 Analogous 
spiro-arsoranes can be formed via condensation of 1,2-amino alcohols9 but there is little 
propensity for covalent bond formation between As(V) and thiols, which prefer to 
undergo single electron transfer redox reactions, which occurs naturally via thiol-
disulfide rich reductase enzymes.10 
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Reduction of arsenate (As(V)), furnishes trivalent arsenicals (As(III)), which dominate 
the therapeutic and toxic potential of arsenic due to their high affinity for thiols. For 
example, the activity of As2O3 is believed to be underpinned by the affinity of arsonous 
acid (As(III)), formed in aqueous solutions of As2O3, for thiol groups, readily forming up 
to three As-S covalent bonds.11 In the intra- and extracellular milieu thiols are present as 
free thiols or intra-/intermolecular disulfides and it has been postulated that the affinity 
of As(III) for thiols is enhanced for chelating vicinal or neighbours-through-space 
(proximal) dithiols, such as those presented by naturally occurring disulfide bonds.12  
 
Figure 1.1: Structure of clinically relevant organic arsenical chemotherapeutics. 
 
The activity of clinically relevant organic arsenicals 4-(N-(S-glutathionylacetyl)amino) 
phenylarsonous acid (GSAO),13  4-(N-(S-penicillaminylacetyl)amino) phenylarsonous 
acid (PENAO)14 and S-dimethylarsino-glutathione (ZIO-101; Darinasparin)15 is 
associated with disruption of mitochondrial functional (Figure 1.1). In the case of GSAO 
and PENAO, Cys57 and Cys257 of mitochondrial adenine nucleotide translocase (ANT) 
are cross-linked, leading to opening of the mitochondrial permeability transition pore 
(MPTP) and loss of mitochondrial membrane potential.16 The specificity of GSAO and 
PENAO for the ANT dithiols exemplifies the thermodynamically driven sequence 
specificity of As(III)-arsenicals for Cys-Xxx-Xxx-Cys and proximal dithiols. The 
specificity can be enhanced further by protein engineering and/or molecule design 
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strategies. Tetra-cysteine sequences Cys-Cys-Xxx-Xxx-Cys-Cys engineered into native 
protein sequences bind organic bis-arsenicals with much greater affinity than mono- and 
native dithiol equivalents and has been utilized to develop highly specific fluorescent 
labels (vide infra).17-19 More notably, controlling the spacing between the arsenical 
functional groups in bis- and tris-arsenicals elicits stronger binding (Kd ~ 50 nM)20 to 
native proteins that contain redox-active thiol and disulfide rich domains,21, 22 such as 
those associated with protein folding (e.g. protein disulfide isomerase, PDI) and redox 
homeostasis (e.g. thioredoxin), than mono-arsenical analogues (Kd ~ 1 μM).23 
Notwithstanding the clinical renaissance in the use of the arsenicals in chemotherapy, or 
their discrete and distinctive (bio)chemical reactivity, particularly the high affinity and 
tunable specificity for (di)thiols, the application of organic arsenicals in polymer and 
biomaterials science has been limited. Here we aim to compile the present literature 
pertaining to polymeric arsenicals and organic arsenicals employed in biomateria ls 
science, particularly focusing on bio-imaging and self-assembled (polymeric and 
liposomal) nanoparticles. We hope to stimulate interest in an area where we see great 
potential and synergy between the chemical and biological activity of arsenic, which, if 
harnessed appropriately could lead to the development of potent, highly specific 
macromolecular arsenicals for therapeutic and/or diagnostic nanomedicine.  
1.2 Polymeric arsenicals; synthesis and applications  
Metal-based polymers and organometallic polymers can be synthesized in a number of 
ways resulting in polymers with metals distributed either through the main polymer chain 
or pendent side chain groups. Chain-growth polymerization is possible via anionic or 
radical mechanisms while step-growth polycondensation, of organopolysiloxanes for 
example, is an academically and industrially significant process generating materials rich 
in functionality and application. Appending appropriate ligands through polymer chains 
also makes the formation of coordination polymers possible. Here we will focus on the 
methods employed to date to prepare organoarsenic polymers and discuss the potential 
applications of these materials. 
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1.2.1 Backbone functional polymeric arsenicals  
1.2.1.1 Polycondensation 
Interfacial polycondensation emerged as an efficient technique for the synthesis of 
organometallic polymers in the 1960’s and 1970’s,24 gaining popularity as the method of 
choice for the synthesis of Group 14/15 metal-containing polymers.25 The process 
exploits the low-energy barriers of Lewis acid – Lewis base reactions interacting at the 
interface of an immiscible aqueous/organic solvent mixture generated under 
mechanically stirred conditions. A variety of polymers have been prepared employing 
Group 14/15 organometallic dihalides as Lewis acid monomers and organic di- or 
multifunctional nucleophiles (e.g. diols, diamines, diacids) as the Lewis base monomers. 
An early example of the synthesis of an arsenic (As) containing polymer utilized 
triphenylarsine dichloride as the Lewis acid, and a range of diamines as Lewis bases, 
resulting in the formation of the As(V)-polyamines.26 Polymerisation was rapid, 
occurring within 20 secs with the precipitated polymers isolated in modest yields (< 50%). 
The weight average molecular weight (Mw) of the soluble fraction of the precipitated 
polymers was of the order of 105 g.mol-1. 
 
Scheme 1.1 General reaction scheme and conditions for the interfacial polymerisation of lewis 
acidic arsenic dihalides (here dichlorides) and a complimentary lewis basic where X = OH / NH2 / 
COOH. 
Inspired by the clinical resurgence of (in)organic arsenic reagents,27 particularly their 
potential as anticancer, antiviral and antibacterial agents, Gallaher and his team have 
prepared a library of the organoarsenic polymers by the interfacial polycondensa t ion 
approach, utilizing bioactive Lewis bases as comonomers. The rationale for their design 
came from potential synergy between the bioactive metal-centre and Lewis base (Scheme 
1.1), and their inspiration is drawn from data that suggests that Group-15 containing 
polymers can inhibit the growth of some pancreatic cancer cell lines.  
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Triterpenoid natural product, glycyrrhetinic acid, derived from herb liquorice was initia l ly 
investigated as the Lewis base, being able to react with the organoarsenic reagent through 
both the carboxylic acid and alcohol groups.28 Structurally, it is similar to cortisone and 
other corticosteroids and is implicated in the anti-inflammatory properties of liquor ice. 
Furthermore, it has been shown to inhibit prostaglandin metabolism and it is a potent 
inducer of mitochondrial permeability transition which can trigger reactive oxygen 
species induced apoptosis. This is significant as this is also the mechanism by which 
clinically relevant organic arsenicals GSAO and PENAO stimulate cell death through 
cross-linking the proximal thiols of Cys57 and Cys257 of mitochondrial transmembrane 
protein adenine nucleotide translocase (ANT).29  
 
 
Scheme 1.2 Reaction scheme and conditions for the interfacial polymerisation of triphenylarsenic 
dichloride and glycyrrhetinic acid yielding the As(V)-poly(ether ester) within 15 seconds Mw = 
210000 g.mol-1; DPn ~ 270.28 
 
The interfacial polymerisation with triphenylarsenic dibromide was complete within 15 
seconds yielding As(V)-poly(ether esters) with DPn ~ 270 and Mw of 210000 g/mol-1  
(from light scattering photometry) (Scheme 1.2). When unsymmetrical Lewis bases such 
as these are employed, polymers derived from Group-15 Lewis acids can exist with three 
possible bonding arrangements around the metal centre (Figure 1.2). Two of these are 
referred to as symmetrical, i.e. alternating metal centre bonding through the alcohol only 
(1) and the acid only (2), with the other being unsymmetrical, i.e. each metal bonding 
through the acid and the alcohol (4) simultaneously. Furthermore, when bonding to the 
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metal occurs symmetrically through the acid group, the resulting structure can be ‘linear’ 
(2) or bridged/distorted (3) through back-bonding the carbonyl of the acid to the metal 
centre, which is also typical for Group-15 polyesters. Using IR spectroscopy, the resulting 
As-poly(ether ester) was identified to exist predominantly as non-distorted 
unsymmetrical and symmetrical structures.  
 
Figure 1.2 Possible bonding configurations of As(V)-poly(ether esters) derived from unsymmetrical 
Lewis base comonomers; symmetrical (1, 2), distorted symmetrical (3) and unsymmetrical (4). 
 
Analogous organotin polymer drugs have been shown to be cytotoxic with cell death 
occurring via necrosis.25 Therefore, the ability of the As-poly(ether esters) to arrest cancer 
cell growth was assessed by measurement of the effective concentration (EC50) against 
adenocarcinoma (AsPC-1) and epithelioid carcinoma (PANC-1) pancreatic cell lines. 
Moreover, the chemotherapeutic index (CI50) was also determined by comparison of the 
cytotoxicity against non-malignant cell lines, in this case mouse embryo fibroblasts 
(NIH/3T3) and embryonic human lung fibroblasts (WI-38). The As-poly(ether esters) 
were effective against PANC-1 (EC50 = 2.5 μg/mL) compared to Cisplatin (EC50 = 0.34 
μg/mL) but ineffective against AsPC-1, which justified further investigation of related 
polymers. 
 
As-polyesters have been synthesized using thiodiglycolic acid,30 chelidonic acid31 and 
camphoric acid (Figure 1.3).32 The diacid functionality of the Lewis bases employed in 
these polymerisations results in the polymers adopting the symmetrical bridged (3) or 
non-bridged bonding around the As centre. Using triphenylarsenic dichloride the As-
polyesters derived from thiodiglycolic acid and chelidonic acid were obtained with Mw = 
82000 g/mol-1, DPn = 180 and Mw = 170000 g/mol-1, DPn = 350 respectively. In the case 
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of camphoric acid, triphenylarsenic dibromide was employed as the Lewis acid furnished 
an As-polyester with Mw = 140000 g/mol-1, DPn = 250.  
 
Figure 1.3 Other bioactive Lewis base monomers used for the preparation of As(V)-polyesters 
(camphoric acid,32 chelidonic acid,31 thiodiglycolic acid30) and As(V)-poly(amine esters) 
(norfloxacin,33 ampicillin34). 
 
When antibiotics ampicillin and norfloxacin were used as the Lewis base, reaction with 
triphenylarsenic dichloride through their amine and acid functional groups formed As-
poly(amine esters).33, 34 Both antibiotics yield polymers with lower chain lengths and Mw 
(ampicillin DPn = 81; Mw = 53000 g.mol-1 and norfloxacin DPn = 38; Mw = 24000 g.mol-
1) than obtained for the polyesters and poly(ether esters), and like the poly(ether esters) 
the bonding through the arsenic centre can be symmetrical or unsymmetrical (Figure 1.2). 
The anticancer activity of the As-polyesters and the As-poly(amine esters) was assessed 
against a range of pancreatic and non-pancreatic cancer cell lines relative to the 
constituent monomers and Cisplatin used as a clinical reference. The activity of the Lewis 
acid monomers was presented with caution in each case due to rapid hydrolysis and 
accumulation of HX (X = Cl, Br) under the assay conditions. In all cases the Lewis base 
alone was shown to be ineffective at inhibiting cancer cell growth against all cell lines, 
so any activity observed was attributed to the As-polymers. The As-polyesters with 
thiodiglycolic acid exhibited stronger inhibition (EC50 = 0.052 μg/mL)30 of the AsPC-1 
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cell line than Cisplatin, whilst the chelidonic acid As-polyester also inhibited the AsPC-
1 (EC50 = 1.9 μg/mL) as well as estrogen-independent breast adenocarcinoma cells 
(7233/MDA, 0.0044 μg/mL).31 The As-poly(amine ester) derived from norfloxacin also 
inhibited AsPC-1 (16 μg/mL),33 whilst the ampicillin containing polymer was effective 
against PANC-1 (6.43 ng/mL) and estrogen-independent MCF-7/7233 (0.0014 ng/mL).3 4  
The activities of the As-polymers are indeed promising, however the CI50 (against WI-38 
and 3T3 cells) values are erratic and warrant further investigation to identify trends. 
1.2.1.2 Free radical alternating copolymerization 
The incorporation of metal or metalloid elements into the unsaturated polymer backbones 
is an attractive prospect for the generation of (semi)conductive and optically active 
materials.35-37 The key step in any such process is carbon-metal bond formation, which is 
usually achieved by classical electrophilic/nucleophilic substitution pathways or 
hydrometallation.38 An alternative, atom economical approach to the formation of carbon-
metal bonds is radical bismetallation of alkynes,39 which has been employed in organic 
synthesis for the synthesis of metal substituted 1,2-diethylenes.40 This process relies on 
the homolysis of relatively weak metal-metal bonds, initiated thermally or 
photochemically, in the presence of alkynes to trap the metal radicals formed. 
Organoarsenic homocycles, or cyclooligoarsines (RAsn)41, 42 have been known since the 
19th century yet as recently as 2005 the composition of Arsphenamine/Salvarsen was 
resolved as a mixture of organoarsenic homocycles.5 Such structures are composed of 
multiple As-As bonds, the number and stability of which depends largely on the nature 
of the R-groups. For example, when R = Me, five-membered rings are formed and the 
As-As bonds are prone to spontaneous homolysis; whereas if R = Ph six-membered rings 
are exclusively formed which are stable in air, moisture and refluxing benzene. The cyclic 
structures are readily accessible by reduction of the corresponding arsonic acids using 
hypophosphorus acid in the presence of catalytic amounts of KI (Scheme 1.3).43 The 
insoluble product of the spontaneous homolysis of (MeAs)5 has been proposed to be open 
chain oligoarsines, consisting of an As-As backbone, that stack together in ladder-like 
structures.44 Chujo and Naka recognized the potential of these oligomeric As-As 
structures, particularly the organoarsenic homocycles, to act as comonomers for 
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alternating copolymerisation via radical bismetallation in the presence of alkynes to form 
poly(vinylene-arsines).45 
 
Scheme 1.3 Synthesis of poly(vinylene-arsines) from methy/phenyl arsonic acid via cyclic 
homoarsines (MeAs)5 and (PhAs)6. 
 
Organoarsenic homocycles (MeAs)5 and (PhAs)6 have been employed as As-functiona l 
monomers with aromatic terminal acetylenes employed as comonomers. Whilst 
polymerisation of (MeAs)5 can occur spontaneously, reactions are typically initiated by 
thermal decomposition of a radical initiator (2,2’-azobisisobutyronitrile, AIBN) or 
irradiation with a xenon lamp to catalyse homolysis of the As-As bonds, with AIBN 
decomposition being essential for the polymerisation of (PhAs)6. The init ia l 
investigation45 employing phenylacetylene as the terminal alkyne reported number 
average molecular weights (Mn) up to 11500 g.mol-1 for (MeAs)5 and Mn ~ 4000 g.mol-1  
for (PhAs)6. Structural characterization of the products by 1H and 13C NMR confirmed 
the poly(vinylene-arsine) structure with a backbone composed of As-substituted vinylene 
groups with a trans-1,2 geometry. Comparison of the backbone vinyl proton with the 
sidechain protons and elemental analysis implied the 1:1 stoichiometry of the monomers, 




Scheme 1.4. Proposed mechanism for the formation of poly(vinylene-arsines) via ring-collapsed 
radical alternating copolymerization (RCRAC). 
 
Mechanistically the polymerisation is initiated by cleavage of an As-As bond present in 
the organoarsenic homocycles, followed by spontaneous homolysis of the remaining As-
As bonds and collapse of the ring structure (Scheme 4). The resulting arsenic radicals can 
either recombine to form labile As-As bonds, or add to the acetylene monomer leading to 
formation of a new As-carbon bond and vinyl radical, which is proposed to be the rate 
determining step. Vinyl radicals are very short-lived, reacting rapidly with another As-
radical or an As-As bond. The former results in irreversible termination of the 
polymerisation whilst the latter results in formation of an As-radical chain end which can 
either reversibly terminate by recombination, or react with another acetylene molecule. 
Propagation of the vinyl radical chain end by addition to alkyne is not likely. Likewise, 
recombination of vinyl radical chain ends is prohibited by their low concentration (due to 
instability and high reactivity). Thus, the combined sequence of events has been named 
ring-collapsed radical alternating copolymerization (RCRAC) and it is not a classical 
chain-growth mechanism, with conversion and molecule weight analysis by GC (Figure 
1.4A) and SEC (Figure 1.4B/D) respectively indicating step-growth characterist ics 




Figure 1.4 Typical data of RCRAC reaction of (MeAs)5 with phenylacetylene showing A) 
conversion of phenyl acetylene in presence and absence of radical initiation (GC); B) the build-up 
of molecular weight (Mp) as a function of conversion; C) polymer structure according to 1H NMR; 
D) the molecular weight distribution as a function of time measured by SEC.46  
 
The alternating vinylene-arsine backbone imparts interesting electronic structures and 
optical properties onto the resulting polymers as a result of strong absorbance UV region 
(π – π*, C=C) which extends into the visible (n - π*, As-C=C), the latter of which confers 
emissive properties onto the polymers. Specific excitation (λex) and emission (λem) 
wavelengths have been determined by fluorescence spectroscopy and are dependent upon 
on the substituents present in both monomers.47 For example, poly(vinylene-arsines) 
composed of (MeAs)5 and phenylacetylene (PA) give λex = 396 nm and λem = 485 nm 
which are blue-shifted when (PhAs)6 is employed (λex = 375 nm; λem = 437 nm). The 
electronic nature of the acetylene can be altered by the addition of substituents to the 
phenyl ring,47 or by changing to an aliphatic acetylene which only copolymerize with 
(MeAs)5 (Table 1.1).48 When more electron withdrawing acetylenes (4-
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cyanophenylacetylene, 4-CPA) were polymerized with (PhAs)6 faster reactions, higher 
conversions and higher Mn were obtained and the resulting excitation and emission 
spectra of the poly(vinylene-arsines) were red-shifted (λex = 394 nm; λem = 443, 466 nm). 
Conversely, use of an electron-donating acetylene (4-methoxyphenylacetylene, 4-MPA) 
resulted in slower reaction kinetics, lower conversions and blue shifted excitation and 
emission spectra (λex = 341 nm; λem = 402nm) relative to phenylacetylene. In the 
poly(vinylene-arsine) backbone, a donor-acceptor pair exists between an As-lone pair and 
vinylene unit. The presence of an electron-withdrawing group in conjugation with the 
vinylene unit improves the acceptor ability, narrowing the band gap and lowering the 
energy of emission. 













(MeAs)5 PA 11500 48700 4.3 46 485 396 
(PhAs)6 PA 3900 5600 1.4 35 437 375 
(PhAs)6 4-CPA 8400 15100 1.8 29 443, 466 394 
(PhAs)6 4-MPA 3700 5100 1.4 22 402 341 
(PhAs)6 1-NA
d 7600 9900 1.3 33 350 315 
(MeAs)5
e 1-Oct 6500 7800 1.2 45 450 350 
a)SEC, CHCl3; b)isolated yields after precipitation in hexane; c)in CHCl3 at RT; d)1-
naphthylacetylene; e)M2 = 1-octyne, reaction performed in bulk in the presence of 
AIBN.48 
More complex terpolymer and block copolymer compositions are accessible by 
exploiting the relative reactivity of the As-radicals with other Group-15 radicals, such as 
those derived from organostibine (antimony, Sb) homocycles, or through 
copolymerization with more tradition vinyl monomers.49 As-radicals react more readily 
with electron poor acetylenes, such as dimethyl acetylenedicarboxylate (DMAD), than 
Sb-radicals.50 However, the corresponding vinyl radicals react preferentially with Sb-
radicals. Consequently, in the copolymerization of (MeAs)5/(PhSb)6/DMAD = 1/1/2 the 
relative reactivities of the Group-15 radicals furnished a periodic terpolymer composed 
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of the vinylene-arsine-vinylene-stibine repeating unit. Increasing the (MeAs)5 monomer 
feed had little effect on the final polymer composition whereas increasing the (PhSb)6  
monomer feed to (MeAs)5/(PhSb)6/DMAD = 1/1/2 resulted in a higher molecular weight 
terpolymer with a higher proportion of the Sb-units compared to As-units. This was 
attributed to the vinylene-arsine-vinylene-stibine periodic structure initially being formed 
until all the (MeAs)5 was consumed, at which point the (PhSb)6 and DMAD continued to 




Scheme 1.5 Synthesis of organic arsenical terpolymers via copolymerization in the presence of A) 
cyclo-organostibine (PhSb)6; B) activated vinyl groups styrene (Sty) and methyl methacrylate 
(MMA) 
Terpolymerisation of (MeAs)5 and phenylacetylene in the presence of activated vinyl 
groups styrene (Sty) and methyl methacrylate (MMA) resulted in block-like copolymers 
with one block composed of the vinylene-arsine repeating unit and the other being 
composed of Sty/MMA (Scheme 1.5B).51 Using the copolymerisation with Sty as a 
model, reducing the activated monomer feed ratio resulted in small reductions in Mn 
whilst increasing the Sty feed ratio resulted in polymers with higher Mn values (10200 to 
15500 g.mol-1). The block-like structures were inferred by NMR and SEC. The presence 
of the conjugated vinylene-arsine block was also supported by UV-vis and fluorescence 
spectroscopy whereby the terpolymers formed exhibited comparable absorption and 
emission profiles to the copolymers derived from RCRAC of (MeAs)5 and 
phenylacetylene, in the absence of Sty, with increasing the Sty feed resulting in a blue 
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shift in both λex and λem.  When 2,3-dimethyl-1,3-butadiene was employed as the activated 
vinyl monomer, a random terpolymer composed of a random distribution of the both 
vinylene-arsine and arsine-butadiene repeating units was obtained.51 Interestingly, whilst 
probing the mechanism of this polymerisation it was recognized that the reaction (MeAs)5  
with 2,3-dimthyl-1,3-butadiene under incandescent light, in the absence of other radical 
initiators, furnished a cyclic diarsine.52 As observed for organoarsenic homocycles, the 
As-As bond in cyclic diarsines is prone to homolysis in the presence of catalytic amounts 
of AIBN, and the As-radicals formed readily copolymerize with activated vinyl 
monomers such as Sty and MMA resulting in unconjugated polymers with As-units 
distributed through the backbone. These methods represent novel routes to the formation 
of polymers with As distributed through the polymer backbone. Additionally, these can 
have pendent functionalities for specific properties and/or reactivities incorporated by 
simply varying the styrenic or (meth)acrylic comonomers.  
 
Extended conjugated polymer networks have been synthesized by terpolymerisation of 
organoarsenic homocycles (PhAs)6 with phenylacetylene and p/m-diethynylbenzene 
(DEB).53 The p/m-DEB monomers reacted faster than phenylacetylene with the p-DEB 
exhibiting the faster rate of conversion. This was reflected in the polymers obtained with 
increasing the p/m-DEB monomer feed from 0 – 10 – 30 % (w.r.t to total acetylene 
monomer feed) resulting in an increase in Mw (3100 – 11800 g.mol-1) and Tg (92.9 – 101.7 
°C). The enhanced reactivity of both the acetylene moieties of p-DEB compared to m-
DEB was confirmed during polymerisation of equimolar amounts of phenylacetylene and 
p/m-DEB. Macroscopic precipitation as a result of gelation occurred when p-DEB was 
employed whereas a soluble crosslinked polymer (Mw = 8000 g.mol-1, Tg = 103.7 °C) was 
obtained in the presence of m-DEB. The soluble crosslinked polymers presented red-
shifted excitation and emission relative to linear poly(vinylene-arsine) analogues 
increasing from λex = 375 nm to 394 nm and λem = 437 nm to 473 nm respectively 
indicating that increasing the level of crosslinking resulted in extended conjugation and a 
narrower band gap between the donor and accepter groups. Finally, the film forming 
abilities of the polymers was assessed by drop-casting and performing a qualitative peel 




The presence of As-lone pairs throughout the backbone of poly(vinylene-arsines) has 
been exploited to prepare coordination polymers with transition metal salts and 
complexes.54 Polymers derived from (PhAs)5 formed metal coordinated polymers upon 
addition of CoCl2 in acetone at various ratios of polymer:CoCl2. However, coordination 
to polymers derived from (PhAs)6 was not observed due to the more sterically 
encumbered poly(vinylene-arsine) backbone. When formed at a 1 : 1 stoichiometry of 
CoCl2 : As the bivalent CoII was oxidatively labile forming a more stable trivalent species 
upon oxidation. However, the bivalent metal centre could be stabilized by complexation 
with an excess of polymer CoCl2 : As = 1 : > 4. The CoII content in the coordination 
polymers was determined using an EDTA assay to sequester unbound CoII in solution and 
the electronic structures were confirmed by UV-vis spectroscopy through which CoCl2 : 
As = 1 : 1 showed a signal for metal-ligand charge transfer, indicative of an oxidized 
trivalent Co-species, which was not present upon increasing the polymer concentration 
(CoCl2 : As = 1 : > 4). Ruthenium-poly(vinylene arsine) complexes have also been 
reported using a cis-(bpy)2RuCl2.2H2O complex. At a ratio of Ru : As = 1 : 2 up to 20 % 
of the arsine units in the polymers derived from (MeAs)5 were bound to Ru-complexes, 
and no coordination was reported for polymers derived from (PhAs)6. Finally, the 
coordination ability between As and transition metals has been exploited for stabiliza t ion 
of colloidal dispersions of silver nanoparticles (AgNPs) (Figure 1.5).55 In the absence of 
the poly(vinylene-arsine) polymers reduction of AgNO3 in DMF resulted in deposition of 
silver metal. However, in a 1 : 1 ratio of AgNO3 : poly(vinylene-arsine) colloida l 
dispersions were obtained as confirmed by the surface plasmon absorption band at ~400 




Figure 1.5 Colloidal dispersions of silver nanoparticles can be formed from the reduction of AgNO3 
in the presence of coordinating poly(vinylene -arsines). UV-vis and TEM confirm the presence of 
AgNPs within 0.5 hours. Scale bar = 200 nm.55  
 
There are exciting potential applications of these conjugated and coordinated polymers in 
a number of fields including electronics, non-linear optics, catalysis and chemotherapy. 
As a single example, the ability to coordinate platinum and osmium (and many others) 
complexes to arsenicals has been demonstrated and in the case of Pt-As complexes,5 6  
potent inhibition of a broad range of the cancer cells, including Cisplatin-resistant cells, 
has been demonstrated which certainly encourages further investigation of these 
materials.   
1.2.2 Pendent functional polymeric arsenicals  
1.2.2.1 Free radical polymerization (FRP) 
There has been interest in the incorporation of the arsonic acid functional group into 
polymers prepared by FRP since the 1970s based on their polyelectrolyte structure and 
heavy-metal chelation ability for use in ion exchange resins. In these examples, the 
arsonic acid functionality was introduced into styrene-divinyl benzene resins post-
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polymerisation, via the traditional steps of nitration, reduction and diazotonization of the 
aromatic groups, followed by substitution using sodium arsenite.57, 58 This multi-step 
process allows substitution of up to 50% of the benzene rings present, with little control 
over the distribution of the functional groups in the resin.  
 
Commercial arsonic acid reagents, for example o/p-arsanilic acid, are attractive starting 
materials for the preparation of arsonic acid functional reagents with the aniline amine 
group proving to be useful functional handle for synthesis. With respect to arsonic acid 
functional vinyl-monomers, o/p-(meth)acryloylaminophenylarsonic acid monomers have 
been prepared by amidation of the  o/p-arsanilic acid using (meth)acryloyl chloride 
(Scheme 1.6).59, 60 The crystal structures have been solved61-63 and p-
methacryloylaminophenylarsonic acid in particular shows good non-linear optical (NLO) 
properties, exhibiting a large second-harmonic generation using a 1.06 μm Nd-YAG IR 
laser which produced a green (534 nm) output. These properties arise from subtle 
differences in the molecular structure62 and conformation,64 in particular the 
(as)symmetry of the intermolecular hydrogen bonding network. Upon crystallization this 
results in formation of two crystals structures; noncentrosymmetric orthorhombic crystals 
which are responsible for producing the second-harmonic generation output and 
centrosymmetric triclinic crystals which are unable to exhibit the property based on NLO 
theory. 
 
Scheme 1.6 Synthesis of o/p-(meth)acryloylaminophenylarsonic acid monomers 
 
o/p-(Meth)acryloylaminophenylarsonic acid monomers have been polymerized by FRP 
in DMF at 70 °C using AIBN as an initiator.59, 65 Polymerisation of the monomers in their 
Na+ salt forms was also carried out in H2O at 70 °C using potassium persulfate as a water 
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soluble initiator. Dilatometry was employed to investigate the kinetics of the 
polymerisations of o/p-methacryloylaminophenylarsonic acid which were shown to be 
first order in initiator and greater than 1 with respect to monomer, which is not uncommon 
for electrolyte monomers. Low molecular weight oligomeric species (Mn < 2100 g.mol-1) 
were formed when o/p-methacryloylaminophenylarsonic acid were employed whilst o/p-
acryloylaminophenylarsonic acid furnished higher molecular weight polymers (Mw < 
39000 g.mol-1). The structure of the polymers was confirmed by IR and 1H NMR with 
the Mn of the methacylamides determined by vapour pressure osmometry, whilst SLS was 
used to determine Mw of the acrylamides. The colligative properties such as reduced 
viscosity and flocculation ability, were assessed as a function of the oligomer 
concentration and pH. Flocculation analyses were performed using a standard jar test in 
which the polymer was added in variable concentrations (1 – 5 mg.mL-1) to waste sewage 
water from the authors’ institute followed by turbidity measurements. At constant pH (pH 
= 2), the performance of both polymers as flocculants, in their salt forms, increased as a 
function of concentration. Increasing the pH reduces the flocculation efficiency rapidly 
as the pH is raised from 2 to 4, thus passing the pKa1 of the arsonic acid moiety, before 
steadily increasing with increasing pH. Reduced viscosity measurements show two 
maximum values at pH 2 and 10 respectively, with local minima occurring at pH 4. This 
was attributed to polymer chain expansion and conformation changes as a result coil 
expansion, which is typical behavior for polyelectrolytes. Therefore, the floccula t ion 
efficiency was tentatively attributed to changes in polymer coil expansion. 
 
The sodium salts of o/p-methacryloylaminophenylarsonic acid have been copolymerized, 
using a range of monomer feed ratios, with sodium (meth)acrylate and acrylamide by 
FRP in H2O at 70°C using potassium persulfate as an initiator and their physiochemica l 
properties have been evaluated by on-line (with SEC) and off-line multi-angle light 
scattering (MALS).66, 67 The experimental copolymer compositions were extrapolated 
from the As-content which was determined by atomic absorption spectroscopy (AAS). 
Homopolymers of o/p-methacryloylaminophenylarsonic acid reach high molecular 
weight (Mw = 1.3 x 106 g.mol-1) whilst compositional analysis against the monomer feed 
revealed that all copolymers were richer in sodium (meth)acrylate or acrylamide than the 
As-monomers. This was reflected by the reactivity ratios which were determined for all 
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the polymerisation systems in which rAs < 1 and r2 > 1 (rAs = As-monomer; r2 = sodium 
(meth)acrylate and acrylamide) suggesting a random copolymer structure. Molecular 
weights of the copolymers were of the order of Mw = 105 g.mol-1 with the Mw and radius 
of gyration decreasing with decreasing As-monomer content. 
 
Homopolymers of o/p-acryloylaminophenylarsonic acid have been employed for a one-
step ‘green’ synthesis of the Au and Ag colloidal dispersions in H2O, where the polymers 
have the dual properties of reducing agent and stabilizer for the nanoparticles formed.6 8  
The p-acryloylaminophenylarsonic acid polymer was able to reduce HAuCl4, according 
to the emergence of absorption at 557 nm (SPR band). The reaction was slow, reaching 
completion with 243 h. The resulting particles, stabilized by the polymer, were 
polydisperse with sizes ranging from 5-80 nm according to TEM (Figure 1.6). 
Alternatively, o-acryloylaminophenylarsonic acid similarly afforded reduction of 
HAuCl4 over 140 h with an absorbance peak emerging at 547 nm. However, over longer 
time periods the absorbance decreased which suggested that the ortho polymers were 





Figure 1.6 Temporal evolution of UV-vis absorption and typical TEM images of the nanoparticles 
formed after addition of HAuCl4 (top) and AgNO3 (bottom) to the polymer derived from p-
acryloylaminophenylarsonic.68  
 
Both polymers were able to reduce AgNO3 and stabilized the Ag0 particles formed. The 
mechanism of particle formation is slightly different for each monomer according to 
differences observed in the absorption spectra. Two distinct maxima emerge with the 
para polymer (387 nm and 496 nm) over 220 h, whilst these peaks coalesce to a single 
maximum (414 nm) after ~100 hrs. The two maxima were attributed to different size 
particles which was confirmed by TEM with the para-polymer furnishing two distinct 
distribution of particles at 2-15 nm and 40-60 nm respectively (Figure 1.6). The ortho-
polymer, exhibiting a single maximum at 414 nm, also yielded particles with two 
distributions however, TEM revealed that the majority of the particles formed were of a 
smaller size (2-15 nm) with a minor population of larger particles (25-40 nm). Additiona l 
work is perhaps required to improve the particle size distribution of the particles formed 
in this process but the one-pot, ‘surfactant’- free, aqueous conditions of this process are 
attractive as a relatively ‘green’ route to metallic nanoparticles. 
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1.2.2.2 Reversible deactivation radical polymerization (RDRP) 
As-functional (co)polymers prepared by FRP have shown some interesting properties, 
particularly with respect to their use as flocculants and surface-active molecules due to 
the ionization potential and ion-exchange properties of pendant arsonic acid moieties. The 
composition, and in some cases the performance, of these materials is somewhat limited 
by the lack of control over the FRP methodology. One approach to improve compositiona l 
control is via reversible deactivation radical polymerization (RDRP) which exploits the 
activation-deactivation equilibrium of active chain-ends to control radical formation (i.e. 
concentration), monomer addition (i.e. chain-growth) and deactivation events during 
radical polymerizations. Active chain ends include (i) alkyl halides in Cu-mediated 
radical polymerizations such as atom-transfer radical polymerization (ATRP)69 and single 
electron transfer living radical polymerization (SET-LRP);70, 71 (ii) thiocarbonylthio for 
reversible addition fragmentation chain-transfer polymerization (RAFT);72 (iii) 
alkoxyamines for nitroxide-mediated polymerization (NMP).73 Recent advances in the 
field of RDRP allows this activation-deactivation equilibrium to be manipulated to afford 
unprecedented control over molecular weight and molecular weight distribution (Ð). 
Furthermore, through the use of functional monomers and initiating/mediating reagents, 
homo- and (multi)block copolymers can be prepared with precise control of the end-group 
functionality and discrete control over the functional domains present throughout the 
polymer composition.74-78   
p-Arsanilic acid has already been shown to be a convenient synthon for the one-step 
synthesis of (meth)acrylamide monomers.59, 65 The amine functionality has also been 
exploited for the one-step synthesis of an arsonic acid, As(V)-functional initiator (AsBr), 
via amidation using 2-bromoisobutyryl bromide, for Cu-mediated RDRP.79 The As(V)-
functional α-haloamide AsBr was employed to initiate aqueous SET-LRP80 of a range of 
acrylamide and acrylate monomers, as well as copolymers with the As(V)-functiona l 
acrylamide monomer (AsAm). Homopolymerizations initiated by AsBr, with target DPn,th 
= 20-100, reached quantitative conversion within 30 minutes and were well controlled (Ð 
< 1.20). Similarly, copolymerizations of variable ratios of PEGA and AsAm with fixed 
total DPn,th = 20 reached full conversion within 30 minutes and retained good control 
throughout (Ð < 1.30). The differential reactivity of arsenicals for thiols was then 
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sequentially exploited to achieve highly efficient and highly selective protein/peptide -
polymer conjugation.79  
 
 
Figure 1.7 Synthesis of As(V)PPEGA480 via aqueous SET-LRP followed by post-polymerization 
modification by reduction and complexation with glutathione (GSH) to form the bis(GSH) 
As(III)PPEGA adduct.79 
 
Pentavalent arsenic (As(V)) does not form covalent bonds with thiols, preferring to 
undergo two consecutive single electron transfer reductions to yield trivalent arsenic 
(As(III)) which has a high affinity for thiols, readily forming covalent bonds. An α-As(V)-
functional PEGA480 homopolymer (As(V)PPEGA) was sequentially reduced and 
substituted by GSH to yield an α-As(III)-functional homopolymer (As(III)PPEGA) 
(Figure 1.7). The affinity of As(III) for thiols is markedly enhanced for the proximal, or 
closely-spaced dithiols, which was utilized to achieve peptide-polymer conjugation via 
disulfide bond re-bridging using salmon calcitonin (sCT) as a model peptide. 
Conjugations were fast and efficient reaching full conversion within 45 minutes using a 
small stoichiometric excess (1.2 eq) of As(III)-functional polymer (Figure 1.8). The 
selectivity of As(III) for dithiols in the presence of other nucleophilic amino acid residues, 
including monothiols of free cysteine, was qualitatively exemplified using BSA and 
reduced BSA (rBSA). Comparison with other thiol reactive reagents, N-ethyl maleimide 
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(NEM) and dibromomaleimide (DBM), showed that whilst NEM and DBM reacted 
indiscriminately with monothiols and dithiols present in rBSA, As(III) reagents react 
preferentially to re-bridge the reduced disulfides present in rBSA. This efficient and 
highly specific approach to conjugation has great potential in the field of drug-delivery, 
particular with respect to antibody-drug conjugates where heterogeneity in product 
formulation is a clinical limitation. 
 
Figure 1.8 A) Conjugation of sCT to (GSH)2-As(III)PPEGA480 (2.5 eq) via sequential reduction-
conjugation. B) Release of sCT from sCT-4 using EDT (bottom spectra) and control reaction of 4 
and EDT (top spectra). 79  
 
Organic arsenicals are also compatible with RAFT polymerization. This was first reported 
using a pinacol protected As(V)-acrylamide (AsAm(pin)2) synthesized in a two-step 
reaction from p-arsanilic acid. Homopolymerization of AsAm(pin)2 (DPn,th = 10-50) 
performed in trifluoroethanol (TFE) at 65 °C using AIBN as initiator and 2-(((butylthio)-
carbonothioyl)thio)propanoic acid as the chain-transfer agent was well controlled (Ð < 
1.40) (Table 1.2).81 The livingness of the RAFT polymerization was exemplified by chain 
extension of a [AsAm(pin)2]10-macroCTA with dimethylacrylamide (DMAm) which 
yielded an amphiphilic block copolymer [AsAm(pin)2]10-b-DMAm100 (Ð = 1.10) which 
underwent self-assembly in aqueous solution to yield nanoparticles (Dh = 147 nm).  
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-a - 330 81 - 39000 2.51 
10 10 310 97 4600 4000 1.10 
20 10 330 94 8600 5600 1.15 
50 5 365 96 22000 10000c 1.38 
a)SEC DMF; b)FRP [M] = 0.5 M, [AIBN] = 1 mol%; c) SECTD (DMF): Mn,TD = 29500 
gmol-1, Ɖ = 1.36, Rh,TD = 2.5 nm, Rg,TD = 3.0 nm, α = 0.44. 
 
Statistical copolymers of AsAm(pin)2 and DMAm furnished well controlled DMAm100-
n-co-[AsAm(pin)2]n copolymer scaffolds (n = 10/20/50, Ð < 1.10). The pendent As(V)-
functional group can be manipulated via post-polymerization modification. Initia lly, 
under acidic conditions the pinacol groups can be removed to furnish reactive arsonic 
acid functional groups. Subsequent reduction and substitution in the presence of excess 
thiol reagents results in transformation of the pendent As(V) group to thiol-substituted 
As(III) groups. This has been achieved using organic thiols mercaptoethanol and methyl 
thioglycolate as well as biologically relevant thiols cysteine and GSH to demonstrate the 
potential of polymeric arsenicals as reactive and responsive polymer scaffolds (Figure 
1.9).    
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Figure 1.9 Manipulation of the polymeric arsenical scaffolds by sequential treatment with acid and 
thiols confirmed by 1H NMR, CDCl3.81  
 
Most recently, Stenzl and co-workers have prepared an unprotected methacrylamide 
arsenical monomer derived from organic arsenical drug 4-N-(S-
penicillaminylacetyl)amino phenylarsonous acid (PENAOMAm) (Figure 1.10).82 This 
was copolymerized with PEGA (3-15 wt%) to form the hydrophilic block of an 
amphiphilic block copolymer (MMA-b-[PEGA-co-PENAOMAm]; Mn = 25-40 x 103 
g.mol-1; Ð < 1.25). The rationale for this is to improve the bioavailability and efficacy of 
PENAO which suffers from the typical clinical limitations associated with organic drug 
molecules. The MMA-b-[PEGA-co-PENAOMAm] amphiphiles self-assembled in 
aqueous solution to furnish polymer nanoparticles (Dh = 84-234 nm; cmc = 0.5 – 82 
μg.mL-1). The PENAO-functional nanoparticles exhibited greater activity (inhibit ion; 
IC50 = 0.8 ± 0.02 μM) and cellular uptake compared to free PENAO drug (IC50 = 2.7 ± 
0.3 μM) when compared using 143B human sarcoma cells. In agreement with preceding 
work, the reactivity of the pendent arsenous acid (As(III)) groups was confirmed upon 
reaction with mono and dithiols which has implications on the cellular localization of the 
nanoparticles. PENAO and related organic arsenical drug GSAO, are proposed to cross-
link proximal thiols of mitrochondrial transmembrane protein adenine nucleotide 
translocase (ANT) which is an important component of the mitrochondial permeability 
pore. Confocal microscopy suggested that nanoparticles were localized to the 
mitochondria, suggesting the pendent PENAO groups were inhibiting cell prolifera t ion 
via a similar mechanism to PENAO and certainly justifies further in vitro and in vivo 




Figure 1.10. PENAO decorated polymer micelles prepared by RAFT polymeris ation exhibit 
high chemical affinity for thiol containing groups and mitochondrial localization in vivo.82 
 
1.3 Bio-imaging  
Labelling proteins for visualisation is an invaluable technique to help understand the 
functioning, dynamics and localisation of the biological machinery that drives living 
organisms. Minimally invasive medical imaging has become crucial to health care, and 
labelling specific proteins that are markers for diseases is an increasingly attractive 
method for effective diagnoses. The affinities of arsenic for proteins provide mult ip le 
possible opportunities for labelling and biomedical purposes.83 For example, p-
azidophenyl arsenoxide (PAzPAO)84 was incubated with live cells to label arsenic 
binding proteins without disrupting the membrane. The labelled proteins were then 
captured by strained alkyne azide cycloaddition with biotin functiona l 
dibenzylcyclooctyne and streptavidin coated magnetic beads. The captured proteins were 
released from the arsenic via addition of DTT and investigated by shotgun proteomics, 
identifying 48 proteins, including antioxidant proteins (thioredoxin, peroxiredoxin, 
peroxide reductase, and glutathione reductase) which well-defined dithiols sequences in 
their active sites. 
 
The affinty of arsenic for protein thiols/disulfides has also been exploited to develop 
antibody-As-radioisotope conjugates that can undergo positron emission, enabling 
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tumour specific imaging via positron emission tomography (PET). Jennewein et al. 
employed monoclonal antibody Bavituximab-74As (β+; t1/2 = 17.8 days) conjugate for 
PET imaging of the 3D vasculature of tumours a rat model (Figure 1.11).85 Other As-
positron emitters for PET imaging include 71As (β+; t1/2 = 64 h) and 72As (β+; t1/2 = 26 h) 
which has been studied for the development of theranostic radiopharmaceuticals upon 
conjugation to monoclonal antibodies, dithiol chelating cofactors and thiolated 
mesoporous silica nanoparticles.86 Higher energy positron emitters such as 76As (β-; t1/2 = 
26.3 h) and 77As (β-; t1/2 = 38.8 h) have also been considered as radiotherapeutics.87  
 
Figure 1.11Antibody functionalised with radioactive arsenic (top) and whole body planar 
scintigraphy of prostate tumour bearing rat, injected with 5 MBq of 74As-antibody conjugate. The 
phosphor plate image was overlaid with x-ray picture to provide anatomic correlation.85  
 
Polymer scaffolds have also been labelled with As-radioisotopes which is important from 
a polymer-based nanomedicine perspective, in which non-invasive evaluation of 
biodistribution and accumulation is highly desirable. An end-group and side-chain thiol 
functional analogue of  FDA-approved polymer N-(2-hydroxypropyl)methacrylamide 
(HMPA) was synthesised by RAFT and conjugated to 72/74As(III).88 The relatively long 
t1/2 of 72As and 74As radio-labelled polymer and the stability of the conjugates (> 48 h) in 
saline implies that such strategies could indeed apply to imaging the long-term fate of 




Alternatively, the affinity of organic arsenicals for dithiols has been utilized to target 
imaging modalities (e.g. fluorophores, radionuclides) to particular cellular processes. To 
this end, the limited membrane permeabilty of organic arsenical drug GSAO has proved 
to be an advantageous property for the imaging of cell death using both fluorophore and 
radionuclide conjugated GSAO derivatives.89 Increased accumulation of GSAO 
fluorophore conjugates in apoptic induced cells led to binding of biotin-GSAO to 90 kDa 
Heat shock protein (Hsp90), which is abundant, yet inaccessible to GSAO, in the 
cytoplasm of healthy eukaryotic cells. Furthermore, a rabbit and mouse in vivo model has 
been been developed to image cell death during myocardial infarction.90 The myocardia l 
accumulation of a radionucluide molecular imaging agent; 111In-GSAO conjugate, was 
investigated via SPECT/CT and was correlated to both apototic and nectrotic cell death 
processes (Figure 1.12). 
 
 
Figure 1.12. Fluorescence confocal microscopy showed cells that were positive for caspase 3 
(apoptosis marker) were also positive for Cy5.5-GSAO (left); SPECT/CT image of a mouse bearing 
a Lewis lung carcinoma tumour in the shoulder area, 5 hours after administered with 111In-DTPA-
GSAO in the tail vein (right).89  
 
Fluorescent organic (bis)arsenical probes (Figure 1.13) were introduced by Tsein et al. 
20 years ago and have become the most notable arsenical reagents for imaging 
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purposes.17, 91, 92 Fluorescein arsenical hairpin binder bis-EDT (FlAsH-EDT2) was first 
reported in 199893 followed by resorufin arsenical hairpin binder bisethanedithio l 
(ReAsH- EDT2) in 2002.94 There are two key features of these bis-arsenicals, the first 
being the arsenic interatomic distances (5-6 Å), which promote strong and highly specific 
binding to tetracysteine (TC) peptide sequences where two vicinal dicysteines are spaced 
apart by two intervening amino acid residues (Cys-Cys-Xxx-Xxx-Cys-Cys). The other 
key feature is rotomer restricted fluorogenicity.95 FlAsH-EDT2 and ReAsH-EDT2 are 
quenched prior of TC-conjugation and this is thought to be due to photoinduced electron 
transfer (PET) between freely rotating dithiaarsanes and the fluorophore. Upon TC-
conjugation the rotation about the As-Aryl bond is restricted, preventing the PET induced 
quenching leading to a remarkable (up to 50000x) increase in fluorescent intensity. 
 
The photochemical properties of bis-arsenical fluorescent tags can be readily tuned. 
While FlAsH-EDT2 and ReAsH-EDT2 are green and red emitters respectively, CHoXAsH 
exhibits blue emission in a region that might be useful as a FRET donor with GFP94 and 
fluorescence of BArNile-EDT296 and CrAsH-EDT297 were reported to be dependent upon 
the environment. Fluorinated bis-arsenical F2FlAsH-EDT2 has similar wavelength of 
absorbance and emission compared to FlAsH but with a higher quantum yield and 
increased photostability. F4FlAsH on the other hand has an emission in a region 
intermediate to FlAsH and ReAsH and increased fluorescence lifetime. In addition, 
F2FlAsH and F4FlAsH can both be used as FRET donor and acceptor pairs.98 Though 
these tags are optimised for TC-sequences engineered into the termini of native proteons 
they are less suitable for binding and imaging of dynamic, independently folded CxxC 
sequences which are ubiquitous in proteins that maintain redox homeostasis. Such targets 
have been successfully targeted using organic bis-/tris-arsenicals20 and there is great 
potential for precision, polymeric arsenicals to be developed to interface, probe and effect 




Figure 1.13 Schematic representation of the specificity of bis -arsenicals for tetracysteine sequences 
and structure for bis-arsenicals synthesized with a range of emission profiles. 
 
A complementary red emitting cyanine-based bisarsenical, AsCy399, 100 with larger 
interatomic distance between the arsenic atoms (14.5 Å) has also been developed, 
preferentially binding to longer TC with two helical turns (CCKAEAACC). This makes 
it possible to distinguish between proteins that are simultaneously labelled with FlAsH. 
Similarly to FlAsH, the fluorescence is dependent on blocking the quenching by 
dithiaarsanes through interchanging of EDT with the cysteine pairs. The formation of 
fluorescent complexes with AsCy3 were also observed to form faster, within seconds 
(compared to a timescale of minutes for ReAsH and FlAsH). 
 
With the development of super high resolution microscopy (sub-diffraction), and the 
resulting potential for analysing images more accurately, there is a need for probes that 
can be used with the technology, to generate high quality images. The combination of 
Cy3-Cy5 has been reported for use in Stochastic Optical Reconstruction Microscopy 
(STORM).101 Pulsed red light is used to excite photoswitchable Cy5 into a long lived dark 
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state, which is then recovered by excitation of proximal Cy3 with green light. The 
resulting controlled fluorescence allows the high resolution microscopy (below 20 nm) to 
form the detailed images, using many pictures made into a composite.  Squier et al 
reported Cy3-Cy5 derivative, AsCy3Cy5,102 with Cy3 component as the bis-arsenica l 
scaffold for targeting TC tag. The separation of Cy3 and Cy5 is less than 2.1 nm, whic h 
was important as the distance between the dyes for photoactivation of Cy5 is much steeper 
than FRET (below 3 nm, below 5 nm for FRET).103 This allowed single molecule imaging 
of alpha subunit of the RNA polymerase (RpoA) with resolution below 100 nm and 
potential to be even further enhanced as low as 20 nm.102 
 
1.4 Combining nanoparticles and organic arsenicals 
While the focus of this literature review is of organic arsenicals, encapsulation and 
delivery of As2O3 using liposomes, polymer nanoparticles, and inorganic nanopartic les 
has attracted significant attention in an attempt to improve efficacy and mitigate toxicity 
of As2O3chemotherapies. For example, As2O3 has been encapsulated in liposomes104-107 
and polymeric nanoparticles108, 109 for mono and combination therapies through which 
active targeting can be improved via incorporation of antibodies and ligands on the 
surfaces. Likewise, inorganic metal-AsOn@SiO2 composite nanoparticles have been 
developed for improved cellular uptake and pH-dependent release of therapeutic As2O3. 
110-112
 
Organic arsenicals with a single arsonic acid group have been employed as surface active 
ligands for the formation of 2D self-assembled monolayers (SAMs),113 and for the 3D 
modification of the Fe3O4 nanoparticles.114 Alkyl arsonic acids have been shown to be 
versatile and robust ligands for the formation of SAMs at oxide surfaces includ ing 
titanium oxide and silicon oxide.113 The alkyl arsonates were more reactive than the 
related alkyl phosphonates which was exemplified by the formation of alkyl arsonate 
SAMs at the surface of borosilicate glass which was not possible with alkyl phosphonates. 
SAMs were characterized by drop-shape analysis (water contact angle), FT-IR and 
nanoscratching measurements to determine small-scale mechanical properties. Alkyl 
arsonate SAMs demonstrate greater potential as wear-protection coatings by providing 
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better protection against micronewtonian forces (nanoscratch) than the phosphonate 
counterparts. For example, comparing the normalized percentage protection of titanium 
oxide shows the alkyl arsonate SAMs provide 100% surface protection against 
micronewtonian forces up to 105 μN whereas phosphonate equivalents afford between 
45-75 % protection of the same range. 
Inspired by literature associated with the high affinity of arsenic for iron-oxide based 
absorbent materials (for water purification),115, 116 azido-functional p-arsanilic acid has 
been investigated as a functional ligand for the stabilization and modification of Fe3O4 
nanoparticles (Figure 1.14A).114 Quantitative comparison of surface coverage and 
packing density respectively revealed that the arsonic acid ligand (32 μmol.g-1; 1.1 
molecules nm-1) performed better than both catechol (20 μmol.g-1; 0.67 molecules nm-1) 
and carboxylate (16 μmol.g-1; 0.55 molecules nm-1) ligand equivalents (Figure 1.14B). 
Furthermore, the arsonic acid ligands where also found to be more stable than the catechol 






Figure 1.14 A) Schematic representation of the phenylarsonic acid moiety anchoring to the surface 
of Fe3O4; B) Amount of the anchoring as a function of concentration relative to tradition anchoring 
groups; C) Accumulated detachment of anchoring groups as following aqueous wash cycles; D) 
anchor stability as a function of pH.114  
 
Contrary to this data, arsenoacetic acid ligands, contain both arsonic acid and carboxylic 
acid functional groups, have been reported to undergo ligand exchange with undecanoic 
acid ligands at surface of Fe3O4 nanoparticles. This exclusively yields the carboxylate 
coordinated nanoparticles with the arsonic acid group presented at the surface of the 
particles.117 In this case, the lability of the C-As bond of alkyl arsonic acids in the presence 
of thiol reagents was exploited to elicit tumour specific cytotoxicity. The alkyl arsonic 
acid group (As(V)) presenting nanoparticles were designed as anticancer prodrugs which 
could be activated in the presence of elevated thiol (GSH) concentrations associated with 
cancer cells. Using HepG2 and HeLaS3 as model cancer cells and primary mouse 
hepatocytes as non-malignant controls, reductive cleavage of the alkyl arsonic acid, with 
release of toxic As(III) species, was shown to be more prevalent in the cancer cell lines 
reducing viability to 40% (HepG2) and 70% (HeLaS3) at 100 μg.mL-1 whereas  viability 
of the hepatocytes was maintained across the concentration range (Figure 1.15). As this 
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specificity is attributed to the redox environment, arsonic acid functional materials 
combined with imaging modalities (including MRI, fluorescence, radiolabels) could be 
developed as theranostics for the diagnosis (e.g. GSH biomarkers), treatment and tracking 
of cancer cells. 
 
Figure 1.15 Effect of As2O3, naked iron oxide nanoparticles, and the modified nanoparticles on the 
viability of normal cells ((a) primary mouse hepatocytes) and tumor cell lines ((b) HepG2 and (c) 
HeLaS3). Cells were incubated with various concentrations of the samples for 72 h. Results are 
expressed as viability (%  viable cells in comparison with the control) versus the arsenic content for 
upper three graphs.117  
Soft polymer and protein based nanoparticles have also been prepared for the delivery of 
arsenicals to cancer cells. An amphiphilic, biodegradable diblock copolymer PEG-b-(α-
carboxylate-ε-caprolactone) (PEG-b-PCCL) was synthesized by ROP. Thiol groups, for 
arsenical conjugation, were introduced into the hydrophobic caprolactone block via 
amidation of the pendant carboxylate group using mercaptohexylamine (PEG-b-
PCCLSH).118 The resulting thiol functional block polymers could be assembled in water, 
toluene and DMAc forming particles with Dh = 136 nm, 35 nm and 54 nm respectively. 
In the presence of trivalent organic arsenical phenylarsine oxide (PAO), self-assemb ly 
resulted in the formation of PAO-functional nanoparticles whereby the PAO could be 
covalently bound through conjugation to one or two pendant thiol groups, or physica lly 
encapsulated by electrostatic interactions (Scheme 1.7). Particle size analysis revealed 
that the PAO-functional particles were slightly larger in water (Dh = 151 nm) and more 
stable with cmc decreasing from 92 μg.mL-1 to 70 μg.mL-1 providing indirect evidence 
for the covalent mode of encapsulation which could proceed with a degree of stabilizing 




Scheme 1.7 Encapsulation of PAO into PEG-b-PCCLS H and PEG-b-PCCL micelles. The unloaded 
PAO was removed by sequential dialysis against DMAc and water. Possible interactions between 
PAO and polymers include 1 sulfur residue on 1 As atom, 2 sulfur residues on 1 As atom (intra- 
/interchain) and ionic interactions between thiol groups and hydrolyzed PAO. When no thiol 
groups exist in PEG-b-PCCL, the encapsulation of PAO in PEO-b-PCCL micelles is based on only 
hydrophobic interaction between PAO and PCCL blocks.118  
 
Further evidence for was drawn from maximum loading of PAO into the thiol functiona l 
particles (2.4 wt%) which was significantly greater than a non-thiol functional control 
particles (0.17 wt%). Chemical release studies showed that PAO release could be 
triggered by the addition of GSH, which is advantageous for targeted release in cancer 
cells. Indeed, IC50 values (MDA-MB-435) of the PAO-functional particles were similar 
to PAO (< 0.04 mg.mL-1), but there was little selectivity of cancer cells using this 
formulation as similar IC50 values were obtained against health cell lines (human 
fibroblast BJ cells). This was attributed to the polymer concentration range studied 
(0.00004-0.04 mg/mL-1) which was below the cmc of the PAO-nanoparticles. 
In order to address the thermodynamic stability and improve the cancer cell targeting of 
As-functional nanoparticles, terpolymers in which the hydrophobic α-carboxylate-ε-
caprolactone block has been modified to include additional ε-caprolactone, to increase 
hydrophobicity, have been prepared.119 The lowest cmc value was obtained from the 
triblock PEG-b-PCCLSH-b-PCL (11 μg.mL-1) compared to PEG-b-PCL-b-PCCLSH and 
PEG-b-(PCCLSH-co-PCL) (36 μg.mL-1). Here, sodium arsenite was used for 
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encapsulation of a trivalent arsenical and loadings of 3-4 wt% were possible via simila r ly 
covalent and physical interactions described above. Release profiles of As-loaded 
particles derived from the terpolymers correlated with particle stability and As-loading. 
Finally, cell uptake (MDA-MB-435) was correlated to the properties (stability, surface 
charge, As-loading/release) of the As-functional particles. It was found that PEG-b-
PCCLSH-b-PCL > PEG-b-PCL-b-PCCLSH and PEG-b-(PCCLSH-co-PCL) > free 
As(III) which raises the possibility of fine-tuning the particle properties by manipula t ing 
polymer composition which could be advantageous for arsenical and/or multidrug co-
encapsulation for combination chemotherapies (Figure 1.16). 
 
Figure 1.16  In vitro release of As(III) from micelles at 37 °C in (A) water, (B) RPMI-1640 cell 
culture medium, and (C) RPMI-1640 medium supplemented with 10%  FBS. Data are presented as 
mean ± SD (n = 3) of triplicate samples. The arsenic release from the micelles at 0 h was 
reorganized into a bar graph (D). One-way ANOVA with post-test of Tukey’s multiple comparison 
test was performed among three types of arsenic encapsulated micelles in a same solvent and 
among micelle solutions prepared in three different solvents. Micelle 1b had significantly higher 
initial release than 2b or 3b (*P < 0.05) in H2O, RPMI-1640, and RPMI 1640 supplemented with 
10%  FBS. Micelles prepared in RPMI-1640 supplemented with 10%  FBS had significantly higher 
initial release than the corresponsive micelles prepared in H2O or in RPMI-1640 (*P < 0.05).119 
 
An alternative method for improving active targeting to cancer cells involves the 
conjugation of the ligands to the surfaces of nanoparticles. The polymeric system 
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described above has been adopted to prepare protein-based nanoparticles/nanodrugs. 
Folate-labelled Human-Serum-Albumin (FA-HSA) contains one free thiol group and 17 
disulfide bonds which can readily exposed under reductive conditions in order to interact 
and form covalent bonds with As(III)-species, in this case arsenic trioxide (ATO).120 The 
average loading of ATO (ICP-OES) was found to be ~4 ATO per FA-HSA and discrete 
particles of Dh = 43 nm were identified by DLS. Release of the ATO was dependent upon 
the pH and reductive environment with enhanced rates of release as the pH was lowered 
or [GSH] increased. Competition assays in the presence and absence of free fola te 
revealed that the FA-HSA-ATO particles targeted folate receptor-β (FRβ, K562 cells). 
Furthermore, treatment of these cells with FA-HAS-ATO stimulated up regulation of the 
receptor which enhanced cellular uptake and accumulation in a range of FRβ-positive cell 
lines. This was supported by in-vivo evaluation (Figure 1.17) that demonstrated the FA-
HSA-ATO particles had blood circulation half-life, which coupled with the targeting 
imposed by the FA-ligands resulted in greater tumour growth inhibition (45 day surviva l) 
compared to only ATO (28 day survival) and HSA-ATO (36 day survival) in the absence 
of FA-ligands. This is promising for targeted delivery of arsenicals to a broader range of 





Figure 1.17 Schematic for the synthesis of FA-HAS-ATO and in vivo targeting ability, blood 
circulation, and tissue biodistribution of FA-HSA-ATO. a) In vivo targeting ability of FITC HSA-
ATO injected i.v. in K562 tumor-bearing mouse. b) Biodistribution of ATO, HSA–ATO, and FA-
HSA-ATO in main mouse organs, as determined by ICP-OES. Results are expressed as a 
percentage of the total injected dose per tissue mass (% ID g -1). Data are shown as mean:SD (n=3). 
c) Blood circulation curves of ATO, HSA–ATO, and FA-HSA-ATO in mice, as determined by ICP-
OES. Data are shown as mean:SD (n=3).120  
1.5 Arsenolipids and arsenoliposomes 
The efficacy of ATO against hematologic malignancies is yet to be matched for solid 
tumours. A number of liposomal strategies have been considered and are under 
development in order to improve the therapeutic index of ATO as a single and 
combination chemotherapy.107, 121-123 These liposomes are formulated from traditiona l 
PEG, phosphocholine and cholesterol-based lipids that exploit metal-ion gradient- load ing 
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mechanisms to load inorganic As(III) in the form of arsenous acid. Here we will focus on 
organic arsenical containing liposomes for the formulation of arsonoliposomes, which 
have also been reported and investigated for use in drug delivery (Figure 1.18).124-126 
 
Figure 1.18 General structure of arsonolipid constituents of arsenoliposomes. 
 
Arsonolipids are synthetic analogues of naturally occurring arsenolipids.127 They are 
related to conventional phosphonolipids through the polar head group with the 
phosphonate being replaced by arsonate. The typical route the arsonolipids involves ring-
opening of glycidol to with sodium arsenite to give the key 1,2-dihydroxypropyl-3-
arsonic acid intermediate as a mixture of diastereomers (rac-, R-, S-).128 Acylation of the 
mono- and di-tetrabutylammonium salts of the resulting acids furnishes the arsonolip ids 
in 20-40% yield after neutralization.129, 130  This yield can be improved by reducing the 
arsonic acid (As(V)) to a dithioarsonite (As(III)) before diol acylation and oxidation of 
the As(III) back to As(V) using H2O2 (35-55%).131 Other mono-arsonolipids have been 
synthesized in this way from 2,3,4-trihydroxybutylarsonic acid, the product of ring-
opening of 3,4-epoxybutane-1,2-diol by sodium arsenite.132 Pseudo-arsonolip ids 
analogues, containing bis-arsonic acid groups, have also be synthesized from 
epihalohydrin133 and 1,4-dibromo-2,3-butanediol134 respectively. 
Conventional approaches to liposome formation including thin-film hydration, sonication 
and reversed phase evaporation were not successful for the preparation of 
arsonoliposomes. However, an adaptation of the ‘bubble method’135 allowed fabrication 
of pure (C12-18; Dh = 251 – 329 nm) and mixed (with phospholipids; Dh = 247-346 nm) 
arsonolipids either in the presence or absence of cholesterol the sizes of which could be 
reduced by ~ 50% when subjected to probe sonication immediately after formation.1 3 6  
The physiochemical effects of changing the arsonolipid (C12-18)137 and overall lipid 
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composition138 of the vesicles has been evaluated based on the resulting vesicle size 
distribution, surface charge, encapsulation and retention (of hydrophilic cargo) efficiency. 
For example, in mixed arsonolipids the size of vesicles increases as function of the 
arsonolipid content. Incorporation of PEGylated phospholipids into these liposome 
compositions results in small changes in vesicle sizes (80-100 nm), decreases in surface 
ζ-potential by a factor of 10 and an enhancement in stability in presence of plasma 
proteins and divalent cations (e.g. Ca2+).139, 140  
Pharmacokinetics and biodistribution profiles of arsonolipids revealed that lipid 
composition had a significant effect on liposome stability and distribution after 
intraperitoneal administration.141, 142 For example, arsenic levels in the blood were much 
higher for pegylated-arsonoliposomes and mixed arsonoliposomes containing 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC; 11.1 – 21.7 % of injected dose at 2 h) 
than for those containing phosphatidylcholine (PC; 0.269 % of injected dose at 3 h). 
The intrinsic antiparasitic and anticancer activity of arsonoliposomes, focusing on 
compositions that include C16 arsonolipids (10/27 mol%), pegylated/non-pegylated 
phospholipids and cholesterol (2 : 1 lipid/cholesterol) have been studied in vitro and 
briefly in vivo. Antileishmanial activity was measured again two wild type and two drug-
resistant lines of Leishmania. Arsonolipids simply dispersed in DMSO were not active 
(IC50 > 100 μg.mL-1), while arsonoliposomes were active (IC50 0.21 – 5.88 μM) with 
greater activity exhibited against the resistant Leishmania. Structurally, the mixed 
arsonolipids were also show to be more active than the liposomes composed entire of 
arsonolipids.143 This trend was also observed against an acute strain of Trypanosoma 
brucei brucei which inspired further in vitro and in vivo evaluation against a chronic 
trypanosome model. Here the liposome composition had a significant effect on the 
antitrypanosomal activity with the PC-based mixed arsonoliposomes showing activity 
against the acute strain model whilst more stable DSPC-based mixed arsonolip ids, 
hypothesized to be more suitable for treatment of the chronic infection, were inactive.1 4 4  
This contradiction of the pharmacokinetics reported141, 142 indicates that the balance 
between vesicle membrane fluidity (PC vs DSPC) and hematological stability is crucial 
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to maximize activity which implies that pegylated PC-based arsonolipids could be 
candidates for treatment of chronic Trypanosoma strains. 
Thus far anticancer activity of arsonoliposomes has only been evaluated in vitro with 
particular focus on the effects of the arsonolipid components137 and the overall liposome 
composition.145 Activity has been measured against two ‘normal’ cell lines (HUVEC, 
RAME) and a range of cancer cells with conventional phospholipid analogues employed 
as As-free controls.145, 146 In line antiparasitic activity, unformulated arsonolipids were 
not active.130 Conversely, the preliminary results relating to all arsonoliposomes studied 
validates the working hypothesis that the presence of arsenic in the vesicle membrane 
activates arsonoliposomes against cancer cells to much greater extent than ‘normal’ cells 
(e.g. IC50 HL-60 = 0.85 μM; IC50 HUVEC = 253 μM). A general mechanism of 
arsonoliposome toxicity is currently unknown, with C12-based formulations causing cell 
death by apoptosis in a similar fashion to ATO, whilst C14,16,18-based formulations show 
little evidence of apoptosis. Arsonoliposomes do show enhanced interactions with cancer 
cells (HL-60) compared to ‘normal’ cells (HUVEC),145 which is opposite to what has 
been reported for conventional phospholipid-based liposomes,147 and this could be 
attributed, in part, to the enhanced cellular uptake and toxicity effects of arsonoliposomes. 
The reactivity of arsonic acid groups, present on the vesicle surface, for thiol groups has 
also been implicated as a trigger for site specific activity via destabilization of the vesicles 
at cancer cells which possess higher local concentrations of thiol containing reagents such 
as GSH.148 The potential of combining the intrinsic anticancer activity of the 
arsonoliposomes with the loading of synergistic therapeutics (through control of the 





1.6 Conclusions and outlook 
Though the use of arsenicals in polymer and biomaterials science is not widespread, there 
are examples of main-chain, side-chain and end-group functional polymeric arsenicals 
that have been employed for applications ranging from macromolecular 
chemotherapeutics to flocculants. Appreciation for the distinctive reactivity of the As(V) 
and As(III) has further been exploited to prepare conjugated vinylene-arsine polymers 
and highly specific thiol reactive polymeric arsenical scaffolds. Higher order structures 
including arsenoliposomes and self-assembled polymeric arsenical nanoparticles, with 
intrinsic bioactivity and/or drug delivery capabilities have also been prepared from 
discrete arsonolipids and block copolymeric arsenicals respectively. The latter are 
synthetically accessible through the advances made in RDRP over recent years. We and 
others have only just started to prepare well-defined As-functional materials, so there is 
still much, and we are excited to learn about the physiochemical and biochemica l 
properties of these polymers and nanoparticles.  
The most recognized application of organic arsenicals is in bio-imaging which has been 
achieved using pro-fluorescent bis-arsenicals, radiolabelled polymeric arsenicals and 
radio-labeled protein/antibody-As conjugates. In all cases, the imaging output relies on 
the affinity of As(III) for thiols, either through simple conjugation of the imaging motif 
to a synthetic or biological scaffold, or through targeting engineered protein sequences 
for highly specific, thermodynamically driven labelling. The notion of affinity/avidity in 
relation to As-(poly)thiol interactions and the chelate effect has been demonstrated using 
organic arsenicals, whereby bis- and tris-arsenicals bind (di)thiol rich proteins more 
strongly than mono-arsenical adducts. It is this correlation between protein sequences (i.e. 
(di)thiol distribution) and (poly)arsenical affinity/specificity that is perhaps the most 
stimulating area of future research. In light of what is already known regarding the 
chemotherapeutic (and indeed cytotoxic) mechanism of action of organic arsenicals, there 
is great potential in combining the chemical and biological activity of arsenic to develop 
of a new platform of reactive/responsive polymers and nanomaterials. Thus, it is possible 
to imagine that arsenical spacing and distribution can be controlled through the synthet ic 
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strategy, whilst the reactivity of the arsenicals (As(V) vs As(III)), and therefore the 
specificity for a given protein or family of proteins could be temporally controlled, 
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Chapter 2 : Synthesis, aggregation and responsivity of 
block copolymers containing organic arsenicals 
 
 
The materials presented in this chapter is directly reproduced from a communication with 
permission from the publishers, where I was the first Author: Polym. Chem., 2018, 9, 
1551–1556. This was published together with Seiji Tani (I supervised during his MSc 
project and has carried out earlier investigation presented in this work in the 2016-17 
academic year, Raoul Peltier (who has carried out the XTT presented in this work), Emily 
H. Pilkington (who has carried out the TEM presented in this work), Andrew Kerr (who 
has carried out the AFM presented in this work), Thomas P. Davis (collaborator) and Paul 
Wilson (supervisor and corresponding author). 
 
Abstract 
Block copolymers containing an organic arsenical (AsAm) have been synthesised by 
aqueous SET-LRP. The block copolymers are pH and thermoresponsive, forming 
nanoparticles in aqueous solution. Under reductive conditions the particles are stabilised 
through the formation of As-As bonds and stability can be tuned as a function of the 






Living systems crosslink (bio)macromolecules in order to stabilise intra- and 
intermolecular interactions, supporting complex tertiary and quaternary structures and 
self-assembled (bio)macromolecular complexes. Such biochemical processes have 
inspired the development of a chemical platform to control the properties and function of 
polymers through crosslinking. Crosslinking synthetic linear polymers not only alters 
physical properties such as glass transition temperature, it has been exploited to create 
architectures beyond one dimensional linear structures such as single chain 
nanoparticles,1, 2 star/branched polymers,3, 4 and nanogels.5 In particular, responsive 
materials that utilise reversible covalent bond formation that can be uncrosslinked on 
demand by specific environmental triggers are attractive targets for drug delivery, 
sustainability and chemical sensors.6 In a biological context, boronate esters have been 
demonstrated by Sumerlin et al. as a pH and sugar responsive cross-linker to form 
hydrogels,7, 8 with self-healing properties in acidic environment, and self-assembled 
particles that dissemble in presence of sugars.9-11 Other types of dynamic cross-linking 
such as hydrazones12, 13 and disulfides14, 15 are reported in the literature for intracellular 
drug delivery in response to endosomal pH and redox environment. 
 
Scheme 2.1 Oxidation states of Arsenic as monovalent arsines (As(I)), trivalent arsenous acid 
(As(III)) and pentavalent arsenic acid (As(V)). 
 
Arsenic is an interesting candidate for dynamic cross-linking, due to its interchangeab le 
oxidation states each with distinct chemical reactivity. For example, pentavalent arsenic 
(As(V)) will not form covalent bonds with thiols, preferring to undergo single electron 
transfer reduction. Trivalent arsenic (As(III)) can be formed from the reduction of As(V) 
by two equivalents of thiol and in this oxidation state arsenic has a high affinity for thiols, 
readily forming covalent As-S bonds, which is markedly enhanced for dithiol reagents.1 6  
The affinity for mono- and dithiols has been exploited for post-polymerisa t ion 
modification and protein/peptide-polymer conjugation of As-functional polymer 
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scaffolds.17, 18 Under stronger reducing conditions, As(V) can be directly reduced to As(I), 
which has been reported to proceed with reductive coupling to form Asn homocycles 
comprised of As-As bonds (Scheme 2-1).19 The As-As bonds are weak but have been 
exploited in synthesis for the preparation of salvarsan20 and as a source of monomer for 
‘ring-collapsed radical alternating copolymerisation’ to form poly(vinylene arsines).21-25 
 
Until recently, the polymerisation of As-functional monomers by chain-growth 
polymerisation was only reported by free radical polymerisation.26-30 The advent of 
reversible deactivation radical polymerisation (RDRP) techniques such as Reversible 
Addition-Fragmentation chain-Transfer (RAFT),31 atom transfer radical polymerisa t ion 
(ATRP)32, 33 and single electron transfer living radical polymerisation (SET-LRP)34  
enables exquisite control of chain-end functionality which has been harnessed for the 
synthesis of well-defined (multi)block copolymers.35, 36 In previous work, a protected As-
functional monomer, prepared in a two-step synthesis from p-arsanilic acid, was 
employed to prepare As-functional homo- and copolymers by RAFT.17 In order to access 
the interesting reactivity of the pendant As-functional groups, the resulting polymers 
require an additional post-polymerisation processing step to afford deprotection. It would 
be beneficial to develop a method through which an As-functional monomer could be 
incorporated into polymers without the need for the additional protection (monomer) - 
deprotection (polymer) steps. 
 
In this chapter, the synthesis of block copolymers containing an As(V)-functiona l 
monomer (AsAm) by aqueous SET-LRP is reported. At elevated temperatures As(V)-
functional nanoparticles are formed which, for the first time, are stabilised by crosslink ing 
through the reductive coupling of As(V) to give As(I)n. The stability of the resulting 
particles as a function of the AsAm monomer feed is also investigated in aqueous and 
model biological solutions. 
 
2.2 Results and Discussion 
2.2.1 Polymeric arsenical synthesis 
Poly(ethylene glycol) methyl ether acrylate (PEGA, Mn = 480 g.mol-1) and N-
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isopropylacrylamide (NIPAm) are hydrophilic monomers that have been successfully 
polymerised by aqueous SET-LRP previously. Therefore, PEGA was selected as the 
corona-forming block and NIPAm, with its ability to undergo phase transition at elevated 
temperatures (LCST = 32 °C), was selected as the core-forming block. For optimal chain 
extension and block efficiency, the PEGA blocks (DPn,th = 20) were synthesised first then 
chain extended with NIPAm (DPn,th = 80) via one-pot, sequential chain extension in 
accordance with previous work.35 The incorporation of As-functionality was achieved by 
statistical copolymerisation of varying amounts of AsAm in either the PEGA or NIPAM 
block, whilst keeping the overall chain length of the polymer constant (DPn = 100, 
Scheme 2.2).  
 
 
Scheme 2.2 Synthesis of As-functional block copolymers by aqueous SET-LRP 
 
Initially, a non-As functional control polymer PEGA20-b-NIPAm80 was synthesised with 
homopolymerisation of PEGA in water, complete within 15 mins (>99% conv., Mn,SEC = 
11800 g.mol-1, Đ = 1.07). Addition of a deoxygenated aliquot of NIPAm then furnished 
the targeted block copolymer PEGA20-b-NIPAm80 (P2.1, 98% conv., Mn,SEC = 25400 




































Figure 2.1 1H NMR spectrum (top) and GPC (DMF, bottom) chromatogram of PEGA20-b-
NIPAm80; P2.1, Mn,th = 19400 gmol
-1, Mn,SEC
  =25400 gmol-1, D = 1.27 
 
Arsenical monomer, 4-(N-acrylamido)phenylarsonic acid (AsAm), was then incorporated 
into corona-/core-forming blocks by altering the monomer feed ratio of either the first 
block (PEGA20-n-co-AsAmn, P2.2 n = 3, P2.3 n = 5) or the chain extension (NIPAm80-n-
co-AsAmn, P2.4 n = 5, P2.5 n = 10). Successful inclusion of AsAm into the block 
copolymer was confirmed by 1H NMR with appearance of aromatic signals of AsAm (Hj,k 
(P2.2, P2.3) and Hl,m (P2.4, P2.5) Figure 2.2) at 7.5-7.7 ppm in addition to the signals 
corresponding to PEGA (Hg,i) and NIPAm (Hl,m (P2.2, P2.3) and Hj,k (P2.4, P2.5)). The 
relative integrals were translated into an experimental polymer composition which 
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confirmed the desired increase in AsAm content as a function of the AsAm monomer feed 
ratio (Figure 2.2, Table 2.3).  
 







































































Figure 2.2 1H NMR of (PEGA20-n-co-AsAmn)-b -NIPAm80 (P2.2, n = 3; P2.3 n = 5) (top) and PEGA20-
b-(NIPAm80-n-co-AsAmn) (P2.4, n = 5; P2.5, n = 10) 
 
 
Block copolymerisation was confirmed by SEC analysis (Figure 2.3) which showed a 
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shift to higher molecular weight upon chain extension. Increasing the amount of AsAm 
in either block appeared to have a detrimental effect on the control of the polymerisa t ion 
as indicated by deviations in theoretical (Mn,th) and experimental number average 
molecular weight (Mn,SEC) and higher dispersities (P2.2-P2.5, Đ = 1.2 – 1.8) than expected 
from aqueous SET-LRP polymerisations (Table 2.1).  

































































Figure 2.3 GPC (DMF) chromatogram (top left) P2.2: block 1 Mn,th = 9200 gmol
-1, Mn,SEC
  =11100 
gmol-1, D = 1.51 (black) and block 2 Mn,th = 19400 gmol
-1, Mn,SEC
  =25100 gmol-1, D = 1.41 (red); (top 
right) P2.3: block 1 Mn,th = 8800 gmol
-1, Mn,SEC
  =16500 gmol-1, D = 1.51 (black) and block 2 Mn,th = 
19000 gmol-1, Mn,SEC
  =37500 gmol-1, D = 1.81 (red); (bottom left) P2.4: block 1 Mn,th = 9800 gmol
-1, 
Mn,SEC
  =7900 gmol-1, D = 1.13 (black) and block 2 Mn,th = 20700 gmol
-1, Mn,SEC
  = 20000 gmol-1, D = 
1.19 (red); (bottom right) P2.5: block 1 Mn,th = 9800 gmol
-1, Mn,SEC
  =10100 gmol-1, D = 1.16 (black) 
and  block 2 Mn,th = 21500 gmol
-1, Mn,SEC
  =26000 gmol-1, D = 1.19 (red) 
2.2.2 Thermoself-assembly  
The thermoresponsive behaviour and propensity for aggregation for each polymer was 
investigated by variable temperature dynamic light scattering (DLS) of aqueous solutions 
of the polymers (1 mg/ml) at 5 °C intervals between 25-60 °C. PNIPAm80 synthesised by 
aqueous SET-LRP underwent macroscopic precipitation as expected between 35-40 °C 
(Figure 2.4), whereas the control block copolymer P2.1 formed small aggregates with 










































Figure 2.4  GPC (DMF) chromatogram (top) and thermoresponsive behaviour by DLS (bottom) of 
P(NIPAM)80, Mn,th = 9300 gmol
-1 MnSEC = 14500 gmol
-1, D = 1.15 in aqueous solution (1 mg/ml) (see 












































Figure 2.5 Hydrodynamic diameter (number % ) as a function of temperature and intensity, 
number and volume distributions of P2.1, PEGA20-b-NIPAM80 in aqueous solution (1 mg/ml) (see 
Appendix C, S2.5 for supporting information). 
 
Incorporation of AsAm into the corona-forming block also resulted in the formation of 
nanoparticles the size of which increased as a function of the AsAm monomer feed (P2.2, 
Dh = 20 nm; P2.3, Dh = 33 nm, Figure 2.6).  
 







































































































Figure 2.6 DLS, particle size as a function of temperature of P2.2, (PEGA17-co-AsAm3)-b-NIPAM80 
(left) and P2.3, (PEGA15-co-AsAm5)-b-NIPAM80 (right) in aqueous solution (1 mg/ml) (see Appendix 
C, S2.6 for supporting information). 
 
































Figure 2.7 Particle size as a function of temperature for PEGA20-b-(NIPAM80-n-co-AsAmn) in 
aqueous solution (1 mg/ml) (see Appendix C, S2.7A and S2.7B for supporting information). 
 
However, when AsAm was incorporated into the core-forming NIPAm block (P2.4 and 
P2.5) no self-assembly was observed (Dh = 4 nm, Figure 2.7). Under the reaction 
conditions the pendent arsenic acid group of AsAm is ionised (Na+ salt) and hydrophil ic. 
It was hypothesised that incorporation into the NIPAm block precluded the expected 
phase transition. Consequently, the pH of the polymer solutions was measured and found 
to be 10.3. Acidification of the polymer (P2.4) solution using HCl to close to neutral (pH 
= 6.6) had little effect resulting in no particle formation (Dh = 8 nm). However, further 
acidification to pH = 2.5, which is closer to the pKa of arsenic acid (pKa1 ≈ 2)37 results in 
protonation of the arsenic acid groups leading to the formation of particles with Dh = 30 
nm (Figure 2.8). In an identical titration, polymers P2.2 and P2.3 underwent self-
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assembly across the pH range forming nanoparticles, the sizes of which increased as the 
pH decreased (pH 10.3 = 48 nm; pH 2.5 = 98 nm, Figure 2.8).  
 
 
Figure 2.8 Changes in hydrodynamic diameter of (PEGA15-co-AsAm5)-b-NIPAM80 (P2.3, left) and  
PEGA20-b-(NIPAM70-co-AsAm10) (P2.5, right) between 25 °C and 60 °C as a function of pH in 
aqueous solution (1 mg/ml) (see Appendix C, S2.8A and S2.8B for supporting information). 
 
2.2.3 As(I) stabilised nanoparticles 
In pure aqueous solution all the nanoparticles formed from P2.1 – P2.5 dissembled upon 
rehydration of the NIPAm block on cooling to 25 °C. Under reducing conditions (aqueous 
H3PO2), the pendent arsenic acid group (As(V)) can undergo reductive coupling to 
As(I),19 with formation of As-As bonds in the form of Asn homocycles. It was 
hypothesised that reductive coupling could provide a novel approach to crosslinking and 
stabilisation of the organic arsenical copolymer nanoparticles derived from P2.2 – P2.5. 
The polymers (10 mg/ml) were dissolved in an aqueous solution of H3PO2 prior to heating 
at 60 °C to facilitate both self-assembly and reduction processes. Under these conditions 
both P2.2 and P2.3 formed particles with Dh of the order of 40 nm and 80 nm respectively 
by DLS. However, the presence of the AsAm (n = 3, 5) in the corona-forming block was 
not sufficient to stabilise the particles formed after heating for 10 – 90 minutes, in line 
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with previous methods employed to achieve reductive coupling.20 Disassembly was 
observed within 10 minutes upon cooling back to 25 °C (Figure 2.9).  
































Figure 2.9 Temporal changes in the particle size of the cross-linked particles of (PEGA20-n-co-
AsAmn)-b-NIPAM80 (P2.2, P2.3) after heating in hypophosphorous solution (10 mins, 10 mg/ml). 
DLS cell was heated from 25 – 60 °C over 120 secs followed by 60 secs equilibration time before 
being held at 60 °C for 10 – 90 mins. Cooling of the cell occurred over 120 secs followed by 60 secs 
equilibration after which measurement of stability commenced (t = 0, 25 °C) (see Appendix C, 
S2.9A and S2.9B for supporting information). 
 
 
Conversely, when AsAm was confined to the more densely packed core of the particles 
derived from P2.4 (NPAs-5) and P2.5 (NPAs-10), the particles formed (Dh = 45 nm) upon 
heating at 60 °C in the presence of H3PO2 retained their assembled structure upon cooling 
for up to 60 minutes, suggesting successful crosslinking through the formation of As-As 





Figure 2.10 Temporal changes in the particle s ize of the cross-linked particles of PEGA20-b-
(NIPAm80-n-co-AsAmn)  (P2.4, P2.5) after heating in hypophosphorous (10 mg/ml). DLS cell was 
heated from 25 – 60 °C over 120 secs followed by 60 secs equilibration time before being held at 
60 °C for 30 mins (P2.4, red) and 10 mins (P2.5, blue) respectively. Cooling of the cell occurred over 
120 secs followed by 60 secs equilibration after which measurement of stability commenced (t = 0, 
25 °C) (see Appendix C, S2.10A and S2.10B for supporting information).   
 
The nature of the crosslinking was inferred from IR spectroscopy through disappearance 
of the As-O signals associated with the pendent arsenic acid (As(V)) moieties (Figure 
2.11). Increasing the amount of AsAm in the monomer feed from P2.4 (n = 5) to P2.5 (n 
= 10) resulted in the formation of more stable particles, with P2.5 forming stable particles 
after only 10 minutes of crosslinking, whereas P2.4 required at least 30 minutes to form 








































Figure 2.11 IR spectrum of purified PEGA20-b-(NIPAm70-co-AsAm10) (P2.4) showing 
disappearance of the As-O signals upon crosslinking via reductive coupling in H3PO2.   
 


















Time after heating (min)
 60 °C for 10 min
 60 °C for 30 min
25°C
 
Figure 2.12 Stability of particles derived from PEGA20-b-(NIPAM75-co-AsAm5) (P2.4) after heating 
at 60 °C in aqueous H3PO2 for 10 mins and 30 mins. DLS cell was heated from 25 – 60 °C for 120 
secs followed by 60 secs equilibration time before being held at 60 °C for 10 mins (black) and 30 
mins (red) respectively. Cooling of the cell occurred over 120 secs followed by 60 secs equilibration 
after which measurement of stability commenced (t = 0, 25 °C) (see Appendix C, S2.12 for 





The particles formed from P2.5 (NPAs-10) exhibited thermoresponsive character, 
reversibly contracting and swelling upon heating and cooling cycles (Figure 2.13), in 
accordance with the transition of the core from a hydrophobic to hydrophilic state 
respectively. 
 
Table 2.1 As-functional block copolymers synthesised by aqueous SET-LRP. 1H NMR in D2O. SEC 
in DMF. 
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Figure 2.13 Reversible contracting and swelling of particles derived from PEGA20-b-(NIPAM70-co-
AsAm10) at 60 °C and 25 °C respectively in aqueous H3PO2 (10 mg/ml) (see Appendix C, S2.13 for 
supporting information). 
 
The enhanced stability of NPAs-10 was further confirmed following purification and re-
dispersion of the crosslinked particles in deionised water (1 mg/ml, Figure 2.14). Whereas 
NPAs-5 was shown to disassemble during the purification process (dialysis against 
Entry Structures 










 Control         
P2.1 PEGA20-b-NIPAm80 > 99% 9800 11800 1.07 98% 20000 25400 1.27 
          
P2.2 (PEGA17-s-AsAm3)-b-NIPAm80 > 99% 9200 11100 1.51 > 99% 19400 25100 1.41 
P2.3 (PEGA15-s-AsAm5)-b-NIPAm80 > 99% 8800 16500 1.29 > 99% 19000 37500 1.81 
          
P2.4 PEGA20 -b-(NIPAm75-s-AsAm5) > 99% 9800 7900 1.13 > 99% 20700 20000 1.49 
P2.5 PEGA20 -b-(NIPAm70-s-AsAm10) > 99% 9800 10100 1.16 > 99% 21500 26000 1.19 
P2.6 PEGA20 -b-(NIPAm65-s-AsAm15) > 99% 9800 9200 1.18 > 99% 22200 21000 1.42 
P2.7 PEGA20 -b-(NIPAm60-s-AsAm20) > 99% 9800 9200 1.22 > 99% 22900 25600 1.57 
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deionised water), NPAs-10 retained its self-assembled structure and thermorespons ive 
properties (Figure 2.15). Transmission electron microscopy (TEM) and atomic force 
microscopy (AFM) of NPAs-10 confirmed the formation of nanoparticles with sizes < 100 
















































Figure 2.14 The size distribution curves of the cross-linked nanoparticles formed from PEGA20-b-
(NIPAM70-co-AsAm10) in deionised water after dialysis at the temperatures of 25 °C and 60 °C. (see 


























Figure 2.15 Reversible contracting and swelling of the purified particles derived from PEGA20-b-






Figure 2.16 A) Schematic for the simultaneous self-assembly and reductive cross-linking of 
PEGA20-b-(NIPAM70-co-AsAm10) (P2.5) in H3PO2; B) Particle size distribution curves (DLS, 1 
mg/ml, H2O) of PEGA20-b-(NIPAM70-co-AsAm10) P2.5 (black) and the corresponding corsslinked 
nanoparticle NPAs-10 (red); C) TEM image of NPAs-10 (scale bar = 500 nm); D) AFM image if NPAS-10 
(scale bar = 500 nm) (see Appendix C, S2.16 for supporting information).  
 
Two additional polymers were then synthesised to investigate the effect of AsAm 
monomer feed on self-assembly and particle stability. Thus, PEGA20-b-NIPAm80-n-co-
AsAmn (P2.6, n = 15; P2.7, n = 20) were prepared. These were treated with Hydrochlor ic 
acid to deionise the polymer before dialysis. In line with the previous syntheses both 
blocks reached high conversion (> 99%), the presence of each monomer was confirmed 
by 1H NMR (Figure 2.17) and successful chain extension was confirmed by SEC analysis 
(Figure 2.18). The experimental monomer feed was again confirmed by 1H NMR (Table 
2.2); the PEGA feed was determined by t = 0 of the residual reaction mixture, NIPAm 
was calculated from side chain CH (Hj, Fig 2.17) w.r.t PEGA methoxy CH3 (Hi, Fig 2.17) 
and AsAm was calculated from the aromatic protons (Hl,m, Fig 2.17).This was supported 
by cryo-probe 13C NMR which was performed to quantitatively confirm the AsAm 
monomer feed ratio present in the block copolymers capable of forming self-assembled 
nanoparticles (P2.4-P2.7, Figure 2.19, Table 2.2). Backbone secondary carbon, CH2 
(Ca,c,e, Fig 2.19), was used as a reference to calculate the relative monomer feed by 
comparing side chain carbons. Depending on the choice of the carbon the monomer feed 
varied slightly, however successive increase in overall AsAm was consistent with targete d 
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polymer composition (Table 2.2).   

























Figure 2.17  1H NMR spectrum of PEGA20-b-(NIPAM65-co-AsAm15) (P2.6, top) and PEGA20-b-
(NIPAM65-co-AsAm15) (P2.7, bottom) 















































Figure 2.18 GPC (DMF) chromatogram of P(PEGA20) Mn,th = 9800 gmol
-1, Mn,SEC = 9200 gmol
-1, D = 
1.18 and PEGA20-b-(NIPAM65-co-AsAm15) Mn,th = 22200 gmol
-1, Mn,SEC
  =21000 gmol-1, D = 1.42 
(P2.6, left); P(PEGA20) Mn,th = 9800 gmol
-1, Mn,SEC
  =9200 gmol-1, D = 1.22 and (PEGA20-b-(NIPAM60-
co-AsAm20) Mn,th = 22900 gmol
-1, Mn,SEC
  =25600 gmol-1, D = 1.57 (P2.7, right). 
 
Table 2.2 Experimental polymer chomposition based on 1H NMR  
 PEGA NIPAM AsAm 
Entry Theoretical 1H NMR Theoretical 1H NMR Theoretical 1H NMR 
P2.1 20 15.1 80 84.9 0 0 
P2.2 17 15.3 80 82.4 3 2.3 
P2.3 15 13.7 80 83.6 5 2.7 
P2.4 20 13.7 75 82.2 5 4.1 
P2.5 20 15.9 70 74.6 10 9.5 
P2.6 20 18.3 65 71.5 15 14.3 





















Figure 2.19 Cryoprobe 13C NMR spectrum of PEGA20-b-NIPAm80 (P2.1) and PEGA20 -b-
(NIPAm80-n-co-As Amn) (P2.4 n = 5; P2.5 n = 10; P2.6 n = 15; P2.7 n = 20) 
 
Table 2.3:  Table of summary polymer composition based on cryoprobe 13C NMR (Figure 2.37) 
 
AsAm content % NIPAM content % PEGA content % 
Theoretical  ∫ o ∫ p Theoretical  ∫ m ∫ l Theoretical  ∫ h ∫ j 
P2.1 0 0 0 80 89 97 20 16 23 
P2.4 5 3 4 75 78 83 20 13 17 
P2.5 10 9 9 70 76 72 20 14 16 
P2.6 15 14 14 65 68 68 20 19 26 
P2.7 20 17 20 60 70 74 20 21 24 
 Monomer % based on integrals of a,c and e at ∫32.5 – 38.0 ppm as a constant. 
 
Owing to the deionisation treatment, P2.6 and P2.7 underwent self-assembly in aqueous 
solution at elevated temperature (Figure 2.20). P2.6 self-assembled at lower temperature 
(40 °C) than P2.7 with higher AsAm content (45 °C), as a result of incorporation of AsAm 
into the NIPAm block. Nevertheless, the temperature for the self-assembly occurred at 




































































Figure 2.20 Thermal-induced self-assembly of PEGA20-b-(NIPAM65-co-AsAm15) (P2.6, left) and 
PEGA20-b-(NIPAM60-co-AsAm20) (P2.7, right). Hydrodynamic diameter (number % ) versus 
temperature plotted (see Appendix C, S2.20A and S2.20B for supporting information). 
 
Under the same conditions as P2.5, the following polymers P2.6 and P2.7 were cross-
linked, as expected, the resulting nanoparticles were sufficiently stabilised through 
reductive coupling to be re-dispersed in water, whereby the stabilised particles (NPAs-10, 
NPAs-15, NPAs-20) were analysed by DLS (Figure 2.21), TEM, and AFM (Figure 2.22 and 
Figure 2.23). The data obtained for NPAs-15 was in good agreement revealing particle sizes 
< 50 nm whereas for NPAs-20 DLS and AFM were in good agreement but the TEM 
revealed much larger particle sizes (≈ 200 nm). However, in the absence of staining with 
uranyl acetate, TEM of NPAs-20 furnished smaller particles with sizes comparable to those 
obtained from DLS and AFM (Figure 2.24).  
 
Table 2.4 Light scattering (DLS, SLS) of NPAs-10, NPAs-15, NPAs-20. DLS measured in aqueous solution 
(1 mg/ml). SLS measured at variable concentration (Figure 2.25). Mw,NP was determined using Eq 















P2.5 NPAs-10 0.144 1.33 × 106 62 32 43 0.06 
P2.6 NPAs-15 0.176 1.13 × 106 51 28 26 0.06 
P2.7 NPAs-20 0.129 4.00 × 106 148 15 36 0.05 
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Figure 2.21 Particle size distribution (DLS) curves for NPAs-10(black), NPAs-15(red), NPAs-20(blue) 
(Table 2.4) (see Appendix C, S2.21 for supporting information). 
 
 
        
 
Figure 2.22 Representative TEM (left) and AFM (right) of NPAs-15. TEM stained with uranyl 








            
 
Figure 2.23 Representative TEM (left) and AFM (right) of NPAs-20. TEM stained with uranyl 
acetate. Scale = 100 nm 
 
 
Figure 2.24 Representative TEM without staining (left) of NPAs-20. Scale = 100 nm 
 
To determine more accurate particle size data (Radius of gyration - Rg, aggregation 
number - Nagg and nanoparticle molecular weight - Mw,NP) static light scattering (SLS) 
was performed (Figure 2.25), where multiple scattering angles were measured as function 
of concentration to extrapolate the molecular weight at infinite dilutions (Fig 2.25). 
According to SLS analysis, particles NPAs-10 and NPAs-15 were similar, whereas increasing 
the AsAm monomer feed to n = 20 (NPAs-20) resulted in the formation of more densely 
packed particles as indicated by the increase in the Mw,NP (1 x 106 – 4 x 106 g/mol) and 
Nagg (62 -148), which coincided with a decrease in the Dh obtained from DLS (43 – 36 








































































































































































Figure 2.25 Evolution of KC/R in water as function of q2 and concentration for NPAs-10 (top), 
NPAs-15 (middle), NPAs-20 (bottom), obtained by SLS. 
 
The relative stabilities of NPAs-10, NPAs-15 and NPAs-20, were initially investigated in 
aqueous solution at 37 °C, in which NPAs-10 was found to be stable for 48 hours where 
NPAs-15 and NPAs-20 remained stable for at least 96 hours (Figure 2.26).  
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Figure 2.26 Particle size distribution curves of NPAs-10 (left), NPAs-15 (centre), NPAs-20 
(right) as a function of time in aqueous solution (1 mg/ml) (see Appendix C, S2.26A, S2.26B 
and S2.26C for supporting information). 
 
In aqueous glutathione (GSH) at a concentration mimicking intracellular conditions 
([GSH] = 5 mM), further differentiation in particle stability was observed. NPAs-10 was 
stable for only 1 hr with the majority of the nanoparticles undergoing disassembly within 
3 hrs. The faster rate of disassembly was mirrored by NPAs-15 and NPAs-20 which 
disassembled within 12 hrs and 20 hrs respectively (Figure 2.27). The enhanced rate of 
disassembly is attributed to the formation of more enthalpically favoured As-S bonds in 
favour of the weak As-As bonds originally formed through reductive coupling. The trend 
suggests that particle stability can be tuned by adjusting the AsAm monomer feed which 





















































































Figure 2.27 Particle size distribution (DLS), illustrating the relative stability of NPAs-10 (left), NPAs-15 
(centre) and NPAs-20 (right) in aqueous GSH (5 mM, 1 mg/ml) (see Appendix C, S2.27A, S2.27B and 
S2.27C for supporting information) 
 
Finally, the stability was investigated under aggressive oxidative conditions (aqueous 
H2O2, 5 mM). Under these conditions all nanoparticles were completely disassembled 
within 1 hr (Figure 2.28). As the particles were originally crosslinked via reductive 
coupling, it is likely that disassembly occurs under the strong oxidative conditions in 
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Figure 2.28 Particle size distribution curves of NPAs-10 (left), NPAs-15 (centre), NPAs-20 (right) as a 
function of time in aqueous H2O2 (5 mM, 1 mg/ml) (see Appendix C, S2.28A, S2.28B and S2.28C for 
supporting information) 
 
2.2.4 Cytoxicity of the polymeric arsenical nanoparticles 
Considering the successful synthesis, self-assembly and responsive crosslinking of As-
functional block copolymers and with potential biomedical applications in mind, 
evaluation of their toxicity is essential. It has recently been reported that polymeric 
arsenicals exhibit limited toxicity in vitro.17, 18 Here, the acute toxicity of the As-
functional block copolymers (P2.2-P2.7) and the nanoparticles (NPAs-10, NPAs-15, NPAs-
20) were determined in vitro via a standard XTT assay using the human PC3 cell line as 
model. PC3 (human prostate carcinoma) cells were obtained from the European 
Collection of Cell Cultures (ECACC). Pleasingly, it was found that all polymers (P2.2-
P2.7) and their associated nanoparticles (NPAs-10, NPAs-15, NPAs-20) were not toxic at 
























































Figure 2.29 In vitro cell viability of polymers P2.1-P2.7 (top) and nanoparticles NPAs-10, NPAs-15, 





Block copolymers containing an As-functional monomer (AsAm) have been synthes ised 
by aqueous SET-LRP. Various amounts of AsAm have been incorporating into the 
hydrophilic corona-forming block ((PEGA20-n-co-AsAmn)-b-NIPAm80) or the 
thermoresponsive core-forming block (PEGA20-b-NIPAm80-n-co-AsAmn)). The block 
copolymers undergo self-assembly at elevated temperatures (60 °C) to form nanopartic les 
(Dh < 50 nm). Reductive coupling of pendent arsenic acid (As(V)) functional groups has 
been investigated for the first time for crosslinking and stabilisation. The presence of 
AsAm in the corona forming block (n = 3, 5) is insufficient for particle stabilisation upon 
cooling to ambient temperature. Conversely, incorporation of AsAm (n = 5, 10, 15, 20) 
into the more densely packed core of the nanoparticles affords particles that are stable 
upon cooling to ambient temperature. The nanoparticles and the polymers they are 
derived from are non-toxic and the stability of the nanoparticles in aqueous solution and 
model biological solutions (GSH, H2O2) increases as a function of the AsAm monomer 
feed, both of which we believe could be advantageous of biomedical applications. 
 
2.4 Experimental 
2.4.1 Materials and methods 
p-Arsanilic acid, acryloyl chloride, glutathione (GSH), hypophosphorous acid (50%), N-
Isopropylacrylamide (NIPAm, 97%) and poly(ethylene glycol) methyl ether acrylate 
(PEGA, average Mn = 480) were purchased from Sigma Aldrich and used as received. 
HPLC grade water (H2O, VWR international, LLC) was used as the solvent for 
disproportionation and polymerisation. Copper(I) bromide (CuBr, 98%, Sigma-Aldr ich) 
was purified prior to use via sequentially washing with acetic acid and ethanol and then 
dried under vacuum. Tris(2-(dimethylamino)ethyl)amine1 and 2,3-dihydroxypropyl 2-
bromo-2-methylpropanoate2 were prepared as reported in the literature. was synthesized 
according to the literature procedure. Membrane dialysis tubing (nMWCO 3.5 kDa) was 
obtained from Spectrum Laboratories. All other solvents and reagents were purchased 
from commercial suppliers (Sigma-Aldrich, Fisher Scientific) and use as received unless 
otherwise stated.  
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Nuclear Magnetic Resonance (NMR) spectroscopy  (1H  NMR)  spectra  were  recorded  
on  a  Bruker HD  300  spectrometer  (300  MHz) at  27  °C  in deuterated water (D2O). 
Chemical shift values (δppm) are reported in ppm. The residual proton signal of the solvent 
(δH = 4.79 ppm) was used as internal reference. ACDLABS software was used to analyse 
the data obtained. Number-average molar masses (Mn,SEC) and dispersity values (Ð) were 
determined using Size exclusion Chromatography (SEC) with DMF as an eluent. SEC 
analysis was conducted on Polymer Laboratories PL-GPC 50 Plus system using a Polar 
Gel-M guard column (7.5 × 50 mm) followed by two Polar Gel-M columns (7.5 ×300 
mm). DMF (0.1% LiBr) was used as eluent at 1.0 mL min−1 at 50 °C. All polymer samples 
were filtered through a nylon membrane with 0.45 μm pore size before injection (100 
μL). Commercial narrow linear poly(methyl methacrylate) (PMMA) standards in range 
of 2.0 × 102 − 1.0 × 106 gmol−1 were used to calibrate the DMF SEC system. The SEC 
data obtained were analysed using Agilent technologies GPC/SEC software to determine 
Mn,SEC and Ð based on the PMMA calibration. Hydrodynamic diameters (Dh) and size 
distributions were determined by Dynamic Light Scattering (DLS)  on  a  MALVERN 
Zetasizer  Nano  ZS operating  at  25 °C with  a  4 mW He-Ne 633 nm  laser  module. 
Measurements were made at a detection angle of 173° (back scattering). Measurements 
were repeated three times with automatic attenuation selection and measurement position. 
The results were analysed using Malvern DTS 6.20 software. PDI values were calculated 
using equation Eq 2.1 
PDI =  σ2/d2  (Eq 2.1) 
Where σ is the standard deviation, and d is the diameter, both obtained from the number 
distribution. 
2.4.2 Determination of Mw by Static Light Scattering.  
The incremental refractive index, dn/dC, was determined by measuring the refractive 
index of the polymer over a range of concentrations (1.33, 0.66, 0.33, 0.167 mg/ml) . The 
RI was determined using a Shodex RI detector, operating at a wavelength of 632 nm. 
Multiplying the gradient, of the plot of RI vs. concentration, by the refractive index of the 
solvent (water = 1.3325) and dividing by the RI constant of the instrument (−1398000) 
gives the dn/dC of the polymer (table 2.3). Light scattering measurements were obtained 
using an ALV-CGS3 system operating with a vertically polarized laser with the 
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wavelength λ = 632 nm. The measurements were taken at 20 °C over a range of scattering 
wave vectors (q = 4πnsin(θ/2)/λ, with θ being the angle of observation and n the refractive 









. 𝑅𝑡𝑜𝑙𝑢𝑒𝑛𝑒  (Eq 2.2) 
Where Isolution, Isolvent and Itoluene are the scattering intensities of the solution, solvent and 
reference (toluene) respectively, n is the refractive index (nwater= 1.333, ntoluene=1.496) and 
Rtoluene the Rayleigh ratio of toluene (Rtoluene= 1.35 × 10−5 cm−1 for λ = 632.8 nm). The 
optical constant, K, is defined by Eq 2.3, where Na is the Avogadro number and dn/dC is 










 (Eq 2.3) 
In all cases it was verified that the apparent radius of gyration of the systems verified q × 
Rg < 1. The Zimm approximation can thus be used to obtain Eq 2.4. Plotting KC/Rθ as a 
function of q2 for each concentration yielded the apparent radius of gyration Rg of the 
scatterers as well as their apparent molecular weight extrapolated to zero angle, Ma. 










) (Eq 2.4) 
At a given concentration the Rayleigh ratio, Rθ, is related to the apparent molecular 
weight of the sample, given by Eq 2.4. It is only at infinite dilutions, where the 
interactions between scattering particles are negligible, that the apparent molecular 
weight is equal to the true molecular weight. Multiple concentrations were measured and 
a plot of linear regression was used to determine the apparent molecular weight at a 
concentration of 0 mgml-1. 
 
2.4.3 Cell viability 
PC3 (human prostate cancer) cells were cultured in High Glucose DMEM medium 
supplemented with 10% fetal bovine serum. For cell viability evaluation, PC3 cells were 
seeded in a 96 well plate at a density of 1 × 104 cells per well. After 16 hours, the culture 
medium was replaced by fresh media containing a series of dilution of the polymers 
(0.0625, 0.125. 0.25, 0.5, 1 and 2 mg/ml), prepared from stock solutions in PBS at 500 
µM. Following 24 hours incubation, the medium was removed and replaced with fresh 
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medium. The cells were incubated with a freshly prepared solution of XTT (0.2 mg/mL-
1) and N-methyl dibenzopyrazine methyl sulfate (250 µM) in medium for 16 hours. 
Absorbance of the samples was finally measured using a plate reader at 450 nm and 650 
nm. The data presented are representative of a minimum of two independent experiments 
where each sample was measured in triplicate. Errors reported correspond to the standard 
deviation of the mean. 
 
2.4.4 Atomic Force Microscopy (AFM) 
AFM images were acquired in AC mode on a Cypher S system (Asylum Research). The 
probes used were the AC160TS from Olympus probes with a nominal resonant frequency 
of 300 kHz and a spring constant of approximately 40 N m-1 on a Multimode AFM 
(Asylum Research). Images were acquired at a pixel resolution of 512 and a scan rate of 
1 Hz. Samples were diluted to 0.1 mg mL-1 in water and 4 µL of solution was drop-
deposited onto freshly cleaved mica discs. The data were analyzed by the Asylum 
Research software. 
 
2.4.5 Transmission Electron Microscopy (TEM) 
Nanoparticle solutions at a concentration of 0.1 mg/ml were deposited as 5 μl aliquots on 
400 mesh carbon-coated Formvar copper grids and allowed to dry completely. Once dry, 
grids were stained with 1% aqueous uranyl acetate (UA) by touching the grid to 5 μl UA 
and drawing off stain immediately, followed by placing the grid atop a 5 μl drop of UA 
for 15 s in the dark, and drawing off excess liquid as before. Samples were imaged on a 
FEI Tecnai F20 transmission electron microscope, utilising a Gatan Ultrascan 1000 (2k x 
2k) CCD camera 
 
2.4.6 Synthetic procedures  




Potassium hydroxide (5.1 g, 91.8 mmol) was dissolved in deionised water (125 mL).  The 
mixture of  p-arsanilic acid (10.0 g, 46.1 mmol) and Na2CO3 (14.5 g, 137.1 mmol) was 
added portionwise to the KOH to afford dissolution.  Acryloyl chloride (5.6 mL, 68.9 
mmol), in dichloromethane (25 mL) was quickly added into the p-arsanilic acid solution 
at 0 °C. and stirred for 15 minutes.  The aqueous phase was collected are carefully 
acidified (to minimise effervescence) to pH 1 through the addition of H2SO4 (98%) which 
resulted in precipitation of product.  The precipitate was collected by filtration, washed 
with cold water and dried in the vacuum oven overnight to afford the title compound as a 
white solid. (Yielded 11.2 g, 90%) The spectroscopic data matched the reported values in 
the literature.  






































13C NMR spectrum of 4-(N-acrylamido)phenylarsonic acid 
 
General procedure for synthesis of [PPEGA20-n-co-AsAmn]-b-NIPAm80 by aqueous  
SET-LRP.  
Me6Tren (14 μL, 52 μmol, 0.6 eq) was dissolved in HPLC grade H2O (1 ml) prior to 
addition of CuBr (10 mg, 70 μmol, 0.8 eq). The resulting solution was deoxygenated with 
N2 affording disproportionation as indicated by the strong blue colour of the solution and 
precipitation of Cu(0). Simultaneously, in a separate vessel 2,3-dihydroxypropyl-2-
bromo-2-methylpropanoate (1 eq) and PEGA (20-n eq, Mn = 480 g.mol-1) were dissolved 
in HPLC grade H2O prior to addition of AsAm (n eq) dissolved in 0.5 M NaOH (n eq) to 
give a total volume of 2.5 ml. The resulting solution was also deoxygenated by bubbling 
N2 for 15 mins. The monomer/initiator mixture was then added as a single portion to the 
disproportionation solution via deoxygenated syringe. The progress of the reaction was 
followed by 1H NMR and SEC analysis. Upon completion (typically >99% conversion in 
15-30 mins) a deoxygenated solution of NIPAm (80 eq) in HPLC grade H2O (3 mL) was 
added as a single portion to the polymerisation solution via deoxygenated syringe. The 
progress of the chain extension was followed by 1H NMR and SEC. Upon completion the 
Cuprisorb® was added the reaction mixture to remove the (in)soluble copper species prior 
to dialysis (nMWCO 3.5 KDa) against de-ionised water. The purified polymers were 





General procedure for synthesis of PPEGA20-b-[NIPAm80-n-co-AsAmn] by aqueous  
SET-LRP.  
Me6Tren (14 μL, 52 μmol, 0.6 eq) was dissolved in HPLC grade H2O (1 ml) prior to 
addition of CuBr (10 mg, 70 μmol, 0.8 eq). The resulting solution was deoxygenated with 
N2 affording disproportionation as indicated by the strong blue colour of the solution and 
precipitation of Cu(0). Simultaneously, in a separate vessel 2,3-dihydroxypropyl-2-
bromo-2-methylpropanoate (1 eq) and PEGA (20 eq, Mn = 480 g.mol-1) were dissolved 
in HPLC grade H2O (1 mL). The resulting solution was also deoxygenated by bubbling 
N2 for 15 mins. The monomer/initiator mixture was then added as a single portion to the 
disproportionation solution via deoxygenated syringe. The progress of the reaction was 
followed by 1H NMR and SEC analysis. Upon completion (typically >99% conversion in 
15-30 mins) a solution of AsAm (n eq) dissolved in 0.5 M NaOH (n eq) was added to a 
solution of NIPAm (80-n eq) in HPLC grade H2O give a total volume of 4.0 ml and the 
resulting mixture was deoxygenated with N2 prior to addition to the polymerisa t ion 
solution as a single portion via deoxygenated syringe. The progress of the chain extension 
was followed by 1H NMR and SEC. Upon completion the Cuprisorb® was added the 
reaction mixture to remove the (in)soluble copper species prior to dialysis (nMWCO 3.5 
KDa) against de-ionised water. The purified polymers were isolated by lyophilisat ion. 
Alternatively, following completion of the second block, 1 M HCl was added until the 
blue colour of the Cu(II)-Me6Tren complex disappeared and the insoluble Cu(0) was 
filtered off to afford a homogeneous colourless solution which was then dialysed 
(nMWCO 3.5 KDa) against de-ionised water for 2 days changing the water twice. The 
purified polymers were isolated by lyophilisation to obtain white solid (yielded 
approximately between 70 -90 %). 
 
General procedure for self-assembly and crosslinking of [PEGA20-n-co-AsAmn]-b-
NIPAm80 and PEGA20-b-[NIPAm80-n-co-AsAmn].  
The procedure reported for the reductive coupling of organic arsenicals was translated to 
the As-functional block copolymers. Briefly, As-functional polymer was dissolved in a 
deoxygenated aqueous solution of hypophosphorus acid (H3PO2, 10 wt%, 10 mg/ml 
polymer) and deoxygenated KI (1 vol% from a 3 wt% aq solution) was added. The 
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solution was allowed to equilibrate for 16 hrs before heating at 60 0C for 2 hrs. The 
resulting solution was dialysed against deionised water (nMWCO 3.5 KDa) to remove 
the electrolytes for no longer than 24 hrs and changing the water 4 times. The crosslinked 
particles were isolated by lyophilisation to obtain white solid (yielded approximate ly 
between 90-98 %) and were readily re-dispersed in H2O. 
 
General procedure for particle stability and disassembly. 
Polymer nanoparticles NPAs-10, NPAs-15, NPAs-20, were dissolved separately in deionised 
water, glutathione (5 mM) and H2O2 (5 mM) (1 mg/ml). The solutions were filtered 
through (450 μm nylon filters) into separate plastic cuvettes (with a lid) and incubated at 
37 0C in water bath. Disassembly was monitored through the measurement of changes in 
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Chapter 3 : Responsivity of polymeric arsenical self-




The discovery of novel methods to cross-link polymeric particles has been of growing 
interest in polymer science. To date, using arsenic to cross-link polymers has not been 
well reported despite its versatile chemistry. The interchangeable oxidation states of 
arsenic and subsequent changes in chemical properties makes it a promising candidate for 
redox responsive materials. To this end, we have synthesised thermoresponsive, organic 
arsenical containing block copolymers using reversible addition fragmentation chain 
transfer (RAFT) polymerisation capable of simultaneous self-assembly and cross-linking, 
via the organic arsenical pendant groups, at elevated temperatures in the presence of 
polythiol cross-linkers. The formation of As(III)-S bonds subsequently stabilises the 
nanoparticles formed (Dh = 19 - 29 nm) which were characterised by DLS, SLS, TEM 
and AFM. The stability of the particles was tuned by altering the number of thiol groups 
in the polythiol cross-linker and by changing the SH : As stoichiometric ratio. The parent 
block copolymers and nanoparticles are non-toxic and the stability of the nanoparticles in 
aqueous and model biological solutions (5 mM GSH/H2O2) increased with increasing 
thiol functionality (di- < tri- < tetrathiol) and thiol stoichiometry (SH : As = 2.0 : 1.0 > 
1.0 : 1.0). To the best our knowledge, this is the first time that arsenic-thiolate bonding 
has been employed for redox responsive cross-linking of polymeric nanopartic les. 
Moreover, the tuneable responsivity of these nanoparticles and the (bio)chemical activity 
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of organic arsenical reagents could be advantageous for targeted drug delivery and the 
other biomedical applications. 
3.1 Introduction 
Supramolecular self-assembly of polymers has been an emerging theme in polymer 
science, however the dynamic nature of supramolecular self-assemblies often limits its 
applications in the real world. Although covalent stabilisation can tune the dynamic 
nature of polymeric nanoparticles, the presence of functional groups required for cross-
linking can often limit polymerisation protocols. The emergence of Reversible 
Deactivation Radical Polymerisation (RDRP) such as Reversible Addition Fragmentat ion 
Transfer (RAFT)1, 2 and copper mediated polymerisation3-5 has allowed incorporation of 
monomers of various functionality,6-13 and thus permitted orthogonality between cross-
linking and polymerisation of the cross-linkable monomers. Recently these RDRP 
protocols has allowed generation of complex block-copolymers14, 15 and a means of 
introducing cross-linkable functionalities to generate complex nanostructures.16, 17 
Although considerable work has been focused on covalent chemistry that permanently 
cross-links self-assembled structures, recently more attention has been steered towards 
using dynamic covalent bonds for cross-linking polymers that breaks in response to an 
environmental stimuli. Biodegradability is important property to consider for drug 
delivery and other biomedical applications, as it prevents materials from accumulating in 
the body and often correlates to lower toxicity, thus using biologically relevant chemica l 
stimuli to trigger disassembly is quintessential and key for designing nanoparticle system 
for drug delivery. Most notably disulfides,18 boronate esters19 and imines (includ ing 
hydrazones20 and oximes21, 22)23 have been widely reported in this area, with biologica l ly 
relevant stimuli such as glutathione, sugars and pH employed to elicit a desired response. 
This has increasingly attracted interests in various fields beyond drug delivery such as 
biosensors,24 and sustainability,25 thus demonstrating unexplored cross-linking methods 
that are “responsive” can add value in this field. Recently Yang et al has demonstrated, 
the use of 3-methylmaleamidic acid moiety as a pH responsive amide bond linker, using 
2-propionic-3-methylmaleic anhydride as a cross-linker between two polymers to make 
an amphiphilic block copolymer for self-assembly, whilst triggering its collapse under 




Interesting, arsphenamine, which is As(I) containing therapeutic drug used to treat 
syphilis, consists of homocyclic oligomers composed of labile As-As bonds forming the 
core, which oxidatively hydrolyses to form active As(III). The synthesis of arsphenamie 
involves heating an arsonic acid (As(V)) precursor in the presence of a suitable reducing 
agent to As(V) to As(I) which proceeds with the formation of As-As bonds.28 In chapter 
1, As(I) to cross-link micelles formed from block-copolymer containing As(V) in the core 
forming block were developed.29 The resulting nanoparticles were responsive towards 
biologically relevant stimuli, accelerating its degradation with glutathione (GSH) and 
instantly losing its structure with hydrogen peroxide. The stability of the nanopartic les 
increased with increasingly number of Arsenic functionality.  
 
In the present study, the use of arsenic to cross-link polymers is not just limited to 
homocyclisation of As(I). It is widely known that, arsenous acid (As(III)) has high affinity 
towards thiols, which is implicated in biological toxicity as a result of cross-linking 
cysteines of important housekeeping proteins inside cells and has been exploited in 
arsenic based chemotherapeutics.30, 31 The affinity of As(III) towards dithiols has been 
demonstrated for peptide-polymer conjugation, in presence of dithiols.32 Previously 
polymers with pendant arsenic groups have been synthesised as scaffolds for post-
polymerisation thiol modification.33 The nucleophilic exchangeability of thiols with 
arsenic-thiolate bonds are well known, and it’s the basis for widely used fluorescent bis-
arsenicals to bind to thermodynamically favourable tetracysteine tags, through thiol 
exchanges with ethane dithiol adduct.34-38 One of the unique properties of arsenic is it’s 
interchangeable oxidation states, between As(III) and As(V) states, due to the subsequent 
changes in soft to hardness of its Lewis acidity,39 using biologically relevant oxidising 
agents to investigate the changes in thiol affinity to As(III) is therefore interesting. 
 
Herein the cross-linking the self-assembled polymeric arsenicals using multi- functiona l 
thiol cross-linkers is investigated along with the responsivity of the generated 





3.2 Results and Discussion 
In Chapter 2, the possibility of synthesising block copolymers consisting of poly(ethylene 
glycol) methyl ether acrylate (PEGA, Mn  480 gmol-1 ) and N-isopropylacrylamide 
(NIPAm) using aqueous single electron transfer-living radical polymerisation (SET-LRP) 
was reported. Arsenic was incorporated into this copolymer composition through addition 
of organic arsenical monomer, 4-(N-acrylamido)phenyl arsonic acid (AsAm), at various 
feed ratio’s into either the corona forming (PEGA) block or the core-forming  (NIPAm) 
block. The block copolymeric arsenicals were shown to undergo simultaneous self-
assembly and reductive cross-linking at elevated temperature in the presence of a 
reductive environment (H3PO2/KI). Though aqueous SET-LRP is the ideal system for the 
polymerisation of hydrophilic acrylamides and acrylates, hydrolysis of the ω-bromine end 
group can limit further block extension, and the use of relatively high concentrations of 
copper can add additional processing steps.  RAFT has numerous benefits, such as solvent 
versatility, as well temporal control over the reaction, allowing the monomer feed of the 
reaction mixture to be calculated before the polymerisation, which is not feasible with 
continually initiating catalyst systems such as those in SET-LRP and ATRP systems. 
 
3.2.1 Polymeric arsenical synthesis 
To investigate the effect of cross-linking with polythiol reagents on the formation and 
stability of polymeric arsenical nanoparticles, the polymer composition with the lowest 
mole fraction of the AsAm capable of forming stable nanoparticles (PEGA20-b-
[NIPAm70-co-AsAm10]) via the reductive coupling method, was targeted. Furthermore, 
the corona-functional polymeric arsenical [PEGA15-co-AsAm5]-b-NIPAm80 which was 
unable to stabilise nanoparticles was also targeted to determine if these structures could 
be stabilised using polythiol cross-linkers. Having previously used RAFT polymerisa t ion 
for the homopolymerisation of an organic arsenical acrylamide (AsAm(pin)2) this method 
was employed here to synthesise thermoresponsive block copolymeric arsenicals, 
expanding their versatility in polymer synthesis.  
 
The polymerisations were carried out in 2,2,2-trifluoroethanol (TFE).40 For optimal chain 
extension and block efficiency with RAFT polymerisation, the acrylate based PEGA 
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block was synthesised first, followed by chain extension with the NIPAm block, in a one-
pot, sequential chain extension. 
 
Figure 3.1: Scheme of polymer synthesis of Poly(PEGA-NIPAm) diblock copolymers through 
sequential chain extension using RAFT polymerisation. Arsenical monomer (AsAm) initially 
incorporated as pinacol protected AsAm(pin2), subsequently deprotected by acidic dialysis, is either 
fabricated in the NIPAM block (top, P3.1)  or PEGA block (bottom, P3.2). All polymerisations were 
done in TFE at 65 °C for 24 hours using V601 as an initiator. SEC (DMF) of Arsenic functional 
block copolymers showing: first block (black), block chain extension (red), after removing pinacol 
groups (blue) of P3.1 (left) and P3.2 (right). Note that for SEC analysis, the shift in molecular 
weight distribution after deprotection varies depending which block the arsenic is incorporated. 
 
For the synthesis of the targeted ‘core-functional’ polymer P3.1 (PEGA20-b-[NIPAm70-
co-AsAm10]), the polymerisation of the PEGA corona-forming block, in TFE gave good 
control (Mn,th = 10800 gmol-1, Mn,SEC = 8900 gmol-1, D = 1.16) using PABTC as the RAFT 
agent. An initial monomer concentration of 1 M of PEGA and initiator (V601) 
concentration of 9 x 10-4 M ([CTA]0/[I]0 = 50) led to near quantitative conversion (98%) 
at 65 °C after 24 hours. The ratio of monomer feed to CTA was determined from the 
integral of the acrylic vinyl proton at 5.85 ppm and -CH3 of the Z-group belonging to the 
PABTC (δ = 0.91 ppm). This was subsequently chain extended with AsAm(pin)2 and 




























NIPAm with combined monomer concentration of 3 M and 1 x 10-3 M initia tor 
concentration ([MacroCTA]0/[I]0 = 16), reaching full conversion of both monomers in the 
final block after 24 hours. In contrast to the previous study where the sodium salt of the 
arsenic monomer was polymerised in aqueous solution and subsequently 1H NMR carried 
out in D2O, the aromatic peaks can be reliable integrated as in the CDCl3 the aromatic 
peaks and the acrylamide N-H peaks do not overlap (Figure 3.2). From the aromatic 
signal at 7.68 ppm (or alternatively 8.00 ppm) it was possible to accurately determine the 
proportion of AsAm(pin)2 in the monomer feed, furnishing P3.1 with the composition 
PEGA22-b-[NIPAm106-co-AsAm(pin2)15]. It’s important to note, to determine sequentia l 
monomer feed to Macro-CTA the acrylic back bone (-CH-) between 2.0 -2.5 ppm was 
used as a reference to the initial block, however alternatively the methoxy (–OCH3) at 
3.34 ppm can also be used as reliable reference. The block copolymerisation was also 
successfully demonstrated by SEC analysis showing shift to a higher molecular weight 
(Mn,th = 29600 gmol-1, Mn,SEC = 29300 gmol-1, D = 1.27) (Figure 3.1). 
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Figure 3.2 1H NMR (CDCl3) of monomer feed before and after polymeris ation of each block 
for the synthesis of P3.1.  
 
An identical approach was followed for the synthesis of targeted ‘corona-functiona l’ 
polymer P3.2 ([PEGA15-co-AsAm5]-b-NIPAm80). A combined initial monomer 
concentration of 1 M for the PEGA and AsAm(pin)2 monomers with PABTC and V601 
(9 x 10-4 M) ([CTA]0/[I]0 = 39) gave quantitative conversion (98.5 %). The aromatic signal 
corresponding to the AsAm(pin2) monomer at 7.68 ppm was used to determine the 
proportion of AsAm(pin2) in the initial block (Figure 3.3). The ratio of monomer feed to 
CTA was determined by integration of vinylic protons belonging to both monomers (5.63 
ppm) with the Z-group of the PABTC as previously, however as the pinacol groups were 
overlapping with the –CH3 this was taken into account by considering a difference of 
three protons between the two pinacols peaks each with 6 proton’s per AsAm(pin2) 
monomer at 1.28 ppm and 1.01 ppm. The conversion of both monomers were determined 
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by using the aromatic peak at 7.80-7.50 ppm, which was also used as an internal reference 
for subsequent chain extension with NIPAm to determine the monomer feed to macro-
CTA ratio. The chain extension with NIPAm following the similar procedure 
([MacroCTA]0/[I]0 = 16) yielded with quantitative monomer conversion furnishing P3.2 
with a composition of [PEGA17.5-co-AsAm5.5]-b-NIPAm97 and successful chain extension 
was further demonstrated by the SEC analysis, showing successful re-initiation of the 
PEGA-co-AsAm(pin2) as a macro-CTA (Mn,th = 22100 gmol-1, Mn,SEC = 20500 gmol-1, D 
= 1.24) (Figure 3.1). 








































































Figure 3.3. 1H NMR (CDCl3 ) of monomer feed before and after polymeris ation of each block 
for the synthesis of P3.2. 
 
To unleash the reactive arsenic acid As(V) group the pinacol groups of the AsAm(pin2) 
were removed by dialysis against 0.1 M HCl overnight. This was done directly from the 
polymerisation mixture, where both polymers initially precipitated during the dialysis as 
a result of phase separation during solvent exchange. Switching the dialysis media to pure 
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H2O resulted in dissolution of the deprotected polymers which were isolated by 
lyophilisation to obtain the final polymers (Table3.1). The deprotection of the AsAm(pin)2  
units was confirmed by 1H NMR with the disappearance of the pinacol groups at 1.28 and 
1.01 ppm (t and t’ respectively in Figure 3.2 and 3.3). The dispersity of the final polymers 
were similar to values reported previously. Consistent with the decrease in Mn,th as a result 
of loss of pinacol groups, deprotection of P3.1 resulted in a shift to towards lower 
molecular by SEC analysis (P3.1, Mn,th = 27100 gmol-1, Mn,SEC = 20800 gmol-1, D = 1.35). 
Interestingly, the deprotection of P3.2 resulted in a higher apparent molecular weight 
(P3.2, Mn,th = 21200 gmol-1, Mn,SEC = 30500 gmol-1, D = 1.35) (Figure 3.1).  
Table 3.1 Arsenic functional block copolymers synthesised by RAFT. 1H NMR of polymerisation 
mixture in CDCl3 and after deprotection done in D2O. SEC carried out with DMF as an eluent. 
 Polymer Composition 


















P3.1 P[PEGA22] 98 % 10800 8900 1.16    
 P[PEGA22 -b-(NIPAm106-co-AsAm15)] > 99 % 29600 29300 1.27 27100 20800 1.35 
         
P3.2 P[PEGA17.5-co-AsAm5.5] 98.5 % 11100 9000 1.15    
 
P[(PEGA17.5-co-AsAm5.5)-b-NIPAm97] > 99 % 22100 20500 1.24 21200 30500 1.40 
 
Prior to cross-linking, the thermoresponsive behaviour and propensity for self-assemb ly 
of each polymer was investigated by variable temperature dynamic light scattering (DLS) 
in aqueous solutions (1 mg ml-1) by increasing the temperature between 25-60 °C at 5 °C 
intervals. Both P3.1 and P3.2 underwent self-assembly in aqueous solution at elevated 
temperature. When the AsAm units were incorporated into the core-forming NIPAm 
block (P3.1), self-assembly occurred at T = 50 °C (Dh = 33 nm), and the nanopartic les 
contracted further with increasing temperature (Dh = 21 nm at T = 60 °C) (Figure 3.4).  
Interestingly, P3.2 with AsAm units incorporated in the corona forming PEGA block 
underwent self-assembly at lower temperatures (T = 40 °C, Dh = 21 nm), with contraction 
again observed with increasing temperature (Dh = 15 nm, at 60 °C) (Figure 3.5), forming 
smaller aggregates across the temperature range compared to P3.1.  
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Figure 3.4 DLS analysis of thermally induced self-assembly of P3.1. Hydrodynamic diameter 
(number % ) versus temperature plotted (left). The changes in size distribution curves with 
temperature plotted (right) (see Appendix C, S3.4 for supporting information). 





















































Figure 3.5 DLS analysis of thermally induced self-assembly of P3.2. Hydrodynamic diameter 
(number % ) versus temperature plotted (left). The changes in size distribution curves with 
temperature plotted (right) (see Appendix C, S3.5 for supporting information). 
 
One of the benefits of cross-linking thermoresponsive self-assembled polymers is being 
able to follow the success of cross-linking using DLS, by returning the temperature back 
to that which the polymers would otherwise dissemble to unimer’s without successful 
stabilisation. Sumerlin et al have demonstrated retention of nanostructures at ambient 
temperature from polymerisation induced thermal self-assembly (PISA) of NIPAm via 
cross-linking at elevated temperatures.41 Previously, self-assembled thermorespons ive 
polymeric arsenicals were cross-linked by reductive coupling using aqueous H3PO2 to 
reduce As(V) to As(I) which proceeds with the formation of As-As bonds in the form of 
Asn homocycles. Cross-linking through the corona-forming PEGA block (P3.2) using this 
strategy was re-investigated here (Figure 3.6A), but consistent with the previous work, it 
did not result in successfully cross-linked nanoparticles. Cross-linking through the core-
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forming NIPAm block (P3.1) was however successful yielding stable polymer 
nanoparticles (NPAs(I)), as confirmed by light scattering (Dh = 29  nm, Nagg = 23, Figure 
3.6 B/E/F, Table 3.2) and microscopy (TEM and AFM: Figure 3.6 C/D) techniques. 
However, in contrast to the previous work, the nanoparticles were less stable in 
comparison, as these particles disassembled in response to glutathione much faster (3 hr 
compared to 12-20 hr with equivalent amount of AsAm units per chain) (Figure 3.7). This 
is attributed to a lower relative density of AsAm units within the NIPAm core (NIPAm : 
AsAm = 106 : 15 vs 75/72/93 : 10/14/26).    
 
Figure 3.6 A) Schematic for simultaneous self-assembly and reductive cross-linking of P3.1 in 
H3PO2 B) particle size distrubtion curves (DLS. 1 mgml -1, H2O) of P3.1 and corresponding 
nanoparticle NPAs(I) C) TEM of NPAs(I) (scale bar 400 nm) D) AFM of NPAs(I) (scale bar = 400 nm) E) 
Evolution of KC/R in water as function of q2 and concentration for NPAs(I) obtained by SLS. F) Mw 
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Figure 3.7 Particle size distribution (DLS) of aqueous solution of NPAs(I) (1 mg/ml) in presence 5 
mM Glutathione (left) and 5 mM H2O2 (right) as function of time (see Appendix C, S3.7A and 
S3.7B for supporting information). 
 
3.2.2 Stabilisation of polymeric arsenical nanoparticle with multi-thiol cross-
linker 
Due to the lability of the As-As bonds to hydrolysis and oxidation which results in 
disassembly over time, polythiol reagents were investigated as external cross-linkers 
(scheme 3.1) to cross-link the self-assembled nanoparticles through more stable As(III)-
S bonds. Although trivalent arsenic (As(III)) readily reacts with thiols to form As(III)-S 
covalent bonds, pentavalent arsenic (As(V)) must first undergo reduction to As(III). This 
can be achieved via addition of excess thiol, with 2 equivalents required for reduction and 
a further 2 equivalents for bonding. In the context of this work, it was hypothesised that 
this would limit the cross-linking efficiency by diminishing the number of reactive thiol 
groups due to their oxidation (during the initial reduction process) to disulfides. 
Alternatively, non-thiol reducing agents could be considered to achieve in-situ reduction 
prior to addition of the polythiol cross-linkers. With this in mind the reductive conditions 
reported previously (H3PO2, KI, 60 °C) were adopted to afford simultaneous self-
assembly and initiate reduction of As(V). It was proposed that the introduction of 
polythiol cross-linkers would pull the redox equilibrium towards the thiol cross-linked 
As(III) state, due to the formation of more enthalpically favoured As(III)-S bonds. 
Consequently, the polythiol cross-linker would be fed into the reaction as a single portion 
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after 10 minutes of heating to react with and intercept As(III), before reduction to As(I) 
was complete. This hypothesis was verified by heating p-arsanilic acid under reductive 
conditions for 10 minutes prior to addition of a monothiol reagent (thiogylcerol, 2 eq, Fig 
3.8A), which resulted in the trapping of the As(III)-bis-thiogycerol adduct of p-arsanilic 
acid (Fig 3.8B).  
  
Figure 3.8 A) schematic of arsanilic acid with thiogycerol (2 eq) in reductive conditions (H3PO2 / 
KI).  B) HRMS of the reaction mixture with isotopic distribution corresponding to [C12H20AsO4S2 + 
Na]+ species. 
 
Commercially available polythiol cross-linkers with similar interatomic distances 
between each thiol were identified. Pentaerythritol tetrakis(3-mercaptopropiona te), 
(PTM), trimethylolpropane tris(3-mercaptopropionate) (TTM) and hexa(ethylene glycol) 









Scheme 3.1 Thermal induced self-assembly and cross-linking of P3.2 using multi-functional thiol 
cross-linkers in reductive conditions. The cross-linker(s) is added after 10 minutes of heating in the 
reductive conditions. Hypophosphorous acid is used as reducing agent with catalytic amount of 
potassium iodide. 
 
Considering that the pendant As(III) groups can form two bonds to thiols, and to 
investigate the effect of thiol valency of the cross-linkers the stoichiometry of cross-linker 
was set so that [SH]/[As] = 2, for each combination of polymer and cross-linker. For 
example, P3.2 [PEGA17.5-co-AsAm5.5]-b-NIPAm97, which does not form stable 
nanoparticles when subjected to reductive conditions alone, was initially reacted with 
tetra-functional PTM (2.75 eq i.e. 11 eq [SH] w.r.t. [As]) in an attempt to stabilise the 
resulting nanoparticles. However, in line with previous work the formation of stable 
cross-linked nanoparticles was not possible as evidenced by DLS analysis at room 
temperature which showed only unimers (Fig 3.9). This is attributed to the relatively low 
functional density of the As-groups in the corona which is naturally more diffuse than the 
core, thus limiting the proximity of As(III) groups during the cross-linking process.  
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Figure 3.9 Size distribution (DLS) of P3.2 at room temperature after cross -linking with PTM under 
elevated temperature (60 °C) (see Appendix C, S3.9 for supporting information). 
  
Hitherto, cross-linking of core-functional P3.1 (PEGA22-b-[NIPAm106-co-
AsAm(pin2)15]) with the polythiol reagents will be the focus of this investigation.  Thus, 
when P3.1 was subjected to reductive conditions, addition of PTM (7.5 eq) furnished 
stable nanoparticles NPAs-S4, as observed by DLS (Dh = 29 nm, PDI = 0.06) measured at 
room temperature (Figure 3.10). Transmission Electron Microscopy (TEM) shows range 
of sizes (Figure 3.10). Owing to the thermoresponsive nature of the NIPAm core, the 
nanoparticles were able to contract (Dh = 23.0 nm) at elevated temperature and swell (Dh 









Figure 3.10 A) Particle size distribution (DLS) of P3.1(black) and corresponding cross -linked 
nanoparticle NPAs-S4 (blue). B) TEM image of NPAS-S4 (scale bar = 100 nm) (see Appendix C, S3.10 
for supporting information). 
 
Figure 3.11 Reversible contracting and swelling of particles derived of NPAs-S4 at 60 °C and 25 °C 
respectively in deionised water (1 mg/ml) (see Appendix C, S3.11 for supporting information). 
 
Static light scattering (SLS) was used to determine the absolute molecular weight from 
the Zimm plot and therefore the number of polymer chains per particle. Interestingly, 
NPAs-S4 was estimated to have an aggregation number (Nagg) of 278 chains per particle (at 
infinite dilution), which was considerably higher than our previous As-As cross-linked 
nanoparticles. As observed in the Zimm plot, the molecular weight of the nanopartic les 
decreased with concentration, indicative of inter-particle interactions and inter-partic le 
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crosslinking at higher concentration (Fig 3.12). An additional feature of the SLS, is the 
radius of gyration (Rg) which can be obtained by extrapolating the Zimm plot. The ratio 
(ρ) of the Rg and radius of hydration (Rh) (scattering measured at 90°) can provide 
topological information, with Rg/Rh = 0.778 for a compact hard sphere, and 2.36 for a stiff 
rod.42, 43 NPAs-S4 had a ρ value of 1.39, at 1 mg/ml, which increased to 2.04 at higher 
concentration (4 mg/ml), indicating a change in topology, deviating further from spherical 







































































Figure 3.12 Evolution of KC/R in water as function of q2 and concentration for NPAs-S4, obtained by 
SLS. 
 
Figure 3.13 AFM image of NPAs-S4. Left: scale bar = 400 nm. Right: scale bar = 100 nm. 
 
The inter-nanoparticle interaction was observed by Atomic Force Microscopy, (AFM), 
where close examination indicates clustering of the particles is evident (Fig 3.13). 
Although As(III)-S bonds are more stable than the As-As bonds reported previously, the 
bonding can be dynamic particularly in the presence of exchangeable thiols. The stability 
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and responsivity of NPAs-S4 to glutathione (5 mM, 37 °C) was therefore investigated. The 
nanoparticles remained intact, even after one week, as observed by no change in the 
hydrodynamic size (Dh = 30.5 nm, PDi = 0.07) by DLS analysis (Fig 3.14). This is in 
contrast, to the results of Le et al who demonstrated release of phenylarsine oxide 
(As(III)) with glutathione, from the core of a thiol-functional particle stabilised by 
As(III)-S bonds (80% released within the first few hours, with 5 mM GSH).44 This 
suggests that the interaction between arsenicals incorporated into polymer chains with 
PTM is more entropically favourable than the interaction between thiol functiona l 
polymers and phenylarsine oxide.  
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Figure 3.14 Particle size distribution curves of NPAs-S4 as a function of time in aqueous GSH (GSH = 
5 mM, nanoparticle concentration = 1 mg/ml) (see Appendix C, S3.14 for supporting information). 
 
To synthesise nanoparticles that were less densely cross-linked, the amount of cross-
linker was reduced to half the stoichiometry ([SH]/[As] = 1, i.e. 3.75 eq PTM w.r.t. P3.1). 
The resulting nanoparticle, NPAs-S4/2 was successfully prepared and stable at room 




Figure 3.15 DLS analysis of P3.1 (1 mg/ml) showing the success of nanoparticle formation with half 
the stoichiometric ratio of PTM cross-linker (NPAS-S/4, 1 mg/ml) after dialysis at room temperature 
(see Appendix C, S3.15 for supporting information).  
 
Further SLS analysis indicated a smaller molecular weight for these nanopartic les 
compared to when stoichiometric cross-linker was used, with fewer polymer chains (Nagg 




































































Figure 3.16 Evolution of KC/R in water as function of q2 and concentration for, NPAs-S4/2 obtained 
by SLS. 
Heating and cooling cycles of NPAs-S4/2 revealed more pronounced contraction (Dh = 19.2 
nm) and expansion (Dh= 24.2 nm) compared to NPAs-S4 (Fig 3.17), indicative of more 




Figure 3.17 Reversible contracting and swelling of particles derived of NPAs-S4/2 at 60 °C and 25 °C 
respectively in deionised water (1 mg/ml) (see Appendix C, S3.17 for supporting information). 
 
The Zimm plot reveals less concentration dependency on molecular weight (Fig 3.16), 
indicating the absence of inter-particle clustering at higher concentrations which is 
supported by the ρ value of NPAs-S4/2 being lower (1.13) than NPAs-S4 (2.04) across the 
concentration range (Table 3.2). The AFM data for NPAs-S4/2 shows less clustering and a 
more regular distribution of the nanoparticles in contrast to NPAs-S4 (Fig 3.18).  
 
Figure 3.18 AFM image of NPAs-S4/2. Left: scale bar = 400 nm. Right: scale bar = 100 nm. 
 
Despite reducing the cross-linking density by 50%, NPAs-S4/2 also did not show 
responsivity to GSH even after a week at the physiological temperature (5 mM, 37 °C, 
Fig 3.19). 
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Figure 3.19 Particle size distribution curves of NPAs-S4/2 as a function of time in aqueous GSH (GSH 
= 5 mM, nanoparticle concentration = 1 mg/ml) (see Appendix C, S3.19 for supporting 
information). 
 
An alternative way of tuning the cross-linking density is through the thiol valency in the 
polythiol cross-linkers. When P3.1, was subjected to reductive conditions and tri-
functional cross-linker TTM (10 eq w.r.t. P3.1) was added stable nanoparticles NPAs-S3 
were retained (Dh = 25, PDI = 0.09, Fig 3.20) at room temperature and whilst maintaining 
nanostructure.  
Figure 3.20 A) Particle size distribution (DLS) of P3.1(black) and corresponding cross -linked 
nanoparticle NPAs-S3 (red). B) TEM image of NPAS-S3 (scale bar = 100 nm) (see Appendix C, S3.20 
for supporting information) . 
 
With the stoichiometry such that [SH]/[As] = 2, SLS revealed that NPAs-S3 (Nagg = 204) 
was similar to NPAs-S4 with the Zimm-plot showing a molecular weight dependency on 
concentration, indicative of inter-particle clustering at higher concentrations (Fig 3.21). 
This is further evidenced by the increasing ρ value at higher concentrations (Table 3.2) 


































































Figure 3.22 AFM image of NPAs-S3 depicting the clustering when stoichiometric TTM cross -linker is 
used, similar to NPAs-S4. Left: scale bar = 400 nm. Right: scale bar = 100 nm 
 
Reducing the stoichiometric equivalence of TTM (5 eq) furnished stable nanopartic les 
NPAs-S3/2 and similar to NPAs-S4/2 these were slightly smaller size according to DLS (Dh = 
21 nm, PDi = 0.11), but significantly smaller by SLS (NAgg = 26). The same trend was 
observed with respect to the ρ value of NPAs-S3 /2 (1.08, 4 mg/ml), which was smaller than 
NPAs-S3 (2.48, 4 mg/ml) and AFM of the NPAs-S3/2 was found to be similar to NPAs-S4/2 
































Figure 3.23 Particle size distribution (DLS) of P3.1(black) and corresponding cross -linked 




































































The stability and responsivity to GSH (5 mM, 37 °C) was also similar to NPAs-S4 and 
NPAs-S4/2 as both NPAs-S3 and NPAs-S3/2 remained intact even after a week according to 
DLS (Dh = 29.1 nm, PDi = 0.08 and Dh = 23.5 nm, PDi = 0.14 Fig 3.26). This indicates 
that the tri-functional thiol cross-linker has similar entropic barrier to exchange with 
monothiol reagents such as GSH.  
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Figure 3.26 Particle size distribution curves of NPAs-S3 (left) and NPAs-S3/2 (right) as a function of 
time in aqueous GSH (GSH = 5 mM, nanoparticle concentration = 1 mg/ml) (see Appendix C, 
S3.26A and S3.26B for supporting information). 
 
Table 3.2 Light scattering (DLS and SLS) of the nanoparticles. DLS was measured in aqueous 
solution (1 mg/ml). SLS measured at variable concentration. Mw,NP was determined using Eq 2-4. 
Nagg = Mw,NP/Mn,th. Rg is the gradient of Zimm plots and Rh is determined as the size measured from 
the scattering angle at 90 ° from SLS. The ratio Rg/Rh at 4 mg/ml and 1 mg/ml is displayed for 
comparison. 









(1 mg/ml) Dh (nm) PDi 
NPS4 0.137 7.5 x 10
6 277 2.04 1.39 29 0.06 
NPAs-S4/2 0.189 1.4 x 10
6 52 1.13 0.90 23 0.11 
NPAs-S3 0.133 5.5 x 10
6 203 2.48 1.28 25 0.09 
NPAs-S3/2 0.190 7.2 x 10
5 27 1.08 1.11 21 0.11 
NPAs-S2 0.174 7.0 x 10
5 26 1.64 1.60 19 0.11 
NPAs-S2/2 - - - - - 5.4 0.07 
NPAs(I) 0.164 6.3 x 10
5 23 3.42 1.27 29 0.12 
 
 
Finally, the bi-functional cross-linker HDT (15 eq w.r.t. P3.1) was added to P3.1 under 
reductive conditions, yielding stable nanoparticles, NPAs-S2 (Dh = 19 nm, PDi = 0.11, 
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Figure 3.27) which were retained at room temperature.  



































Figure 3.27 DLS analysis (top) showing the nanoparticle formed with stoichiometric equivalence of 
HBT cross-linker (see Appendix C, S3.27 for supporting information). 
 
SLS analysis also indicated that NPAs-S2 (Nagg = 26) had similar molecular weight to NPAs-
S3/2, therefore representing similar number cross-linked polymer chains per nanopartic le. 
Unlike NPAs-S4 and NPAs-S3 the nanoparticles prepared with stoichiometric amount of 
cross-linker NPAs-S2 did not show concentration dependence on molecular weight, and the 

























































Figure 3.28 Evolution of KC/R in water as function of q2 and concentration for NPAs-S2 obtained by 
SLS. 
 
The relatively high ρ value of suggests a prolate ellipsoid topology, by AFM the 






Figure 3.29 AFM (bottom) depicting the clustering of NPAs-S2, similar to NPAs-S4 and NPAs-S3. Scale 
bar of AFM: right = 400 nm, left = 100 nm. 
 
Reducing the stoichiometry (HDT = 7.5 eq) also resulted in stable particles (NPAs-S2/2) 
being retained at room temperature, however the particles were not stable to purifica t ion 
by dialysis against H2O, with unimers being observed by DLS (Fig 3.27). This indicated 
that NPAs-S2 was less stable than NPAs-S3 and NPAs-S4 and more likely to respond to GSH 
(5 mM, 37 °C) stimulus. Indeed, this was the case with NPAs-S2 disassembling between 
48 to 72 hrs (Fig 3.30).  
 
 
Figure 3.30 Particle size distribution curves of NPAs-S2 as a function of time in aqueous GSH (GSH = 
5 mM, nanoparticle concentration = 1 mg/ml) (see Appendix C, S3.30 for supporting information). 
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The dynamic redox chemistry of As is a distinctive characteristic of organic and 
polymeric arsenicals that lends itself to application in the development of responsive 
(bio)nanomaterials. It is known that As(III) can be readily oxidise to As(V) by reactive 
oxygen species (ROS) such as hydrogen peroxide (H2O2).45 Suzuki et al have treated 
blood and organ lysates from animal models (Hamsters and Rats) with hydrogen peroxide 
to liberate As(III) bound proteins as arsenates (As(V)) for arsenic biodistribution and 
metabolite assays.46 Computational studies by Villamena et al suggests As(III) oxidation 
to As(V) by ROS species including hydrogen peroxide is exoergic, and highlight the 
possibility of arsenic cytotoxicity by GSH depletion due to the redox cycling events 
between GSH (As(V) reduction) and ROS (As(III) oxidation).47  
 
The responsivity of the As(III)-S cross-linked nanoparticles to H2O2 (5 Mm. 37 °C) was 
investigated with the proposed response to As-S bond cleavage and oxidation monitored 
as a function of the particle size using DLS (Figure 3.31). The nanoparticles stabilised by 
As(III)-S cross-linking (NPAs-S4, NPAs-S4/2, NPAs-S3, NPAs-S3/2, NPAs-S2) did not 
disassemble instantly, maintaining the hydrodynamic particle sizes over the first 3 hours. 
This is in contrast to the nanoparticles cross-linked by reductive coupling with As-As 
bond formation prepared here as a control (Fig 3.7), and in previous work, which fully 
disassembled within 1 hour after addition of H2O2 (5 mM, 37 °C). Pleasingly, a trend was 
observed relating the nanoparticle stability to the structure of the polythiol cross-linkers 
and the cross-linking density. Thus the stability of the particles decreased with decreasing 
thiol valency in the cross-linkers ([SH] : [As] = 2; NPAs-S4 > NPAs-S3 > NPAs-S2) with NPAs-
S4 undergoing disassembly over 44 hours and NPAs-S3 and NPAs-S2 disassembling over 18 
hours and 6 hours respectively (Fig 3.31).  When the cross-linking density was reduced 
([SH] : [As] = 1; NPAs-S4/2 and NPAs-S3/2) the stability was reduced further with the onset 
of disassembly occurring within 3 hours (Fig 3.31). This trend can be attributed to the 
thiol valency in the cross-linkers i.e. increasing valency PTM > TTM > HDT increases 
the likelihood of inter-chain As(III)-S bonds forming, constituting cross-linking, which 
have to be broken under the oxidative conditions. Intra-chain As(III)-S bonding is also 
possible, and this will have a more detrimental effect when HDT is employed (NPAs-S2) 
as a single intra-chain reaction will consume both the thiol groups present in HDT, 
whereas when PTM and TTM are employed (NPAs-S4 and NPAs-S3), latent thiol groups 
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remain available for cross-linking. These results demonstrate for the first time that 
nanoparticles compromised of polymeric arsenicals, cross-linked via As(III)-S bonds 
have tuneable responsivity to H2O2, which is an attractive stimulus for drug delivery, 
particularly as a responsive linker for peroxisomes targeted delivery is also particula r ly 
interesting, especially in intracellular infections.48 Furthermore, H2O2 is indigenous ly 
produced inside cells for natural cellular processing49 and it’s concentration is increased 
in environments of oxidative stress which occurs in response to inflammation associated 
with a number of disease states including cancer and atherosclerosis and cystic fibrosis.  
 
 
Figure 3.31 Scheme: disassembly of the nanoparticles through release of the cross -linker mediated 
by oxidation of the As(III) to As(V) with hydrogen peroxide. DLS analysis of the disassembly with 
time (black = 0 hr, orange = 3 hr, red = 6 hr, purple = 18 hr, blue = 24 hr, Navy = 44hr) (see 
Appendix C: S3.31A, S3.31B, S3.31C, S3.31D and S3.31D for supporting information). 
3.2.3 Cytotoxicity of polymeric arsenical nanoparticles  
Finally, to dispel concerns regarding the toxicity of organic and polymeric arsenicals, 
which are known to be less toxic than inorganic counterparts, in vitro toxicity of the 
polymeric arsenical P3.1 and the resulting nanoparticles was determined using a standard 
XTT assay with a human breast adenocarcinoma cell line (MDA-231). Using an identica l 
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protocol, polymeric arsenical scaffolds have been shown to be non-toxic between 2 – 20 
μM against MDA-231, whilst nanoparticles derived from thermoresponsive block  
copolymeric arsenicals, similar to those reported here but consisting of As-As cross-
linking, were also non-toxic up to 2 mg/ml against a Prostate cancer cell line (PC3). In 
this work P3.1 was non-toxic up to 5 mg/ml and the nanoparticles were non-toxic up to 2 
mg/ml with the exception of the NPAs-S2 which showed a decrease in cell viability at 
concentration > 0.2 mg/ml (Fig 3.32).  This is attributed to the lower stability of NPAs-S2 
leading to an earlier onset of disassembly, with the products of the disassembly being 
responsible the change in viability. The origin of the toxicity is not known at this stage 
but the released cross-linker is implicated considering that P3.1 is non-toxic over the 
concentration range. Despite this result, and since it occurs at high concentration (from a 
clinical perspective), these results support the potential of using polymeric arsenicals as 



































Figure 3.32 In vitro cell viability of polymers P3.1 and nanoparticles, NPAs-S4, NPAs-S4/2, NPAs-S3, 





Thermoresponsive block copolymeric arsenicals comprised of PEGA and NIPAm, with 
incorporation of organic arsenical acrylamide monomer (AsAm(pin2)) into either the 
core-forming NIPAm block (PEGA22-b-(NIPAm106-co-AsAm(pin2)15, P3.1) or the 
corona-forming PEGA block ([PEGA17.5-co-AsAm(pin2)5.5]-b-NIPAm97, P3.2), have 
been synthesised by RAFT for the first time. Removal of the pinacol groups of 
AsAm(pin2) furnished reactive As(V)-functional groups and the resulting polymers 
formed nanoparticles at elevated temperatures. The reactive As(V)-functional groups 
were targeted for cross-linking under reductive conditions (H3PO2, KI, 60 °C) in the 
presence of polythiol reagents (PTM, TTM, HDT) exploiting the high affinity of the 
As(III) for thiols and affording cross-linking through the formation of As(III)-S bonds. 
The corona-functional polymer P3.2 was not able to be cross-linked even in the presence 
of tetra-thiol cross-linker PTM and targeting 100% cross-linking ([SH] : [As] = 2). 
However, the core-functional polymer P3.1 formed stable nanoparticles in the presence 
of tetra- (PTM, NPAs-S4), tri- (TTM, NPAs-S3) and di-thiol (HDT, NPAs-S2) cross-linkers 
([SH] : [As] = 2), which were more stable than analogous nanoparticles cross-linked by 
complete reductive coupling via As-As bond formation. Characterisation of the 
nanoparticles by SLS and AFM revealed that Nagg and Rg/Rh increased as a function of 
concentration for NPAs-S4 and NPAs-S3 which was manifest as changes in nanopartic le 
topology as a result of inter-particle interactions and aggregation. Conversely, NPAs-S2 and 
nanoparticles prepared targeting 50% cross-linking ([SH] : [As] = 1; NPAs-S4/2, NPAs-S3/2) 
and exhibited more spherical structures and showed little change in Nagg and  Rg/Rh. With 
respect to stability and responsivity of these nanoparticles only NPAs-S2 was shown to 
disassemble in the presence GSH (5 μM, 37 °C) which occurred over 72 hours. In 
contrast, a trend was observed pertaining to disassembly in under conditions mimick ing 
oxidative stress H2O2 (5 μM, 37 °C), whereby the stability of the particles followed the 
trend NPAs-S4 > NPAs-S3 > NPAs-S2 > NPAs-S4/2 ≈ NPAs-S3/2. To the best of our knowledge 
this is the first report in the literature to demonstrate the using polymeric arsenicals cross-
linked via As(III)-S bonding as a responsive mechanism for polymeric nanoparticles. The 
diverse chemistry and non-toxic nature of the polymeric arsenicals and nanopartic les 
demonstrated here and in our previous work, combined with the potential synergy with 
respect to biological activity, strengthens the case for broader acceptance and adoption of 
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polymeric arsenicals as functional and responsive platform for biomaterials science.  
 
3.4 Experimental 
3.4.1 Methods and materials 
Dimethyl 2,2’-azobis(2-methylpropionate) (V601), N-(4-(2,2,3,3,7,7,8,8-octamethyl-
1,4,6,9-tetraoxa-5λ5-arsaspiro[4.4]non-5-yl)-phenyl-2-propenamide) (AsAm(pin2)) was 
synthesised as previously reported33 2-((butylthio)-carbonothioyl) thio propanoic acid 
(PABTC) was synthesised according to the reported literature.50 N-Isopropylacrylamide 
(NIPAm, 97%) was purchased from sigma and recrystallized in hexane from diethyl ether.  
Potassium Iodide, glutathione (GSH), hydrogen peroxide (30 % w/w), hypophosphorous 
acid (50% w/w), poly(ethylene glycol) methyl ether acrylate (PEGA, average Mn = 480), 
tetrakis(3-mercaptopropionate), trimethylolpropane tris(3-mercaptopropionate), and 
hexa(ethylene glycol) dithiol) were purchased from Sigma Aldrich and used as received.  
Nuclear Magnetic Resonance (NMR) spectroscopy  (1H  NMR)  spectra  were  recorded  
on  a  Bruker HD  300  spectrometer  (300  MHz) at  27  °C  in either deuterated chloroform 
(CDCl3) or deutrated water (D2O). Chemical shift values (δ) are reported in ppm. The 
residual proton signal of the solvent (δ H = 7.26 ppm for CDCl3, δ H = 2.50 ppm for D2O) 
was used as internal reference. ACDLABS software was used to analyse the data 
obtained. Number-average molar masses (Mn,SEC) and dispersity values (Ð) were 
determined using Size exclusion Chromatography (SEC) with DMF as an eluent. SEC 
analysis was conducted on Polymer Laboratories PL-GPC 50 Plus system using a Polar 
Gel-M guard column (7.5 × 50 mm) followed by two Polar Gel-M columns (7.5 ×300 
mm). DMF (0.1% LiBr) was used as eluent at 1.0 mL min−1at 50 °C. All polymer samples 
were filtered through nylon membrane with 0.45 μm pore size before injection (100 μL). 
Commercial narrow linear poly(methyl methacrylate) (PMMA) standards in range of 2.0 
× 102 −1.0 × 106 gmol−1 were used to calibrate the DMF SEC system. The SEC data 
obtained were analysed using Agilent technologies GPC/SEC software to determine 
Mn,SEC and Ð based on the PMMA calibration. Hydrodynamic diameters (Dh) and size 
distributions were determined by Dynamic Light Scattering (DLS)  on  a  MALVERN 
Zetasizer  Nano  ZS operating  at  25 °C with  a  4 mW He-Ne 633 nm laser  module. 
Measurements were made at a detection angle of 173° (back scattering). Measurements 
Chapter 3 
120 
were repeated three times with automatic attenuation selection and measurement position. 
The results were analysed using Malvern DTS 6.20 software. PDI values were calculated 
using equation Eq 3.1 
𝑃𝐷𝑖 =  
𝜎2
𝑑2
 (Eq 3.1) 
Where σ is the standard deviation, and d is the diameter both obtained from the number 
distribution.  
 
3.4.2 Determination of Mw by Static Light Scattering  
The incremental refractive index, dn/dC, was determined by measuring the refractive 
index of the polymer over a range of concentrations (1.33, 0.66, 0.33, 0.167 mg/ml) . The 
RI was determined using a Shodex RI detector, operating at a wavelength of 632 nm. 
Multiplying the gradient, of the plot of RI vs. concentration, by the refractive index of the 
solvent (water = 1.3325) and dividing by the RI constant of the instrument (−1398000) 
gives the dn/dC of the polymer (table 3.2). Light scattering measurements were obtained 
using an ALV-CGS3 system operating with a vertically polarized laser with the 
wavelength λ = 632 nm. The measurements were taken at 20 °C over a range of scattering 
wave vectors (q = 4πnsin(θ/2)/λ, with θ being the angle of observation and n the refractive 









. 𝑅𝑡𝑜𝑙𝑢𝑒𝑛𝑒  (Eq 3.2) 
Where Isolution, Isolvent and Itoluene are the scattering intensities of the solution, solvent and 
reference (toluene) respectively, n is the refractive index (nwater= 1.333, ntoluene=1.496) and 
Rtoluene the Rayleigh ratio of toluene (Rtoluene= 1.35 × 10−5 cm−1 for λ = 632.8 nm). The 
optical constant, K, is defined by Eq 3.3, where Na is the Avogadro number and dn/dC is 










 (Eq 3.3) 
In all cases it was verified that the apparent radius of gyration of the systems verified q × 
Rg < 1. The Zimm approximation can thus be used to obtain Eq 3.4. Plotting KC/Rθ as a 
function of q2 for each concentration yielded the apparent radius of gyration Rg of the 
scatterers as well as their apparent molecular weight extrapolated to zero angle, Ma. 












) (Eq 3.4) 
At a given concentration the Rayleigh ratio, Rθ, is related to the apparent molecular 
weight of the sample, given by Eq 3.4. It is only at infinite dilutions, where the 
interactions between scattering particles are negligible, that the apparent molecular 
weight is equal to the true molecular weight. Multiple concentrations were measured and 
a plot of linear regression was used to determine the apparent molecular weight at a 
concentration of 0 mgml-1. 
 
3.4.3 Atomic Force Microscopy (AFM) 
AFM images were recorded on a Bruker Dimension Icon instrument operated in peak 
force tapping mode. The probes used were ScanAsyst silicon tips with a resonance 
frequency of 70 kHz and a spring constant of 0.4 N/m. Samples were prepared by drop 
casting 5 μl of a 1 mg/ml aqueous nanoparticle solution onto a freshly cleaved sheet of 
mica, left to stand for 30 seconds and then dried under a stream of Nitrogen. 
 
3.4.4 Transmission Electron Microscopy (TEM) 
Samples were prepared by placing a 400 mesh carbon coated Formvar copper grid onto a 
20 µL droplet of aqueous nanoparticles (1 mg/ml) in a petri dish, leaving it for 10 minutes 
before drawing off the solution. The grid was then stained by placing onto a 20 µl droplet 
of aqueous solution of uranyl acetate (0.2 wt%), leaving it for 10 minutes before drawing 
off excess liquid and allowed to air-dry overnight. TEM images were acquired using a 
JEOL 2100 transmission electron microscope operating at a 200 kV accelerating voltage. 
Images were captured using Digital Micrograph® and analyzed with ImageJ. 
 
3.4.5 General procedure for RAFT polymerisation.  
A typical synthesis of the first block (A1 described here) is the following: CTA PABTC 
(24.8 mg, 0.1 mmol), PEGA (Mn480) (1000 mg, 2.1 mmol), V601 (0.5 mg, 2.2 μmol) and 
trifluoroethanol (1.5 ml, 1 moldm-3 monomer concentration) was charged into a vial 
equipped with a magnetic stirrer, the vial was then sealed with rubber septum and 
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deoxygenated by stream of bubbling nitrogen for 15 minutes with stirring. The vial was 
suspended in a preheated oil bath at 650C for 24 hrs. NMR of the reaction mixture was 
used to compare monomer consumption before and after the polymerisation and GPC 
sample was taken. No purification was required before chain extension. 
 
3.4.6 A typical chain extension (P3.1):  
The vial with reaction mixture of the first block was cooled before opening to air. NIPAm 
(1136 mg, 10 mmol), AsAmpin2 (644 mg, 1.4 mmol), V601 (1.26 mg, 5.5 2.2 μmol) and 
trifluoroethanol (3.8 ml, 3 mldm-3 monomer concentration) was added directly to reaction 
mixture of first block and mixture was well stirred. The vial was then re-sealed with 
rubber septum and deoxygenated by stream of bubbling nitrogen for 15 minutes with 
stirring. NMR of the reaction mixture was used to compare monomer consumption before 
and after the polymerisation and GPC sample was taken. No purification was required 
before deprotection. 
 
3.4.7 Deprotection AsAm(pin)2 units / removal of pinacol groups (P3.1 and P3.2):  
The polymerisation reaction mixture of P3.1 (and P3.2) was dialysed in 0.1 moldm-3 HCl 
solution over night before changing to deionised water and further dialysed for 24 hours 
in deionised water, changing the water up to 3 times. The dialysed (3.5 K polymer solution 
was lyophilised to yielded P3.1 as white powder (2.4 g, 85 % yield). Similarly for P3.2 
yielded as white powder (2.0 g, 94 % yield). 
 
3.4.8 Determination of monomer conversions and Monomer to CTA /Macro-CTA 
ratio 
The conversions of the monomers were determined by comparing the vinyl protons (δ 
6.50 - 5.50 ppm) to the integration of an internal reference. In the case of P3.1 the three 
methyl protons  belonging  to  the  Z  group  of  the PABTC  chain  transfer agent  (–CH2–
CH3) before  and  after polymerization was used as a reference. For the following chain 
extension (P3.1), the back bone -CH- (∫ δ 2.0 -2.5 ppm) was used as reference to 
determine the monomer to macro CTA ratio. 
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For the synthesis of P3.2 the overlapping pinacol groups with RAFT agent were taken 
into account to get a difference of three protons between the pinacol CH3 (Figure S) to 
get an accurate estimate of the CTA to monomer ratio. For the following chain extension 
(P3.2), the aromatic groups of the AsAm(pin2) units ∫ δ 7.8 -7.5 ppm were used as an 
internal reference to determine the macro-CTA to monomer ratio and monomer 
conversion.  
 
3.4.9 Calculation of Mn,th,  




+ 𝑀𝐶𝑇𝐴  (Eq 3.5) 
Where [M]0 and [CTA]0 are the initial concentrations of the monomer and chain transfer 
agent respectively; ρ is the monomer conversion as determined by 1H NMR, MM and 
MCTA are the molar molar masses (gmol-1) of the monomer and chain transfer agent 
respectively.  
 
3.4.10 General Procedure for Arsenic-thiolate cross-linked nanoparticle synthesis 
AsAm functional polymer (100 mg) was dissolved in deoxygenated aqueous solution (10 
ml) of hypophosphorous acid (H3PO2, 10 wt%, 10 mg/ml polymer) and deoxygenated KI 
(1 vol% from a 3 wt % aq solution) was added. The solution was heated at 60 °C for 10 
minutes before adding the cross-linker. Stock solutions (100 mg/ml in dioxane) of cross-
linkers were prepared and added to preassembled nanoparticle solution to synthesise the 
following; tetrakis(3-mercaptopropionate) was used as a cross-linker to synthesise NPAs-
S4 (12.4 mg, 123 µL of cross-linker solution, 7.5 eq with respect to P3.1) and to synthesis 
NPAs-S4/2 (6.18 mg, 61.8 µL of cross-linker solution, 3.75 eq with respect to P3.1); 
trimethylolpropane tris(3-mercaptopropionate) was used as a cross-linker to synthes ise 
NPAs-S3 (13.5 mg, 135 µL of cross-linker solution, 10 eq with respect to P3.1) and to 
synthesis NPAs-S3/2 (6.73 mgs, 67.3 µL of cross-linker solution, 5 eq with respect to P3.1); 
hexa(ethylene glycol) dithiol) was used as a cross-linker to synthesise NPAs-S2 (11.5 mg, 
115 µL of cross-linker solution, 15 eq with respect to P3.1). The cross-linking reaction 
was left for 2 hours at 60 °C. The resulting solution was dialysed (nMWCO 3.5 KDa) for 
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3 days with deionised water, changing the water twice a day to remove electrolytes and 
dioxane. The cross-linked particles were isolated by lyophilisation to obtain white solid 
(yielded approximately between 95 - 99%) and were readily dispersed in H2O. 
 
3.4.11 General procedure for particle stability and disassembly. 
Polymer nanoparticles (1 mg/ml), were dissolved separately in deionised water, 
glutathione (5 mM) and H2O2 (5 mM). The solutions were filtered through (450 μm nylon 
filters) into separate plastic cuvettes (with a lid) and incubated at 37 0C in water bath. 
Disassembly was monitored through the measurement of changes in particle size (Dh) as 
a function of time by DLS. 
 
3.4.12 Cell viability 
Cell viability was assessed against MDA-231 (human breast adenocarcinoma) cell lines. 
Cells were seeded into a 96-well plate, (1.5 x 104 cells per well), cultured in basal medium 
DMEM (Dublecco’s Modified Eagle Medium) with 10% foetal bovine serum and allowed 
to grow for 24 hours. The medium was then replaced with fresh media and complemented 
with solutions of polymer (0.313, 0.625, 1.25, 2.50, 5.00 mgml-1) prepared from stock 
solutions in PBS (500 μM). Cells were further incubated for 24 hours. The medium was 
replaced with fresh medium containing a solution of XTT (0.2 mg mL-1) and N-methyl 
dibenzopyrazine methyl sulphate (250 μM) and incubated for 16 hours. Cells were then 
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Chapter 4 : Stabilisation and functionalisation of 





The research presented in this chapter was performed in collaboration with Mr Alex 
Evans during his MChem project in the 2017-18 academic year. I supervised the project 
and directed the progress of the research and together we conducted the experimental and 
analytical work. All the discussion was written independently by myself and the data was 




The chemical reactivity of arsenic is a unique feature which changes upon it’s 
interchangeable oxidation states. Alkyl and aryl arsines As(I) exists as oligomers, 
composed of labile and redox responsive As-As bonds. In chapter 2, As(I) was used as a 
cross-linker to form responsive nanoparticles by reductive coupling of arsenous acid 
present in the core of the nanostructure. In the present work, the cross-linking As(I) within 
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the nanoparticles is further elaborated with functional acetylenes in presence of radical 
initiators, to form vinylene-arsine cross-linked particles. This enables further stabilisa t ion 
of the nanoparticles, rendering it non-responsive towards oxidation. Furthermore, 
fluorescent a label was introduced through the incorporation of the O-propargyl 
Rhodamine-B ester as the functional acetylene reagent. Subsequently these fluorescent 
nanoparticles were tracked with in-vitro fluorescent confocal microscopy with the PC3 
cell-line, which showed strong mitochondrial co-localisation, indicating the 
mitochondrial tagging effect of arsenic observed in organoarsenical chemotherapeutics. 
Thus this work demonstrates a novel strategy of cross-linking polymeric nanostructures 
with arsenic whilst retaining the biochemical properties.    
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4.1 Introduction  
The use of arsenic trioxide (Trisenox, As2O3) for effective treatment for acute 
promyelocytic leukaemia has revitalised the therapeutic potential of arsenicals. 1  Such 
clinical renaissance in the use of arsenicals, has increased the acceptance of the use of 
arsenic in the field of polymer and biomaterials science. More recently, organic arsenicals 
4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid (GSAO),2 4-(N-(S-
penicillaminylacetyl)amino) phenylarsonous acid (PENAO)3 and S-dimethylarsino-
glutathione (ZIO-101; Darinasparin)4 have gained much attention for use as  
mitochondrial targeting chemotherapeutic drugs. These trivalent arsenicals (As(III)) 
drugs, work due to their natural high affinity for proximal cellular dithiols, for example it 
has been postulated that GSAO and PENAO, leads to loss of mitochondrial membrane 
potential by cross-linking Cys57 and Cys257 of mitochondrial adenine nucleotide 
translocase, leading to opening of the mitochondrial permeability transition pore.5 
Recently, Stenzel and co-workers have copolymerised a methacrylamide PENAO derived 
monomer, to incorporate the drug into the corona of polymer nanoparticles to improve its 
bioavailability and drug efficacy. More interestingly, the natural targeting properties of 
As(III) leads to mitochondrial colocalisation of the nanoparticles by confocal microscopy.  
The mitochondrial targeting properties of arsenic are an attractive feature and it is an 
excellent target for chemotherapy, considering the essential energy production required 
to maintain cell viability.  
 
The biochemical properties of arsenic is dependent on oxidation state of the As(X) (e.g. 
X = V, III, I), with As(III) being the most widely used for therapeutic applications. Arsines 
(As(I)) or cyclic oligoarsines (RAsn)6, 7 have been known since the 19th century and have 
been used as chemotherapeutic agents to treat syphilis, yet it was only as recent as 2005, 
that the structure of Arsphenamine/Salvarsen was elucidated as a mixture of 
organoarsenic homocycles.8 These cyclic structures are readily accessible by reduction of 
the corresponding arsonic acids using hypophosphorus acid in the presence of catalytic 
amounts of KI.9 As(I) are known to oxidatively hydrolyze, to form arsenous acid As(III). 
This unique redox responsive oligocyclisation of arsenic oxidation state inspired the 
previous chapter where As(I) was utilised for cross-linking self-assembled structures.1 0  
These As(I) stabilised particles were shown to dissemble under model biologica l ly 
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relevant redox conditions and found to be non-toxic (up to 2 mg/ml, Chapter 2). 
 
In 2004, Chujo and Naka recognized the potential of these oligomeric As-As structures 
to act as comonomers for alternating copolymerisation with alkynes to form 
poly(vinylene-arsines) via ring-collapsed radical alternating copolymeriza t ion 
(RCRAC).11 These were typically initiated by thermal decomposition of a radical initia tor 
(2,2’-azobisisobutyronitrile, AIBN) to catalyse the homolysis of labile As-As bonds. The 
resulting arsenic radicals can either recombine to form labile As-As bonds, or add to the 
acetylene monomer leading to formation of a new As-carbon bond (reviewed in Chapter 
1, Scheme 1.4). The structural characterization confirmed the poly(vinylene-ars ine) 
structure with a backbone composed of As-substituted vinylene groups with a trans-1,2 
geometry.11 Irrespective of the initial monomer feed ratio, 1:1 stoichiometry of the 
monomers was maintained as determined through elemental analysis and comparison of 
the backbone vinyl proton with the sidechain protons. Oligo-phenylarsine were found to 
be homolytically more stable than oligo-methyl-arsines, and also required more reactive 
acetylene comonomers. It was reported that aromatic acetylenes derivatives can react 
efficiently with oligo-phenylarsine, as the aromatic stabilization of the vinyl radical was 
essential for the addition of the As radical species. It was also reported that electron 
withdrawing groups (EWG) can stabilize the resulting radical and thus facilitate the 
polymerisation.12 
 
The aim of the work in this chapter was to cross-link self-assembled polymeric arsenicals 
through arsenic displayed on the side chains via the aforementioned RCRAC method. As 
well as stabilising the target nanoparticles, an additional purpose of this work is introduce 
new functionality into the core of the nanoparticles through RCRAC using functiona l 
alkyne motifs. 
 
4.2 Results and discussion 
4.2.1 Polymeric arsenical synthesis 
An identical strategy to that applied in Chapter 3 was employed to synthesis block 
copolymer composed of corona forming poly(ethylene glycol) methyl ether acrylate 
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(PEGA, Mn = 480 gmol-1) block and core forming N-isopropylacrylamide (NIPAm) block, 
which self-assembles at elevated temperature owing to the thermoresponsive nature of 
Poly(NIPAm). Previously, these polymers were thermally self-assembled and 
successfully crossed-linked through the incorporation of the arsenical functional group in 
the core forming NIPAm block. From the earlier investigation with cyclooligoars ine 
cross-linking, the arsenical monomer feed was observed to influence the particle stability 
as function of cross-linking density. This steered the initial focus of this work to vary the 
arsenical monomer feed in the core forming NIPAm block, whilst keeping the corona 
forming PEGA block length constant to investigate the effect of cross-linking density of 
the stability of the corresponding particles. Therefore, in this study polymer compositions 
of P(PEGA20-b-[NIPAM80-n-co-AsAmn]) (P4.1 n = 5, P4.2 n = 10, P4.3 n = 15, P4.4 n 
= 20) were targeted. 
 
So far two approaches to generate the arsenical functional diblock copolymers have been 
demonstrated. In Chapter 2, diblock copolymers were generated with unprotected 
arsenical acrylamide (AsAm) using sodium hydroxide to aid the solubility of the 
monomer, via sequential chain extension by aqueous SET-LRP. However, for more 
precise determination of the block co-monomer feed ratio for subsequent cross-linking in 
Chapter 3, a pinacol protected arsenic acrylamide AsAm(pin)2 was polymerised by RAFT 
polymerisation, with deprotection of the pinacol group yielding polymers with the 
reactive arsenic acid functional group required for cross-linking. It’s noteworthy that 2,2-
trifluoroethanol (TFE) was used a solvent, which is known to be a good solvent for 
hydrophobic and hydrophilic monomers, but also due to its miscibility with water it 
allowed facile aqueous acid dialysis for subsequent deprotection and purification. 1 3  
Considering the former factor, we decided to use the RAFT approach in this investigat ion.  
 
Using the previous RAFT conditions, the initial PEGA block (targeting DP 20) was 
polymerised, with PABTC as the RAFT agent, and subsequently chain extended with 
varying amounts of AsAm(pin)2 and NIPAm (targeting overall DP 80). Conversion was 
monitored via 1H NMR comparing vinyl signals at 5.50 – 6.50 ppm with an interna l 
reference (-CH3 of the Z-group belonging to the PABTC (δ = 0.91 ppm)) for the init ia l 
block and methoxy (-OCH3 at 3.34 ppm) of the PEGA for the chain extension (see 
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Chapter 3). In all cases the initial blocks were close to the desire target DPn (PEGAn DP 
= 20) with narrow molecular weights distributions (Mn,SEC = 8400-10400 gmol-1, Đ = 
1.16-1.27, Table 4.1) and good agreement with Mn,th. The block copolymerisation was 
successfully demonstrated by SEC analysis showing a shift to higher molecular weight 
(Mn,SEC = 17500-22000, D =1.25-1.40, Fig 4.1, Table 4.1), owing to efficient re-initia t ion 
from the PEGA block with acrylamide based monomers. The removal of the pinacol 
groups was carried out using acidic dialysis in accordance to the previous study (Chapter 
3). The deprotection of the AsAm(pin)2 units was confirmed by 1H NMR with the 
disappearance of pinacol groups at 0.95 – 1.35 ppm and further confirmed by SEC 
analysis, showing a shift to lower molecular weight after deprotection (Mn,SEC = 9900-
13900, D =1.19-1.53; Fig 4.1, table 4.1). Successful inclusion of AsAm into the block 
copolymers was confirmed by 1H NMR with appearance of aromatic signals of AsAm 






Figure 4.1 Scheme of Poly(PEGA-NIPAm) diblock through sequential chain extension using RAFT 
polymerisation (as carried out in  chapter 2) with varying amount of Arsenical acrylamide in the 
NIPAm block (P4.1 z = 5, P4.2 z = 10, P4.3 z = 15, P4.4 z = 20). SEC (DMF) of the arsenic functi onal 
block copolymer showing the first block (black), block extension (red) and removing the pinacol 





Figure 4.2 1H NMR (D2O) of the final polymer P4.1-P4.4 
 
Table 4.1 Arsenic functional block copolymers synthesised by RAFT. 1H NMR of polymerisation 
mixture in CDCl3 and after deprotection done in D2O. SEC carried out with DMF as an eluent. 
 


















P4.1 P[PEGA23] > 99% 18000 9400 1.23    
P[PEGA23 -b-(NIPAm73-co-AsAm4)] > 99% 21800 17500 1.27 21200 13900 1.33 
P4.2 P[PEGA27] > 99% 13200 10400 1.27    
 P[PEGA27 -b-(NIPAm80-co-AsAm11)] > 99% 21800 22000 1.40 25400 10500 1.53 
P4.3 P[PEGA23] > 99% 11300 8400 1.23    
 P[PEGA23 -b-(NIPAm66- co-AsAm15)] > 99% 25500 21000 1.25 23100 9900 1.44 
P4.4 
 
P[PEGA24] > 99% 11800 8700 1.16    




The thermal stability of all the polymers was evaluated by thermogravimetric analysis 
(TGA), which revealed evolution of mass loss between 300-400 °C to correlate with 
incorporation of AsAm in the copolymer. However, between 450-600 °C the plateau of 
percentage mass remaining was proportional to the presence of Arsenic. Nevertheless, all 
polymers are stable at < 300 oC (Fig. 4.3).  
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Figure 4.3 Evolution of mass loss with temperature of arsenic functional polymers (P4.1-P4.4) by 
Thermogravimetric analysis. 
 
The thermoresponsive nature of the As(V)-functional polymers and propensity for self-
assembly was investigated by variable temperature dynamic light scattering (DLS). The 
aqueous solutions of all the arsenic functional polymers (1 mg ml-1) exhibiting an increase 
in hydrodynamic diameters (Dh) from 2.1-3.1 nm at 25 °C to 14-20 nm with uniform 





Figure 4.4 Particle size distribution curves of P4.1-P4.4 by dynamic light scattering (1 mg/ml, H2O) 
analysis at 25 °C and 60 °C (see Appendix C: S4.4A, S4.4B, S4.4C and S4.4D for supporting 
information). 
 
Using the method described in Chapter 2, which was inspired by the synthesis and 
structural elucidation of Salvarsen, the polymers were first cross-linked via the reductive 
coupling of the arsenical motifs, forming cyclic oligoarsines, during self-assembly (10 
mg ml-1) at 60 °C. These As(I) cross-linked nanoparticles (termed here as NPAs(I)-n) 
formed stable particles, as previously reported, when sufficient AsAm units were 
incorporated. This was consistent with the previous study when less than 5 AsAm residues 
were incorporated into the chain (P4.1) the nanoparticles dissembled (NPAs(I)-4) during 
the purification process, whereas the polymers containing more than 10 AsAm residues 
(P4.2-P4.4) maintained the self-assembly even after dialysis (NPAs(I)-11, NPAs(I)-15, 
NPAs(I)-18) (Fig 4.5). The stable nanoparticles also exhibited thermoresponsive NIPAm 
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character, causing a decrease in Dh of 1-6 nm at elevated temperature.  
 
Figure 4.5 Particle size distribution curves of NPAs(I)-n (n = 4, 11, 15, 18) by dynamic light scattering 
(1 mg/ml, H2O) analysis at 25 °C and 60 °C (see Appendix C: S4.5A, S4.5B, S4,5C and S4.5D for 
supporting information). 
 
Atomic force microscopy (AFM) and transition electron microscopy (TEM) of NPAs-18 





Figure 4.6 AFM (left, scale bar = 100 nm) and TEM (right, scale bar = 100 nm) of NPAs(I)-18 
 
The formation of cyclic oligoarsines was inferred by the disappearance of the As-O 
signals associated with the pendent arsenic acid moieties by Fourier transform-infra- red 
(FT-IR) spectroscopy (Fig 4.7). This allowed progression to further functionalise and 
stabilise the nanoparticles through RCRAC.  
 
 
Figure 4.7 Infrared spectra of NPAs(I)-18 (red) indicating the absence of As-O stretch (750 cm-1) 




4.2.2 Stabilisation of polymeric arsenical nanoparticle via arsine-vinylene cross-
linking 
In order to combine Chujo’s RCRAC strategy with the present work, propargyl alcohol 
and 2,2'-azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride (VA-044) was used as 
water soluble alkyne and azoinitiator respectively. These two reagents were added as 
deoxygenated aliquots after 30 minutes of initial reductive coupling to form As(I) cross-
linking with P4.1-P4.4, and then left for 16 h at 60 ºC (scheme 4.1). Pleasingly all the 
nanoparticles generated retained the self-assembled structures when cooled back to room 
temperature and survived purification via dialysis (Fig 4.8). RCRAC of phenylarsine was 
previously reported with aromatic acetylenes with electron withdrawing group greatly 
enhancing the propensity for polymerisation, in contrast authors noted that polymers were 
not obtained with aliphatic acetylenes, however in the case of propargyl alcohol, suffic ient 




Scheme 4.1 Cross-linking of Poly(PEGA-NIPAm) diblock copolymer through RCRAC of As(I) in the 
core of the self-assembly and water soluble acetylenes (Propargyl alcohol). The As(I) cross -link 
nanoparticles is initially generated under elevated temperature using H3PO2 to reductive couple the 
arsenic side chains for 10 minutes before the addition of VA-044 and acetylene then left for 2 hours.  
 
Interestingly, whereas nanoparticles generated from P4.1 via reductive coupling alone 
(NPAs(I)-4) did not survive dialysis, the particle cross-linked via reductive coupling in the 
presence of propargyl alcohol and VA-044 retained its self-assembled structure. We 
attribute this increased stability in vinylene-arsine cross-linking to three factors, 1) 
increased degree of cross-linking through polymerisation (versus oligomerization of 
Chapter 4 
141 
cyclicooligoarsines) 2) the trivalent arsenic (As(III)) bridging the vinylene-arsine chain 
has increased inertia towards oxidation 3) stronger relative bond strength through As-C 
(607 KJ mol-1) (versus As-As (382 KJ mol-1))14 which is further stabilised through π-π 
conjugation.15 These nanoparticles also exhibited thermoresponsive character less than 
the As(I) analogues, with decrease in Dh of 1-2.5 nm upon heating at 60 ºC (Fig 4.8). This 
can be ascribed with the factors above yielding a more densely packed and ridged core.  
 
 
Figure 4.8 Particle size distribution curves of NPPgOH-n (n = 4, 11, 15, 18) by dynamic light scattering 
(1 mg/ml, H2O) analysis at 25 °C and 60 °C (see Appendix C: S4.8A, S4.8B, S4.8C and S4.8D for 
supporting information). 
 
Transmission electron microscopy (TEM) and atomic force microscopy (AFM) of 
NPPgO H-18 confirmed the formation of spherical nanoparticles with sizes < 35 nm, which 





Figure 4.9 AFM (left column) and TEM (right column) of NPPgOH-18 (bottom row scale bar = 100 
nm, top row scale bar = 500 nm) 
 
The stability of these vinylene-arsine cross-linked nanoparticles under model biologica l 
redox conditions were initially investigated in presence of reduced glutathione (GSH) at 
37 oC, mimicking intracellular conditions ([GSH] = 5 mM). In Chapter 2, As(I) cross-
linked particles were shown to slowly dissemble (over 96 hrs) by DLS analysis due to the 
formation of more enthalpically favoured As-S bonds (425 kJ mol-1)14 over the weaker 
As-As bonds. In the present work, all the propargyl alcohol cross-linked nanopartic les 
(NPPgO H-n) remained unchanged over a week, due to the stronger As-C bonds along the 




Figure 4.10 Particle size distribution curves of NPPgOH-n (n = 4, 11, 15, 18) by dynamic light 
scattering (1 mg/ml, H2O) as function of time in aqueous GSH (5mM) (see Appendix C: S4.10A, 
S4.10B, S4.10C and S4.10D for supporting information). 
 
The stability of the nanoparticles in the presence of hydrogen peroxide at 37 °C to mimic 
lysosomal oxidative conditions conditions ([H2O2] = 5 mM) was then investigated. All 
the NPPgO H-n were found to more stable than the nanoparticles reported in Chapter 2 and 





Figure 4.11 Particle size distribution curves of NPPgOH-n (n = 4, 11, 15, 18) by dynamic light 
scattering (1 mg/ml, H2O) as function of time in aqueous H2O2 (5mM) (see Appendix C: S4.11A, 
S4.11B, S4.11C and S4.11D for supporting information). 
 
 
Observed increase in stability compared to the analogues in in chapter 2 and 3 where the 
NPs were cross-linked through formation of As-As and As-S bond formation. In 
particular, the resilience to oxidation, in agreement with the seminal work of Chujo et al, 
was taken as an indirect indication of vinylene-arsine bond formation. Attempts to detect 
the vinyl protons by 1H NMR were unsuccessful. Alternative methods of detection, not 
employed here, include IR, Raman and oxidative staining using osmium tetroxide. 
 
To further demonstrate the applicability of the RCRAC a range of functional water soluble 
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alkynes were examined as co-monomer for cross-linking. Given the mechanism of 
RCRAC, it was hypothesised that there would be orthogonality with functional groups 
such as nucleophilic amines and carboxylic acids, in addition, allowing positively and 
negatively charged core nanoparticles to be generated. To this end, propargyl amine and 
propiolic acid were screened as the alkyne comonomers and successfully generated 
stabilised nanoparticles NPPgNH-n and NPPAc-n respectively with the library of arsenical 
polymers (Scheme 4.2).  
 
 
Scheme 4.2 Cross-linking of Poly(PEGA-NIPAm) diblock copolymer through RCRAC of As(I) in 
the core of the self-assembly and water soluble functional acetylenes: propiolic acid and propargyl 
amine to generate nanoparticles: NPPAc-n, NPPgNH-n (n = 4, 11, 15, 18)  
 
These all behaved similarly to the nanoparticles generated with RCRAC cross-linking 
with propargyl alcohol when the temperature was elevated to 60 °C, demonstrated 




Figure 4.12 Particle size distribution curves of NPPgNH-n (n = 4, 11, 15, 18) by dynamic light 
scattering (1 mg/ml, H2O) analysis at 25 °C and 60 °C (see Appendix C: S4.12A, S4.12B, S4.12C 





Figure 4.13 Particle size distribution curves of NPPAc-n (n = 4, 11, 15, 18) by dynamic light scattering 
(1 mg/ml, H2O) analysis at 25 °C and 60 °C (see Appendix C: S4.13A, S4.13B, S4.13C and S4.13D 
for supporting information). 
 
TEM and AFM of NPPgNH-18 and NPPAc-18 further confirms formation of nanopartic les 





Figure 4.14 AFM (left column) and TEM (right column) of NPPNH-18 (bottom row scale bar = 100 




Figure 4.15 AFM (left column) and TEM (right column) of NPPAc-18 (bottom row scale bar = 100 
nm, top row scale bar = 500 nm) 
 
The stability of the particles was subsequently examined with the redox conditions above. 
Interestingly, the nanoparticles cross-linked with propiolic acid degraded over the course 
of a week in hydrogen peroxide, with the lowest arsenic content (P4.1, NPPAc-4) 
dissembling within 24 hours. However, they were stable in presence of glutathione for a 
week (Fig 4.16). In contrast all the nanoparticles generated with propagyl amine were 
stable in oxidative conditions over a week even with P4.1, however P4.1 was unstable in 
presence of glutathione, showing decrease in size after 72 hours (Fig 4.17), however these 
were still larger than unimers. This observation could be due to unreacted AsAm units 





Figure 4.16 Particle size distribution curves of NPPAc-n (n = 4, 18) by dynamic light scattering (1 
mg/ml) as function of time in aqueous H2O2 (5mM, top row) and GSH (5mM. bottom row) (see 







Figure 4.17 Particle size distribution curves of NPPNH-n (n = 4, 18) by dynamic light scattering (1 
mg/ml) as function of time in aqueous H2O2 (5mM, top row) and GSH (5mM. bottom row) (see 
Appendix C: S4.17A, S4.17B, S4.17C and S4.17D for supporting information). 
 
4.2.3 Cytotoxicity of polymeric arsenical nanoparticles  
Considering the biomedical potential of our nanoparticles it was critical to evaluate their 
toxicity. In addition to the parent polymeric arsenicals P4.1-P4.4 the acute toxicity of all 
the nanoparticles (NPPgO H-n, NPPAc-n, and NPPgNH2-n) was determined in vitro via standard 
XTT assay using Prostate carcinoma cell line (PC3) as a model. The parent polymers and 
corresponding nanoparticles were non-toxic up to the maximum concentration that was 
tested (2 mg ml-1) (Fig 4.18).  This was consistent with the results reported in Chapter 2 
and 3. Polymeric arsenical scaffolds exhibit limited cytotoxicity in vitro against the same 
cell-line,6, 18 thus with previous result these findings further highlights arsenic as potential 





Table 4.2 Particle size by dynamic light scattering at 25 °C and 60 °C in aqueous solution (1 mg/ml) 
(PDi calculated from equation 4.1) 
  25 °C 60 °C 
  Dh (nm) PDi Dh (nm) PDi 
P4.1 Polymer 3.12 0.052 13.60 0.077 
 NPAs(I)-4 3.47 0.052 12.02 0.086 
 NPPgOH-4 11.3 0.108 9.47 0.101 
 NPPgNH-4 11.9 0.156 15.4 0.088 
 NPPgAc-4 14.2 0.013 13.4 0.094 
 NPRh-4 19.6 0.129 16.0 0.102 
P4.2 Polymer 2.47 0.046 19.7 0.097 
 NPAs(I)-11 18.8 0.138 12.58 0.100 
 NPPgOH-11 12.7 0.095 14.0 0.119 
 NPPgNH-11 30.9 0.138 28.2 0.126 
 NPPgAc-11 17.6 0.014 20.3 0.102 
 NPRh-11 26.7 0.098 13.8 0.099 
P4.3 Polymer 2.65 0.043 14.2 0.093 
 NPAs(I)-15 10.7 0.107 10.9 0.100 
 NPPgOH-15 14.1 0.106 140 0.119 
 NPPgNH-15 24.9 0.122 23.5 0.142 
 NPPgAc-15 21.5 0.108 22.5 0.110 
 NPRh-15 18.3 0.102 13.8 0.099 
P4.4 Polymer 2.20 0.050 16.9 0.090 
 NPAs(I)-18 16.8 0.133 14.5 0.130 
 NPPgOH-18 15.1 0.099 13.5 0.107 
 NPPgNH-18 23.5 0.022 23.5 0.143 
 NPPgAc-18 21.8 0.090 20.5 0.098 





Figure 4.18 In vitro cell viability of polymers P4.1-P4.4 (top left) and nanoparticles NPPgOH-n (top 
right), NPPgNH-n (bottom left) and NPPAc-n (bottom right) (n = 4, 11, 15 and 18) using XTT viability 
assay with PC3 cell line. 
 
4.2.4 Cellular tracking of polymeric arsenical nanoparticles 
Given that particle size and shape impacts biodistribution in vivo; spherical nanopartic les 
below 50 nm have been reported by many to be the best for tumour accumulation,16, 17 
which makes the cross-linked nanoparticles reported here candidates for drug delivery. In 
order to establish the cellular uptake of the nanoparticles and determine the localisa t ion 
within the intracellular framework, incorporation of an appropriate visualisation probe 
was necessary. The RCRAC method was identified as a possible route to covalently 
introduce functionality suitable for cellular imaging within the core of our nanopartic le 
core. Rhodamine B was chosen as a cheap water soluble fluorescent probe, with a 
convenient handle for alkyne attachment through the esterification of the acid group. The 
O-propargyl-ester derivative of rhodamine B was prepared via standard Steglich 
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conditions, using N,N’-dicyclohexylcarbodiimide (DCC), and catalytic quantities of 4-
dimethylaminopyridine (DMAP) in anhydrous dichloromethane (DCM). The ester 
product was purified by flash column to yield iridescent black crystals, 4 (57% yield), 




Figure 4.19 1H-NMR spectrum and synthesis of O-propargyl-Rhodamine-B ester 
 
Using the aforementioned RCRAC protocol to cross-link P4.1-P4.4 with O-propargyl-
ester rhodamine, fluorescent nanoparticles (NPRh-n) were prepared (Fig 4.20). The 
nanoparticles were purified by acidic dialysis (0.1 M HCl), until no colouration was 
present in the dialysis media, before switching to neutral deionised water and fina lly 
lyophilisation. The nanoparticles generated were comparable in size by DLS analysis (Dh 




Figure 4.20 Cross-linking of Poly(PEGA-NIPAm) diblock copolymer through RCRAC of As(I) in 
the core of the self-assembly and O-propargyl Rhodamine B ester to generate fluorescent 
nanoparticles nanoparticles: NPRh-n (n = 4, 11, 15, 18). Particle size distribution curves by DLS 
(bottom left, 1 mg/ml). Fluorescence spectrum of NPRh-18 (λEx = 553 nm, λEm = 627 nm). 
 
The nanoparticles exhibited fluorescence properties according to fluorescence 
spectroscopy confirming successful loading with the rhodamine (Fig 4.20). The quantity 
of rhodamine was determined using Ultraviolet-visible (UV-Vis) spectroscopy by 
extrapolating the concentration from calibration graph of rhodamine O-propargyl-ester 
(Fig 4.21). This revealed theoretical cross-linking efficiency of 7 – 32 % through RCRAC 





Figure 4.21 UV-Vis calibration curves of O-propargyl Rhodamine B ester yielding theoretical 
crosslinking densities of NPRh-18 = 12 % ; NPRh-15 = 12 % ; NPRh-11 = 7.1 % ; NPRh-4 = 32 % . 
 
Interestingly NPRh-n with the least theoretical cross-linking, NPRh-11 (7 %) exhibited the 
most pronounced contraction under elevated temperature (Fig 4.22), consistent with the 





Figure 4.22 Particle size distribution curves of NPRh-n (n = 4, 11, 15, 18) by dynamic light scattering 
(1 mg/ml, H2O) analysis at 25 °C and 60 °C (see Appendix C: S4.22A, S4.22B, S4.22C and S4.22D 
for supporting information). 
 
Formation of spherical nanoparticles of NPRh-18 was confirmed with AFM and TEM 





Figure 4.23 AFM (left column) and TEM (right column) of NPRh-18 (bottom row scale bar = 100 nm, 
top row scale bar = 500 nm) 
 
The rhodamine incorporated nanoparticles, including the one generated from with the 
lowest arsenic content, were found to be stable under the biologically relevant conditions 





Figure 4.24 Particle size distribution curves of NPRh-n (n = 4, 18) by dynamic light scattering (1 
mg/ml) as function of time in aqueous H2O2 (5mM, top row) and GSH (5mM. bottom row) (see 
Appendix C: S4.24A, S4.24B, S4.24C and S4.24D for supporting information).  
 
Prior to cellular uptake studies, fluorescence normalisation correction curves were plotted 
(Fig 4.25) for each nanoparticle in order to normalise the intracellular fluorescence with 
the intrinsic particle fluorescence to quantify the relative uptake. PC3 cells were then 
incubated with nanoparticles NPRh-n (100 µg mL-1) for 2 hr and washed three times with 






Figure 4.25 Fluorescence calibration curves of NPRh-n (n = 4, 11, 15, 18). Concentration at the linear 
region was used for normalisation. At higher concentration, self-quenching of the fluorophore 
occurs (red dots).  
 
Pleasingly increased intracellular fluorescence was observed as a result of cellular uptake 
of the fluorescent nanoparticles (Fig 4.26, Fig 4.27). Cellular uptake was observed after 
2 hours of incubation with the nanoparticles (Fig 4.26) and did not increase with a longer 
incubation period of 24 hours (Fig 4.27, Fig 2.28). These findings suggest that the 
aforementioned cell viability is a result of the intrinsic non-toxic properties of the 











Figure 4.27 Uptake of NPRh-n (n = 4, 11, 15 and 18) by PC3 cells with 24 hours of incubation (at 37 
°C). 
 
Interestingly increasing the proportion of arsenic within the nanoparticle, greater cellular 
uptake was observed  (Fig 4.28), particularly with NPRh-18 and NPRh-15 showing higher 
uptake than NPRh-10 and NP Rh-4 which can be attributed to increased particle stability as 




Figure 4.28 Relative fluorescence intensity of NPRh-n (n = 4, 11, 15 and 18) in PC3 cells with a 
nanoparticle concentration of 100 µg mL-1 after 2 and 24 hours of incubation. Following 
background reduction using a roll ball model (25 µm), fluorescence associated with rhodamine 
(RFP filter, λex = 531 nm, λem = 593 nm) was assigned as intracellular fluorescence. Data is 
represented as the arithmetic mean ± SD with experiment conducted in triplicates. 
 
To further track the internalisation of the nanoparticle, fluorescent confocal microscopy 
was used investigate the intracellular co-localisation of the internalised nanoparticles. It 
was hypothesised that, the nanoparticles do not enter the cells passively through direct 
translocation across the plasma membrane due to their size, but instead enter through an 
energy depend mechanism involving trafficking through a probable endosomal 
pathway.21 It was therefore reasonable to assume possible trafficking of the nanopartic les 
to the lysosomes upon cellular entry, thus we initially stained PC3 cells with lysosomal 
stain, lysotracker green, and incubated with NPRh-18 (100 µg mL-1) for 24 hours prior to 
imaging to investigate the possible lysosomal co-localisation of the nanoparticles. The 
nanoparticle appears to be punctuated across the cell as observed by the confocal 
microscopy, however they do not appear to co-localise in the lysosomes (Fig 4.29). These 
results suggest avoidance of the nanoparticle towards the lysosomes, in comparison to 



































lysomal localisation (yellow regions, Figure 4.30). In addition the nuclei of the cells were 




Figure 4.29 Confocal fluorescent microscopy images of PC3 cells with NPRh-18. i) Hoechst 33258; ii) 
Rhodamine-B; iii) Lysotracker green; iv) Brightfield image; v) Overlay of channels indicating lack 










Figure 4.30 Confocal fluorescent microscopy images of PC3 cells with free Rhodamine B. i) Hoechst 
33258; ii) Rhodamine-B; iii) Lysotracker green; iv) Brightfield image; v) Overlay of channels 
showing localisation of Rhodamine B relative to the lysosomes. Scale bar = 30 µm. 
 
Considering the arsenic affinity towards mitochondrial as mentioned earlier, the next step 
was to determine the mitochondrial co-localisation of the nanoparticles. The mitochondria 
of PC3 cells were stained with mitotracker-green and incubated with NPRh-18. Although 
the nanoparticles are distributed throughout the cell, juxtaposition of the mitochondria l 
stain and rhodamine shows co-localisation as indicated by in yellow regions as a result of 
superimposing of the two stains (Fig 4.31). This can be attributed due to targeting effects 
of unreacted As(III) within the particle, as from the UV-vis spectra 12 % of the rhodamine 
O-propargyl ester (assuming 1:1 / arsine:alkyne) was incorporated in NPRh-18 forming 
stable As-C bonds, suggesting number of uncross-linked arsenic groups are availab le 
capable of reacting with cellular thiols and therefore functioning as an active 
mitochondria tag. To rule out the co-localisation of the nanoparticle as an artefact of free 








rhodamine was conducted. As the free rhodamine appears to be distributed throughout 
the cell with no strong co-localisation with mitotracker green (Fig 4.32), we can attribute 
our findings as a result of tagging effect of arsenic with thiols present in the mitochondria.  
 
 
Figure 4.31 Confocal fluorescent microscopy images of PC3 cells with NPRh-18. i) Hoechst 33258; ii) 
Rhodamine-B; iii) Mitotracker green; iv) Brightfield image; v) Overlay of channels indicating 










Figure 4.32 Confocal fluorescent microscopy images of PC3 cells with free Rhodamine B (bottom). 
i) Hoechst 33258; ii) Rhodamine-B; iii) Mitotracker green; iv) Brightfield image; v) Overlay of 
channels indicating lack of mitochondrial co-localisation is observed with free Rhodamine-B. Scale 
bar = 30 µm. 
 
4.3 Conclusion 
The ability of arsenic to polymerise with acetylenes is a unique semi-metalloid elementa l 
feature. This method was reported to obtain poly(arsine-vinylene) conjugate polymers in 
2004, but to date an application of this polymerisation has not yet been reported. As 
demonstrated in Chapter 2 and 3, nanoparticles can be generated by cross-linking 
polymers through arsenic by reduction to As(I) or by addition of nucleophilic cross-
linkers. This chapter demonstrates the property of arsenic to polymerise with acetylenes 
as an alternative strategy of cross-linking polymers. In contrast to previous studies, this 
method of cross-linking yielded nanoparticles resistant to oxidation by H2O2. 
Furthermore, this strategy enabled incorporation of additional properties through the 








Rhodamine B ester. This permitted visualisation for in-vitro cellular uptake and tracking 
of the nanoparticle by confocal fluorescent microscopy. The results indicates successful 
uptake of the nanoparticles which become diffusely distributed in the cells, with evidence 
to suggest mitochondrial co-localisation. This mitochondrial targeting property of arsenic 
has recently been exploited by Stenzel to direct polymeric nanoparticles where the 
arsenous acid are displayed on the exterior. We show this targeting biochemical property 
of Arsenic is possibly retained in the even in the core of the nanoparticle. Considering the 
non-toxic nature of these arsenical nanoparticles as confirmed by standard in-vitro XTT-
assay (2 mg/ml), these are promising candidate for benign mitochondrial target ing 
biomaterials. Further investigation into in-vivo study would be interesting to evaluate in-






4.4.1 Materials  
Dimethyl 2,2’-azobis(2-methylpropionate) (V601), N-(4-(2,2,3,3,7,7,8,8-octamethyl-
1,4,6,9-tetraoxa-5λ5-arsaspiro[4.4]non-5-yl)-phenyl-2-propenamide) (AsAm(pin2)) was 
synthesised as previously reported21 2-((butylthio)-carbonothioyl) thio propanoic acid 
(PABTC) was synthesised according to the reported literature.22 N-Isopropylacrylamide 
(NIPAm, 97%) was purchased from sigma and recrystallized in hexane from diethyl ether.  
Potassium Iodide, glutathione (GSH), hydrogen peroxide (30 % w/w), hypophosphorous 
acid (50% w/w), and poly(ethylene glycol) methyl ether acrylate (PEGA, average Mn = 
480) were purchased from Sigma Aldrich and used as received. Membrane dialysis tubing 
(nMWCO 3.5 kDa) was obtained from Spectrum Laboratories.  
 
4.4.2 Nuclear Magnetic Resonance 
Nuclear Magnetic Resonance (NMR) spectroscopy  (1H  NMR)  spectra  were  recorded  
on  a  Bruker HD  300  spectrometer  (300  MHz) at  27  °C  in either deuterated chloroform 
(CDCl3) or deutrated water (D2O). Chemical shift values (δ) are reported in ppm. The 
residual proton signal of the solvent (δ H = 7.26 ppm for CDCl3, δ H = 2.50 ppm for D2O) 
was used as internal reference. ACDLABS software was used to analyse the data 
obtained. 
 
4.4.3 Size Exclusion Chromatography 
Size Exclusion Chromatography (SEC) was conducted using an Agilent 390-LC MDS 
instrument equipped with differential refractive index (DRI), viscometry (VS), dual angle 
light scatter (LS) and dual wavelength UV detectors. The system was equipped with 2 x 
PLgel Mixed D columns (300 x 7.5 mm) and a PLgel 5 µm guard column. The eluent is 
DMF with 5 mmol NH4BF4 additive. Samples were run at 1 ml min-1 at 50 °C. 
Poly(methyl methacrylate) (PMMA) standards (Agilent EasyVials) were used 
for 3rd order calibration between 2 x 102 – 1.0 × 106 g mol-1. Analyte samples were 
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filtered through 450 μm nylon filters pore size before injection. Mn,SEC and Đ values of 
synthesized polymers were determined by conventional calibration using Agilent 
GPC/SEC software. 
 
4.4.4 Dynamic Light Scattering  
Hydrodynamic diameters (Dh) and size distributions were determined by Dynamic Light 
Scattering (DLS)  on  a  MALVERN Zetasizer  Nano  ZS operating  at  25 °C with  a  4 
mW He-Ne 633 nm laser  module. Measurements were made at a detection angle of 173° 
(back scattering). Measurements were repeated three times with automatic attenuat ion 
selection and measurement position. The results were analysed using Malvern DTS 6.20 
software. PDI values were calculated using equation Eq 4.1 
𝑃𝐷𝐼 =  
𝜎2
𝑑2
 (Eq 4.1) 
Where σ is the standard deviation, and d is the diameter both obtained from the numb er 
distribution.  
 
4.4.5 Infrared spectroscopy 
Infrared (IR) spectra were recorded on a Bruker VECTOR-22 FTIR spectrometer using a 
Golden Gate diamond attenuated total reflection cell.  
 
4.4.6 Ultraviolet-visible light spectrometer 
Ultraviolet-visible (UV-Vis) calibration curves for experimental cross-linking density 
was recorded on an Agilent Technologies Cary 60 UV-Vis at a wavelength of 531 nm 
using a cuvette with a 1 cm path length and solutions of 1 mg ml-1.  
 
4.4.7 Fluorescence spectrometer  
The fluorescent intensity was monitored using Agilent Technologies Cary Eclipse 
Fluorescence Spectrophotometer at an excitation wavelength of 553 nm and collection of 
emission at 627 nm based on rhodamine B using a cuvette with a 1 cm path length and 




4.4.8 Thermogravimetric Analysis 
Thermogravimetric Analysis (TGA) spectra were recorded on a Mettler 
Toledo TGA/DSC. Samples were heated from 25 to 600 ºC at 10 ºC min-1 under 
N2 atmosphere. 
 
4.4.9 Atomic Force Microscopy 
Atomic Force Microscopy (AFM) images were recorded on a Bruker Dimension Icon 
instrument operated in peak force tapping mode. The probes used were ScanAsyst silicon 
tips with a resonance frequency of 70 kHz and a spring constant of 0.4 N m-1. Samples 
were prepared by drop casting 5 μl of a 1 mg ml-1 aqueous nanoparticle solution onto a 
freshly cleaved sheet of mica, left to stand for 30 seconds and dried under of Nitrogen. 
 
4.4.10 Transition Electron Microscopy 
Transition Electron Microscopy (TEM) Samples were prepared by placing a 400 mesh 
carbon coated Formvar copper grid onto a 20 µL droplet of aqueous nanoparticles (1 mg 
ml-1) in a petri dish, leaving for 10 minutes prior to drawing off the solution. The grid was 
then stained by placing onto a 20 µl droplet of aqueous uranyl acetate (0.2 wt%), leaving 
for 10 minutes before drawing off excess liquid and allowed to air-dry overnight. TEM 
images were acquired using a JEOL 2100 TEM operating at a 200 kV accelerating 
voltage. Images were captured using Digital Micrograph® and analysed with ImageJ. 
 
4.4.11 General Cell Culture  
PC3 cells were purchased from ECACC and cultured as single monolayers at 310 K in a 
humidified atmosphere containing 5% CO2. Cells were sub-cultured at regular interva ls, 
and passages made by trypsinising cells when at 80-90% confluence. Media used was 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% of foetal calf 




4.4.12 Cell Viability  
PC3 cells were cultured in High Glucose DMEM medium supplemented with 10% fetal 
bovine serum. For cell viability evaluation, PC3 cells were seeded in a 96 well plate at a 
density of 1 × 104 cells per well. After 16 h, the culture medium was replaced by fresh 
media containing a series of dilution of the polymers (0.0625, 0.125, 0.25, 0.5, 1 and 2 
mg ml-1), prepared from stock solutions in PBS at 500 μM. Following 24 h incubation, 
the medium was removed and replaced with fresh medium. The cells were incubated with 
a freshly prepared solution of XTT (0.2 mg mL-1) and N-methyl dibenzopyrazine methyl 
sulfate (250 μM) in medium for 16 h. Absorbance of the samples was finally measured 
using a plate reader at 450 nm and 650 nm. The data presented are representative of a 
minimum of two independent experiments where each sample was measured in triplicate. 
Errors reported correspond to the SD of the mean. 
 
4.4.13 Cell Uptake  
PC3 Cells were seeded into a black 96 imaging well plate with a clear bottom at a density 
of 5000 cells per well and allowed to grow for 24 h. The culture medium was replaced 
with media containing rhodamine labelled nanoparticles (100 µg mL-1) 2 h and 24 h prior 
to imaging. Cellular fluorescence was measured using a Cytation 3 Cell Imaging Multi-
Mode ReaderTM from Biotek®, with quantification from the Gen5TM software. Single 
cells were isolated using the blue channel (Hoechst 33258), and using a secondary mask 
with an area of 12 µm. Following background reduction using a roll ball model (25 µm), 
fluorescence associated with rhodamine (RFP filter, λex = 531 nm, λem = 593 nm) was 
assigned as intracellular fluorescence. Data is represented as the arithmetic mean ± SD 
with experiments conducted in triplicates.  
 
4.4.14 Confocal Microscopy  
7500 PC3 cells were seeded in a 10 well microscopy slide and left to incubate for 24 h, 
at 37°C in 5% CO2 atmosphere. The culture medium was replaced with media containing 
nanoparticles (100 µg mL-1) and incubated for 24 h prior to imaging. Cells were stained 
with 1) Nuclear stain – Hoechst 33258 (0.5 µg mL-1; 30 min), 2) Lysotracker-Green (100 
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nM; 2 h), 3) Mitotracker green (100 nM; 30 min). Immediately prior to imaging, the cells 
were washed with PBS 3x, and finally the media replaced with 100 µL of phenol red free 
DMEM. Cells were imaged with a Zeiss 880 confocal microscope using a 40 x objective, 
at 37°C with the following laser settings: 1) Hoechst dye (blue channel), 405 nm laser, 
420-500 nm emission band. 2) Lysotracker and Mitotracker (green channels), 488 nm 
laser 500-550 nm emission band. 3) rhodamine labelled compounds and free rhodamine 
B (red channel), 561 nm laser (570-630 nm emission band). Images were processed with 
Fiji software.  
 
4.4.15 Synthesis of Propargyl-O-Rhodamine B ester 
 
Rhodamine b (1 eq), DCC (1.5 eq), DMAP (0.2 eq) were dissolved in anhydrous DCM 
(50 ml) and stirred for 30 min. Propargyl alcohol (1.5 eq) were added and stirred at room 
temperature for 16 h. Product purified by flash column in 1% methanol in DCM, the 
resulting product fractions combined and the solvent removed in vacuo to yield iridescent 
black crystals 4 (57% yield). 1H NMR (400 MHz, CDCl3, 298 K) δ = 8.30 (d, JHH = 7.2 
Hz, 1H, Hi), 7.84 (dd, JHH = 7.2, 7.3 Hz, 1H, Hg), 7.75 (dd, JHH = 7.9, 7.3 Hz, 1H, Hh), 
7.31 (d, JHH = 7.9 Hz, 1H, Hf) 7.06 (d, JHH = 9.5 Hz, 2H, He), 6.90 (d, JHH = 9.7 Hz, 2H, 
Hd) 6.80 (s, 2H, Hc) 4.60 (s, 2H, Hj) 3.63 (q, JHH = 13.3, 6.4 Hz, 8H, Hb) 2.40 (s, 1H, Hk) 
1.30 (t, JHH = 6.8, 12H, Ha); 13C NMR (400 MHz, CDCl3 298 K) δ = 164.2, 75.6, 52.9, 






4.4.16 General procedure for self-assembly and crosslinking of PEGA20-b-
[NIPAm80-n-st-AsAmn] via acetylenes 
 
The general procedure for crosslinking through vinyl-arsine required As-functiona l 
polymer dissolution in a deoxygenated aqueous solution of hypophosphorus acid (H3PO2, 
10 wt%, 10 mg/ml polymer) and deoxygenated KI (1 vol% from a 3 wt% aq solution) 
were added. The solution were heated to 60 °C for 30 min. The functionalised acetyleneS 
(2.5 eq. w.r.t. [As]) and VA-044 (0.1 eq w.r.t [As]) were separately dissolved in HPLC 
grade H2O and sparged with N2 before addition to the hot polymer solution which were 
heated for a further 15.5 h. The resulting solution dialysed (nMWCO 3.5 KDa) against 
deionised water for 24 h and the crosslinked particles isolated by lyophilisation. The 
resulting solution of Rhodamine-functional nanoparticle were dialysed (nMWCO 3.5 
KDa) against dilute hydrochloric acid (HCl, 0.1 M) until no further fluorescence in the 
dialysis media were visible by UV-Vis, then further dialysis against deionised water for 
24 h, the crosslinked particles isolated by lyophilisation. 
4.4.17 General procedure for particle stability and disassembly.  
Polymer nanoparticles were dissolved separately in deionised water, aqueous glutathione 
(5 mM) and aqueous H2O2 (5 mM) (1 mg ml-1). The solutions were filtered through (450 
μm nylon filters) into separate plastic cuvettes (with a lid) and incubated at 37 0C in water 
bath. Disassembly was monitored through the measurement of changes in Dh as a function 
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Chapter 5 : Polymeric arsenicals as scaffolds for 




Arsenohydrogels are introduced for the first time as tuneable, responsive and 
biocompatible hydrogels. The distinctive redox reactivity of arsenic has been exploited 
to crosslink high molecular weight (Mw > 300 kDa) polymeric arsenical scaffolds 
(PDMAmx-co-AsAmy) via reductive coupling of As(V) to As(I) which proceeds with the 
formation of As-As in the form of As(I)n homocycles. Arsenohydrogels are formed at 2.5 
wt% of polymeric arsenical scaffold (G’ ̴ 400 Pa) and gel strength is significantly 
increased when the polymer weight fraction is increased to 10 wt% (up to 81 kPa). 
Increasing the mole fraction of arsenic (AsAm, y) increases the crosslinking density, 
reduces the degree of swelling and increases the stability of the gel against hydrolysis and 
oxidation of the As-As crosslinks. The functionality of the polymeric arsenical scaffolds 
has also been exploited to load arsenohydrogels with a model organic arsenical drug. The 
rate and degree of release of the loaded organic arsenical under simulated oxidative stress 
(H2O2) is inversely proportional to the mole fraction of arsenic in the original polymer 
scaffold. Finally, the polymeric arsenical scaffolds and the resulting arsenohydrogels have 
been shown to be non-toxic and capable of encapsulating trypsinized PC3 cells. The 
properties and versatility of the arsenohydrogels further alludes to their potential as a 




Synthetic polymer hydrogels are materials composed of networks of hydrophil ic 
polymers, cross-linked via covalent bonding or physical interactions such as hydrogen 
bonding,1 electrostatic interactions2 and host - guest3 / metal – ligand4 complexation.5, 6 
They are defined by their durability and programmable physical and mechanica l 
properties even at high water contents (> 90%), which lends itself to a number of 
emerging technologies, particularly in healthcare where they are being applied in areas 
such as wound dressings,7 diagnostics,8 drug delivery,9 3D cell culture,10 tissue 
engineering11 and wearable technologies.12  
 
Hydrogels formed through covalent bonding can exhibit static or dynamic properties 
based on the nature of the cross-linking involved.13 For example, the archetypal 
polyacrylamide hydrogel employed in gel electrophoresis, is an aqueous network of 
acrylamide irreversibly cross-linked by a bisacrylamide co-monomer.14 Conversely, 
incorporation of functional groups capable of forming cleavable and/or dynamic covalent 
bonds into polymeric scaffolds has been employed to fabricate dynamic hydrogels which 
elicit spatial and temporal controlled bond formation and degradation, and in some cases 
self-healing properties.15, 16 In this context Schiff bases (including hydrazone17 and 
oxime18), boronate esters19 and disulfides20 are amongst those most widely explored in 
such systems. These dynamic bonds are sensitive to changes in the local pH or redox 
environment, or are competitively exchanged with biologically relevant nucleophiles to 
stimulate material response.  
 
Organic arsenicals have diverse and distinct chemical reactivity which is dependent upon 
the oxidation state of the As(X) (e.g. X = V, III, I) centres present. However, concerns 
about the toxicity of arsenic have limited the use to organic arsenicals in polymer and 
materials science. A clinical renaissance in the use of arsenic trioxide to treat blood born 
malignancies and the subsequent development of more potent organic arsenical 
analogues,21 has inspired investigations into the potential of organic and polymeric 
arsenicals as a platform for functional and responsive (bio)materials.22 To this end, 
pentavalent arsenic, As(V), has been incorporated into well-defined polymer chains at the 
chain-end and/or the side-chains of polymers synthesised by radical deactivation radical 
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polymerisation (RDRP), employing As-functional initiators and monomers respectively. 
These polymers have been shown to be non-toxic in vitro and have been exploited as 
reactive scaffolds for post-polymerisation modification23 and highly specific disulfide 
bond targeting linkers for protein/peptide-polymer conjugation24 via sequential reduction, 
to trivalent As(III), and reaction with thiol/disulfide containing molecules.  
 
Most recently, thermoresponsive block copolymers containing organic arsenicals have 
been synthesised and assembled under reductive conditions (H3PO2, KI) at elevated 
temperatures to generate nanoparticles stabilised as a result of reductive coupling from 
As(V) to As(I).25 This has previously been reported to proceed with the formation As-As 
bonds in the form of As(I)n homocyclic oligomers.26 The stability of the resulting 
nanoparticles in aqueous and model biological solutions (5 mM glutathione) was 
dependent upon the mole ratio of As(V) in the initial monomer feed and all were 
responsive towards oxidation with hydrogen peroxide. To date, this is the only example 
of cross-linking polymers ever reported using the redox chemistry of organic arsenicals. 
Herein, reductive coupling of As(V) to As(I) in hydrophilic polymeric arsenicals is 
demonstrated to furnish macroscopic arsenohydrogels. The resulting gels are non-toxic 
and their physical properties depend upon the As(V) mole fraction and the polymer 
loading in solution (wt%). 
 
5.2 Results and Discussion 
5.2.1 Polymeric arsenical synthesis 
For the preparation of high molecular weight hydrophilic As(V)-functional polymer 
scaffolds, the As(V)-functional acrylamide monomer (AsAm) reported in Chapter 2,25 
was copolymerised with hydrophilic acrylamide monomer dimethylacrylamide (DMAm) 
using free radical polymerisation. Water soluble initiator (VA0-44) was employed at 90 
°C targeting high monomer conversions and high molecular weight polymers. The 
reactions reached full conversion with respect to both monomers within 2 hrs and the 
resulting polymers were directly lyophilised without further purification. The PDMAmx-
co-AsAmy polymers (P5.1 – P5.4, Table 5.1) were synthesised with increasing AsAm 
functionality as observed by NMR (Fig. 5.1). The percentage of AsAm was calculated by 
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comparing either -CH2- the backbone of DMAm and AsAm (1.0 – 1.8 ppm) or CH3- side 
chain of DMAm with –CH- of the backbone (2.1 – 3.0 pm) with aromatic AsAm protons 




Figure 5.1 NMR of polymeric arsenical scaffolds PDAmx-co-AsAmy synthesised by free radical 
polymerisation. 
 















P5.1 P(DMAm0.98-AsAm0.02) 95000 460000 4.8 
P5.2 P(DMAm0.96-AsAm0.04) 81000 330000 4.1 
P5.3 P(DMAm0.94-AsAm0.06) 110000 450000 4.1 
P5.4 P(DMAm0.92-AsAm0.08) 56000 310000 5.5 





Increasing Arsenic content was also confirmed by the increase in υ = 854 cm-1 
corresponding to the As-O absorption in IR spectroscopy (Fig. 5.2). Molecular weight 
data was obtained by aqueous size exclusion chromatography (SEC) which revealed that 
each polymer had high molecular weight (Mw > 300 kDa, Fig. 5.3). 
 
 



















































Figure 5.3 Molecular weight data for polymeric arsenical scaffolds P5.1 – P5.4 obtained from 
aqueous SEC 
 
5.2.2 Hydrogel preparation and characterisation 
The polymers were cross-linked via the reductive coupling method described in Chapter 
2 which was inspired by the synthesis and structural elucidation of Salvarsen (Scheme 
5.1).27 Hydrogels were formed at 2.5 wt% and 10 wt% polymer after heating at 60 °C in 
the presence of aqueous H3PO2 and KI for 30 minutes, according to qualitative inversion 
tests (Fig 5.4). Attempts to form gels at 1 wt% of the arsenical polymers were 





Scheme 5.1 General scheme for the formation of arsenohydrogels by reductive coupling of 
polymeric arsenical scaffolds 
 
 
Figure 5.4 Inverse test qualitatively demonstrating gelation at 2.5 wt%  and 10 wt%  with no 
gelation occurring at 1 wt%  
 
Interestingly P5.3 and P5.4 with increased amounts of AsAm units induced syneresis at 
2.5 wt % after the initial gel formation, expelling 40% of the aqueous solution (Fig 5.5). 
This macroscopic contraction is typically observed with highly cross-linked polymeric 
gels at low polymer weight concentration.28  
 
 
Figure 5.5 Image of 2.5 wt %  arsenohydrogels P5.1 – P5.4 in which P1 and P2 formed stable gels P3 




The formation of the 2.5 wt % gel was followed by rheology in oscillation mode (0.1% 
strain). The transition from liquid to gel was observed at the cross over point between the 
storage (G’) and loss (G’’) moduli (t < 500 secs) and G’ values indicated that very soft 
gels were formed under these conditions (G’ < 400 Pa) (Fig. 5.6). At this point the self-
healing ability of the arsenohydrogels was briefly investiga ted.  
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Figure 5.6 Rheology of the arsenohydrogel formation of P5.1 (top left) P5.2 (top right) and P5.3 
(bottom) at 2.5 wt % , strain 0.1 %  and frequency 1 Hz (oscillation mode). 
 
At this point the self-healing ability of the arsenohydrogels was briefly investigated. 
However, despite the potentially dynamic nature of the arsine bonds,29-32 the gels were 
not self-healable under the conditions investigated in this work. Analytically this was 
indicated by the loss of gel integrity observed in the 2nd cycle of the amplitude sweep 
during rheology of P5.1 (2.5 wt%, Fig. 5.7). Chemically, additional experiments 
including addition of reductive cross-linking solution at the fracture point to (re)form 
Arsine(I) bonds, and UV irradiation to reshuffle labile As(I) bonds by homolytic fission 
and recombination failed to stimulate healing of the fractured gel matrix.   
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Figure 5.7: Amplitude sweep of hydrogel of P5.1 at 30 °C and frequency of 1 rad s -1 1st cycle (left) 
and 2nd  
 
When arsenohydrogels were prepared at 10 wt% polymer the macroscopic structure was 
retained with no syneresis observed irrespective of the AsAm feed ratio. The viscoelast ic 
properties of these hydrogels were determined by Dynamic Mechanical Analysis (DMA) 
in frequency sweep mode. The G’ was consistently higher than G’’ across the range of 
frequency tested, indicating the hydrogels were stable and behaved as viscoelastic solids 
(Fig. 5.8). Increasing the polymer weight fraction from 2.5 wt% to 10 wt% increased the 
G’ by 2 orders of magnitude from ~400 Pa to 33 – 81 kPa. The data obtained from the 
DMA was verified by comparison to that obtained from rheology of the same hydrogel 
formulations (Fig. 5.9).  
 


















Figure 5.8 Frequency sweep of arsenohydrogels from DMA analysis. Storage moduli (filled in 






















Figure 5.9 Frequency sweep of P5.2 (10 wt% ) measured by rheology 
 
The morphology of arsenohydrogels (10 wt%) was investigated by SEM of lyophilised 
gels after 24 hours of dialysis (Fig 5.10). After dialysis, the gels prepared with higher 
AsAm mole fraction (P5.4) show a retention of more densely cross-linked gel matrix at 
the microscopic scale. Furthermore, the increasing arsenic content present in the 






Figure 5.10 Scanning electron microscopy of pore like structures in 10 wt %  arsenogels after 
dialysis (24 hr): P5.1 (top left), P5.2 (top right), P5.3 (bottom left) and P5.4 (bottom right), Scale bar 
= 2 µm. 
 
Table 5.2: Elemental analysis summary from EDX of the arsenohydrogels. 
 
Wt %a 
C N O As 
P5.1 41.41 9.46 46.52 2.61 
P5.2 35.67 9.89 51.24 3.20 
P5.3 37.24 9.73 48.15 4.89 
P5.4 39.45 11.09 43.06 6.41 
aOther elements such as potassium, iodide and phosphorous is not taken into account.  
 
The arsenohydrogels (10 wt %) were swollen in water (Fig 5.11). The degree of swelling 
was determined by the % swelling (Ws – W0/W0) x 100 (where Ws is the mass of the 
swollen gel and W0 is the mass of dried gel). The swelling of the gel derived from P5.1, 
with the smallest AsAm mole fraction was 760% after 24 hours compared to 25% for 
P5.4 with the highest AsAm mole fraction (Fig. 5.12). Swelling of P5.1 continued over 6 
days and did not reach equilibrium. The gels derived from P5.2 and P5.3 followed the 
same trend, with P5.2 reaching 720% and P5.3 reaching 250% after 6 days of swelling. 
Chapter 5 
188 
Images of the arsenohydrogels swelling show that swelling proceeds with retention of the 
gel structure (Fig. 5.11). The swelling of P5.1 indicates that this proceeds to the point at 
which the swollen gel fills the base of the beaker (Fig. 5.11, t > 72 hours). The swelling 
properties of the arsenohydrogels can be rationalised by the degree of crosslinking the 
relative susceptibility of the As-As bonds, that constitute the crosslinking, to hydrolys is 
and then oxidation. Under reductive conditions the formation of As-As bonds is favoured. 
However, during the swelling experiment, the reducing agent(s) are gradually removed 
which exposes the relatively weak As-As bonds to hydrolysis and re-oxidation, under 
ambient condition, of the As(I) to As(III) and As(V). The impact of this on the gel integr ity 
is most prevalent at lower crosslinking densities (P5.1). At the highest crosslink ing 




Figure 5.11 Images for the swelling analysis for arsenohydrogels derived from P5.1-P5.4. Numerical 
data can be found in Table 5.3 (and Graphical data, Fig. 5.12). Swelling was performed in de-
ionised water.  
 
Table 5.3: Degree of swelling (Ws-W0/W0) x 100 for P5.1-P5.4 in de-ionised water 
 
Time / hr  
24 48 72 96 120 
P5.1 760 1440 5040 7880 10950 
P5.2 160 220 370 540 720 
P5.3 100 110 160 170 250 
P5.4 25 45 55 65 80 
P5.2 P5.1 P5.3 P5.4 
P5.2 P5.1 P5.3 P5.4 
P5.2 P5.1 P5.3 P5.4 
P5.2 P5.1 P5.3 P5.4 
































Figure 5.12 Swelling ratio of the arsenohydrogels derived from P5.1-P5.4 calculated as (Ws-W0)/W0 x 100 
where W0 is the weight of the hydrogel after drying in the oven and Ws is the weight of the swollen hydrogel at 
a definite time interval (Table 5.3). Swelling was performed in deionised water. 
 
5.2.3 Biocamptibility of arsenohydrogels 
For polymeric arsenicals and arsenohydrogels to be considered for biological applications 
it is important to consider their cytotoxicity. Thus, polymers P5.1-P5.4 were investigated 
for toxicity in vitro using a standard XTT assay. Consistent with our previous results23-25 




























Figure 5.13 XTT cytotoxicity assay of arsenic functional polymers (P5.1-P5.4) with PC3 cells  
 
To investigate the potential use of arsenohydrogels as scaffolds for 3D cell culture, gels  
were made with P5.1 and thoroughly purified by dialysis to remove excess H3PO2 and KI 
then dried by lyophilisation. The dried gels were then swollen in the cell growth media 
containing freshly trypsinized Prostate Cancer cells (PC3), and imaged using confocal 
fluorescent microscopy. The image of live, replicating cells was conducted using nuclei 
active staining (Hoechst). The cells retained the spherical morphology (Fig. 5.14) 
obtained after trypsinisation indicating that the cells were encapsulated in the gel matrix 
and not fixed to either the surface of the gel or culture plate. This was confirmed by z-
stack tomography (Fig. 5.15) which shows that the cells interact with the gel matrix across 






Figure 5.14 Confocal microscopy of arsenohydrogels (P1, 10 wt% , after dialysis and lyophilisation) 




Figure 5.15 z-stack tomography of the PC3 cells encapsulated an arsenohydrogel matrix, imaged 
with Hoechst dye. 
 
5.2.4 Loading and release of organic arsenicals from arsenohydrogels  
The principle of controlled drug release by environmental stimuli has become a central 
focus in the development of responsive materials for biomedical applications. 3 3  
Considering the oxidative responsive nature of the arsine bonds, and the clinical relevance 
of organic arsenicals such as 4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid 
(PENAO)34 and 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid (GSAO),35 the 
potential to incorporate an organic arsenical as a model therapeutic into the 
arsenohydrogels was investigated. Thus, it was hypothesised that this could be achieved 
by physical encapsulation into the gel matrix and/or via covalent incorporation into 
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domains of As(I)n cyclooligoarsine crosslinking. To investigate this, arsenohydrogels (2.5 
wt%) were prepared in the presence of p-arsanilic acid as the model organic arsenical. In 
the presence of an excess of p-arsanilic acid (3.8 wt %), the initial gelation took longer 
due to incorporation of the monomeric organic arsenical competing with cross-linking 
between polymeric arsenical chains (4 hours at 60 °C or 2 hours at 80 °C). Interestingly, 
this competition between cross-linking and incorporation of organic arsenical completely 
eliminated the syneresis observed previously for the gels derived from P5.3 and P5.4 at 
2.5wt % suggesting a lower degree of cross-linking present in each formulation. The 
relative release of the p-arsanilic acid from the arsenohydrogels at room temperature in 
aqueous solution and under simulated oxidative stress (aqueous H2O2 5 mmol) was 
monitored by HPLC (Fig. 5.16). In pure aqueous solution, very little release was 
observed. Conversely, in an aqueous solution containing a stoichiometric amount (with 
respect to total arsenic content) of H2O2, evidence of release of p-arsanilic acid was 
detected over 48 hours until a plateau was reached. A trend in release with respect to 
copolymer composition was apparent, with the rate and degree of release being inversely 
proportional to the AsAm mole fraction in the copolymer composition ((P5.1 > P5.2 > 
P5.3 > P5.4). This was attributed to increased covalent incorporation of the p-arsanilic 





Figure 5.16 Release of p-arsanilic acid from arsenohydrogels from P5.1 (black), P5.2 (red), P5.3 
(blue) and P5.4 (green) in aqueous solution (empty) and under simulated oxidative stress using 
stoichiometric H2O2 (filled) (see Appendix C: 5. for supporting information) (see Appendix C, 
S5.16A, S5.16B, S5.16C, S5.16D and S5.16E for supporting information). 
 
5.3 Conclusions 
Arsenohydrogels have been successfully prepared for the first time. Reductive coupling 
of As(V) to As(I) has been exploited to crosslink high molecular weight (Mw > 300 kDa) 
polymeric arsenical scaffolds (PDMAmx-co-AsAmy). Gels were formed when the 
polymer weight fraction was ≥ 2.5 wt% with soft gels (G’ ̴ 400 Pa) being formed at 2.5 
wt%. Gel strength significantly increased (up to G’ = 81 kDa) when the polymer weight 
fraction was increased to 10 wt%. The properties of the gels depend on the mole fraction 
of AsAm in the polymer scaffolds as increasing the AsAm mole fraction resulted in 
increased crosslinking density, reduced swelling capacity and increased resistance to 
hydrolysis and oxidation of the As-As crosslinks. The polymeric arsenical scaffolds and 
the resulting arsenohydrogels were found to be non-toxic in vitro and the gels were 
capable of encapsulating PC3 cells within a 3D arsenohydrogel matrix. Finally, the 
arsenohydrogels have been shown to be functional through the loading of p-arsanilic acid 
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as model arsenical drug. The relative release of model arsenical drug in aqueous solution 
and under simulated oxidative stress demonstrates the redox responsive characteristics of 
systems containing organic arsenicals. This investigation further demonstrates the 
distinctive reactivity and versatility of organic and polymeric arsenicals, and the 
properties of this first generation of arsenohydrogels are promising for biomateria ls 
applications in the future. 
 
5.4 Experimental 
5.4.1 Materials and instruments: 
AsAm was synthesised according to the literature.25 N,N-Dimethylacrylamide (DMA) 
were filtered through a basic aluminium oxide (activated, basic, Brockman I, standard 
grade) to remove the radical inhibitor. 2,2′-azobis[2-(2-imidazolin-2yl)propane] 
dihydrochloride (VA-044, Wako), hypophosphoric acid and HPCL-grade H2O (sigma-
aldrich, 50%) were used without further purification.  
 
Nuclear Magnetic  Resonance (NMR) spectroscopy  (1H  NMR  spectra)  were  recorded  
on  a  Bruker HD  400  spectrometer  (400  MHz) at  27  °C using D2O as solvent and the 
residual proton signal of the solvent (δ H = 4.75 ppm) was used as internal reference. 
Chemical shift values (δ) are reported in ppm. ACDLABS software was used to analyse 
the data obtained. Number-average molar masses (Mn,SEC) and dispersity values (Ð) 
were determined using Size exclusion Chromatography (SEC). Agilent PL50 instrument 
equipped with differential refractive index (DRI) detector. The system was equipped with 
Aquagel OH mixed M column (300 x 7.5 mm) was used alongside with an 8μm aquagel 
guard column The mobile phase used was 80% NaNO3 in water at 0.1 M and 20% 
methanol. Samples were run at 1ml/min at 35 °C. Poly(ethylene oxide) standards (Agilent 
EasyVials) were used for calibration. Analyte samples were filtered through a membrane 
with 0.45 μm pore size before injection. FT-IR spectrometer using a Golden Gate diamond 




5.4.2 Calculation of AsAm content with respect to DMA by 1H-NMR  
Method 1 





 = [𝑀]𝐷𝑀𝐴 
Method 2 





 = [𝑀]𝐷𝑀𝐴   
 




The transition from solution phase to gel phase was monitored by following the storage 
moduli and loss moduli. Measurements were performed on an Anton Paar MCR 302 
rheometer using a parallel plate with diameter of x mm and measuring gap of 1 mm. The 
normal force was kept constant at 1 N during measurements and all measurements were 
performed at 30 °C (maintained by a Peltier system). All the analysis was conducted by 
adding pre-gel solution between the plates and forming the gel before or during the 
analysis. Gel formation was monitored with constant frequency of 1 rad s-1 and a constant 
strain of 0.1 %. When conducting the amplitude sweep, a constant frequency of 1 rad s-1 
was applied and strain was ramped logarithmically from 1 % to 500 %. For the frequency 
sweep, a constant strain of 0.1 % was applied and frequency was ramped logarithmica l ly 
from 0.1 to 100 rad s-1.  All the data was analysed using RheoCompass software. 
 
5.4.4 Dynamic mechanical analysis (DMA) 
Dynamic mechanical analysis was performed on a Perkin Elmer DMA8000 in tension 
mode. Frequency sweeps were performed from 1 to 25 Hz at room temperature 
(approximately 25 °C). Hydrogels were prepared in silicone moulds as standard and then 




5.4.5 Reverse Phase High performance liquid chromatography (RP-HPLC) 
Both sample  analysis  conducted from  a  RP-HPLC system (Agilent 1260 infinity series 
stack) equipped with a 1260 Quat Pump VL, a degasser and a fraction collector (FC-AS). 
Samples were injected using Agilent 1260 auto-sampler with 5 μL injection (Draw and 
injection of 200 μL/min). The RP-HPLC was fitted with Eclipse XDB-C18 column (150 
x 4.6 mm) 5 micron packing (100Ǻ). Detection was achieved using an Agilent 1260 
variable wavelength detector connected in series with UV detection monitored at 280 nm. 
The total flow rate was set to 1.0 mL/min and the temperature of the column was set to 
20 °C. The mobile phase condition is as follows. Mobile phase A: 100% water with 
0.04%v/v TFA; Mobile phase B: 100% MeCN with 0.04%v/v TFA (see SI for gradient). 
The standard analysis method is as followed:  
Time (min) A (%) B (%) 
0.00 90.0 10.0 
15.00 50.0 50.0 
25.00 0.0 100.0 
27.00 90.0 10.0 
35.00 90.0 10.0 
 
 
5.4.6 SEM and EDX analysis 
SEM analysis together with EDX was performed to determine the pore structure and 
arsenic content of the gels. The prepared hydrogels were cut using a scalpel to expose the 
internal structure, a roughly 3 mm2 fragment was then mounted onto SEM stages using 
double sided conductive copper tape, which served as an adhesive and provided 
electrostatic screening. The samples were subsequently coated in gold for 15 seconds 
using a Polaron 5C 7640 sputter coater and the surface structure visualised using a Zeiss 
Gemini SEM- field emission scanning electron microscope at an accelerating voltage of 
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either 10 or 15 keV. Elemental analysis was carried out during SEM imaging on the same 
samples using an Oxford instruments X-Max 150 large area SDD electron dispersive X-
ray analysis (EDX) detector.  
 
5.4.7 Cell viability 
Cell viability. PC3 (human prostate cancer) cells were cultured in High Glucose DMEM 
medium supplemented with 10% fetal bovine serum. For cell viability evaluation, PC3 
cells were seeded in a 96 well plate at a density of 1 × 104 cells per well. After 16 hours, 
the culture medium was replaced by fresh media containing a series of dilution of the 
polymers (0.25, 0.5, 1, 2, 4 and 8 mgml-1), prepared from stock solutions in PBS at 500 
µM. Following 24 hours incubation, the medium was removed and replaced with fresh 
medium. The cells were incubated with a freshly prepared solution of XTT (0.2 mg/mL-
1) and N-methyl dibenzopyrazine methyl sulfate (250 µM) in medium for 16 hours. 
Absorbance of the samples was finally measured using a plate reader at 450 nm and 650 
nm. The data presented are representative of a minimum of two independent experiments 
where each sample was measured in triplicate. Errors reported correspond to the standard 
deviation of the mean. 
 
5.4.8 Fluorescent confocal imaging of cells seeded in arsenohydrogels 
In each chamber slide, 30 000 cells of PC3 (prostate cancer cell-line) in 300 µl of DMEM 
media were seeded together with the dried hydrogel (vide infra). Also, the control cells 
without a hydrogel were prepared and incubated for 24 hours at 310 K. The co-culture of 
PC3 and hydrogel was stained by adding 12 ul dye Hoechst 33342 (1 mg/ml) which 
targets nucleus (60 min, 310 K). Samples were analysed using a Zeiss LSM710 laser 
scanning confocal microscope (Diode laser; excitation: 405 nm; blue emission: 410-585 
nm). 12-bit images were obtained at room temperature using an EC Epiplan-Neofluar 20x 
/0.50HD M27 and a C-Apochromat 63X /1.20 W Korr M27 with ImmersolW immers ion 
fluid on the objective lens on the microscope. The image stacks were projected along the 
z-axis using either sum-intensity or maximum-intensity projections. Data were processed 





5.4.9 General Procedure for polymer synthesis via Free Radical Polymerisation. 
AsAm was solubilised in water with 1 eq of Sodium Hydroxide and added into a cooled 
aqueous solution of DMA (1 M) with VA-044 (0.01 eq with respect to total monomer 
content). The solution was degassed for 15 minutes before heating the solution at 90 °C 
for 2 hours. The full consumption of the monomer was confirmed by NMR before freeze 
drying directly to yield white solids (> 99 %).  
 
5.4.10 General Procedure for arsenohydrogel synthesis.  
For 2.5 wt % gels 25 mg of AsAm bearing polymers (P1-P4) was initially dissolved in 
800 μL of HPLC grade water before adding 200 μL of concentrated hypophosphoric acid 
solution (50%) and 10 μL of 3 wt % potassium iodide solution. The solution was heated 
at 60 °C for 30 minutes, this resulted in successful clear gel formation however P3 and 
P4 macroscopic gel contraction was observed. For 10.0 wt % gels 100 mg of AsAm 
bearing polymers (P1-P4) was initially dissolved in 800 μL of HPLC grade water before 
adding the 200 μL of concentrated hypophosphoric acid solution (50%) and 10 μL of 3 
wt % potassium iodide solution. The solution was heated at 60 °C for 30 minutes, this 
resulted in formation of pale yellow gels and stable to syneresis.  
 
5.4.11 Gel Prep for Cell seeding 
10 wt% arsenohydrogels were prepared as described above, in 2 ml solution on a 3 cm 
diameter silicon mould. The gels were then dialysed in 100 ml deionised water over 24 
hours changing the water 6 to 8 times. Dried arsenohydrogels were obtained by 
lyophilisation.  
 
5.4.12 Loading arsenohydrogels with model organic arsenical.  
For 2.5 wt % gels 250 mg of AsAm bearing polymers (P1-P4) was initially dissolved in 
8 ml of HPLC grade water before adding the 2 mL arsanilic acid (380 mg) freshly 
dissolved in concentrated hypophosphoric acid solution (50%) and 100 μL of 3 wt % 
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potassium iodide solution. The solution was heated at 60 °C for 4 hrs, this resulted in dark 
red gels.  
 
5.4.13 Release study of the arsanilic acid loaded arsenohydrogels with RP-HPLC.  
The 2.5 wt% gels described above were loaded with arsanilic acid in 50 ml falcon tubes 
in HPLC grade water, filling up to 50 ml line. The aqueous phase was stirred regular ly 
without disturbing the gels, 200 µL sample from aqueous phase was taken at 3 hr, 12 hr, 
24 hr, 48 hr and 144 hr for HPLC analysis. The arsanilic acid released was identified by 
comparing the arsanilic acid (in hypophosphoric acid solution) to assign the retention 
time of the arsanilic acid released. The height of the intensity of the peak corresponding 
to arsanilic acid was measured and compared to the theoretical maximum concentration 
after release (7.6 mgml-1).  
 
5.4.14 Hydrogen peroxide mediated release study of the arsanilic acid loaded 
arsenohydrogels with RP-HPLC.  
200 µL of 30 wt % H2O2 (approximately stoichiometrically equivalent to arsanilic acid) 
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Chapter 6 : Conclusion and perspective 
The use of organoarsenic in the field of polymer and biomaterials science has been largely 
overlooked due to concerns regarding the toxicity of arsenic. Arsenic is a distinct ive 
element that exhibits diverse chemical reactivity depending upon its oxidation state. It’s 
chemical properties and interaction at the biological interface alludes to potential 
applications in biomaterial science. Arsenic can exist in various oxidation states, (V, III 
and I), with As(I) capable of forming cyclic oligomers through the formation of As-As 
bonds. Polymeric arsenicals have been previously synthesised through polycondensat ion, 
exploiting the Lewis acid properties of the arsenic centres (As(V), As(III)). Additiona lly, 
As(I) oligomers have been copolymerised with acetylenes through radical mediated 
homolysis. The focus of the work in this thesis, was to generate nanoparticles and 
hydrogels with tuneable and functional properties through cross-linking polymers with 
the unique properties of arsenic and investigate their properties as potential candidates for 
biomaterials applications.  
 
To this end, acrylamidic monomer(s) with pendant arsanilic acid groups used for cross-
linking were synthesised from commercially available phenylarsonic acid derivative, p-
arsanilic acid. This enabled convenient synthesis one-pot synthesis of the arsenic acid 
containing monomer (AsAm) by functionalising the aromatic amine.  
 
In Chapter 2, thermoresponsive PEGA-NIPAm diblock copolymers were generated 
through aqueous SET-LRP, with random incorporation of AsAm in either the PEGA or 
NIPAm blocks, using sodium hydroxide to solubilise AsAm. The resulting polymers self-
assembled at elevated temperatures. When AsAm was presented in the core forming 
NIPAm block, the self-assembly was found to be pH dependent, forming nanopartic les 
when the pH was below the pKa of the arsenic acid. Nevertheless, the aim of this init ia l 
investigation was to cross-link polymers through reductive coupling of arsenic acid 
(As(V)) to oligomeric arsines (As(I)), which involved using hypophosphorous acid as a 
reducing agent, rendering the pH suitable for self-assembly. The formation of 
nanoparticles was monitored by dynamic light scattering. Upon cooling back to room 
temperature, retention of the nanoparticle at room temperature was indicative of 
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successful cross-linking. Reductive coupling of AsAm stabilised the nanoparticles when 
AsAm was present in the core forming NIPAm, however it did not yield stable 
nanoparticles when the AsAm was presented on corona forming PEGA block. Further 
study showed the stability of the nanoparticle increased with increasing incorporation of 
AsAm in the polymer. 
 
In Chapter 3, nanoparticles were generated with equivalent polymer scaffolds, 
synthesised by RAFT polymerisation, through addition of poly-thiol cross-linkers. As an 
external thiol cross-linker was used to stoichiometrically react with the AsAm units, it 
was important to determine the monomer feed in the polymer composition as accurately 
as possible. In this study a pinacol protected arsenical acrylamide was co-polymerised 
into the core forming NIPAm block using TFE as a solvent. The deprotection undermild ly 
acidic dialysis yielded As(V) functional polymers equivalent to those in chapter 2. The 
cross-linking density was tuned by thiol functionality of the cross-linker, forming stable 
nanoparticles with tetra-thiol (PTM), tri-thiol (TTM) and di-thiol (HDT) cross-linkers. 
When 100% cross-linking was targeted ([SH]:[As] = 2), the Nagg and topology  of the 
nanoparticles were concentration dependent due to inter-particle interaction and 
aggregation. However when 50% cross-linking was targeted the ([SH]:[As] = 1), 
nanoparticles exhibited more spherical character and less concentration dependency on 
aggregation. The aim of this work was to investigate arsenic-thiolate bonds as responsive 
cross-linking form the polymeric arsenical nanoparticles. The stability of the 
nanoparticles correlated with the thiol functionality of the cross-linker and the targeted 
[SH]:[As]. As a result, nanoparticles formed with tetra-thiol and tri-thiol cross-linker did 
not dissemble in presence of glutathione, via thiol exchange due to an entropic barrier, 
however dissembled when di-thiol cross-linker was observed. The stability towards 
oxidation by hydrogen peroxide increased with increasing thiol functionality (di- < tri- < 
tetrathiol) and thiol stoichiometry ([SH] : [As] = 2.0 : 1.0 > 1.0 : 1.0). Interestingly the 
nanoparticles with 100% cross-linking were more toxic, which was attributed to the 
release of the cross-linker within the cell. Considering the potential for these nanopartic les 
as drug delivery vectors, the responsivity of arsenic thiolate-bond demonstrates promising 




Cyclic arsine(I) oligomers are known to undergo RCRAC with acetylenes to form 
alternating poly(vinylene-arsines), which have been previously reported to be resistant to 
oxidation by hydrogen peroxide. Considering the previous nanoparticles formed through 
As(I) oligomerisation and arsenate-thiolate bonds discussed in the chapter 2 and 3 were 
prone to oxidation and therefore dissembled in presence of hydrogen peroxide, it was 
therefore interesting to investigate cross-linking through the formation of vinylene-ars ine 
bonds to form resilient nanoparticles in the subsequent Chapter. In Chapter 4, PEGA-
NIPAm diblock copolymers with AsAm incorporated in the NIPAm block were generated 
by RAFT polymerisation as discussed in chapter 3, then As(I) cross-linked nanopartic les 
were formed in-situ via reductive coupling of AsAm as discussed in Chapter 2. When 
water soluble acetylenes, propargyl alcohol were added with radical initiator source, 
stable nanoparticles were formed. To study further the robustness of this cross-linking 
polymerisation strategy, propargyl amine and propiolic acid were also investigated as 
acetylene source, which yielded stable nanoparticles, thus demonstrating the functiona l 
group tolerance of this strategy. It is important to note that all the nanoparticles cross-
linked through this strategy did not dissemble in presence of hydrogen peroxide using the 
previously used condition (chapter 2 and 3), consistent with the reported properties of 
poly(vinylene-arsine) polymers. 
 
As this unique strategy enables introduction of additional functionality through the 
acetylene motif, the next goal in this chapter was to incorporate a fluorescent label to help 
determine the cellular uptake and the co-localization of the nanoparticle. To this end, 
propargyl-O-rhodamine B ester was synthesised and polymerised with As(I) cross-linked 
nanoparticles. The subsequent fluorescently labelled nanoparticles were shown to be 
successfully taken up by PC3 cells after 2 hours of incubation. Confocal fluorescent 
microscopy shows diffuse distribution of the nanoparticles throughout the cell with the 
lack of lysosomal co-localisation. Interestingly strong mitochondrial co-localisation was 
observed, suggesting a biochemical property of mitochondrial tagging effect of As(III) 
was retained.  
 
The focus in chapters 2 to 4 was generating polymeric nanoparticles using arsenical 
pendant groups presented in well-defined diblock copolymers as cross-linking motifs. In 
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Chapter 5, the reductive coupling described in chapter 2 is utilised to form chemica l cross-
linked hydrogels. Poly(DMAmx-AsAmy) were synthesised by FRP,  and  hydrogels were 
made at concentrations low as 2.5 wt% when cross-linked through the formation of As(I) 
oligomerisation. However at higher cross-linking density ([DMAm]:[AsAm] < 96 : 4) the 
hydrogels underwent syneresis, which were preventable at higher weight concentration 
(10 wt%). The hydrogels were responsive towards oxidation, showing an increasing 
swelling profile as a result of oxidation, which was sensitive to the cross-linking density. 
3D cell culturing of these gels was carried out by rehydration of dialyzed/lyophilized gels 
with trypsinized solution of cells. Finally, p-arsanilic acid, as a model arsenical drug, was 
encapsulated in the hydrogels by reductive coupling and formation of the bridging 
polymer-arsanilic acid As(I) mixtures. The release of the p-arsanilic acid was stimulated 
by oxidation with H2O2, where increased covalent incorporation of the p-arsanilic acid 
into the domains of As(I)2 cyclooligoarsine crosslinking was found to slow the release, as 
observed with higher incorporation of AsAm in the polymer. 
 
Further work to generate arsenohydrogels through addition of multithiol cross-linking 
agent or further curing of As(I) cross-linked arsenohydrogels through RCRAC (used in 
chapter 4) and investigate the chemical/physical/mechanical properties would be 
interesting.  
 
In conclusion, this investigation demonstrates the distinctive reactivity and versatility of 
polymeric arsenicals, and the properties of this first generation of polymeric nanopartic les 
and arsenohydrogels chemically cross-linked through arsenic centres are promising for 
biomaterials applications in the future. Furthermore, considering the potential for 
biomedical application, all the materials polymers and nanoparticles were not toxic (2 
mg/ml) when examined by standard XTT assay. In the future, in-vivo investigat ions 
would be interesting to evaluate the further the biocompatibility of polymeric arsenicals, 







Chapter 7 Microscale Synthesis of Multi-block 
Copolymers Using Ultrafast-RAFT Polymerization 
 
ABSTRACT:  
Ultrafast reversible addition-fragmentation chain-transfer polymerization (RAFT) in 
presence of air was previously described. Herein, we demonstrate this method can be 
scaled down to 2 μL using inserts typically used in vials for SEC analysis, as a 
polymerization vessel. By careful cooling and mixing of the sequential monomers 
between chain extensions, well defined pentablock copolymers were successfully 
generated with a total volume of 10 μL. This work demonstrates the suitability of scale 









Polymerization in standard chemistry laboratory reaction vessels becomes increasingly 
difficult at increasing smaller scales. Transfer of advanced polymer synthesis techniques 
to smaller scales will allow for the high-throughput screening of polymer composition for 
biomaterial discovery and has previously been demonstrated by step growth 
polymerisations.1, 2 However low scale-screening using controlled polymerizat ions 
methods was only recently achieved by Chapman et al to investigate the influence of 
polymer architecture on materials properties.3 
 
Typically polymerizations are carried out with reaction volumes between 50 ml and 0.5 
ml,4-7 as these ranges are practical for the conventional reaction vessels and 
deoxygenation processes necessary for typical Reversible Deactivation Radical 
Polymerization (RDRP). Note that, the latter condition limits scales of the reactions, as 
using nitrogen sparging or freeze pump thaw cycles to deoxygenate the reaction media is 
not practical at ultralow volume, due to inherent loss of volatile monomer and solvents. 
Hence oxygen tolerant RDRP protocols are necessary to allow polymerizations to be 
carried out at microscale. To this end, Boyer et al have performed ultralow volume 
reactions (20 μL) in 96 well plates, using photo-catalysed redox Reversible Addition 
Fragmentation Chain Transfer (RAFT) polymerization without deoxygenation in 
presence of air.8 This enabled screening of different homopolymers, diblock copolymers, 
star architectures and nanoparticles formulations. 
 
RDRP protocols without deoxygenation have become an emerging topic, however many 
of these protocols requires external stimuli,9 additives8 or oxygen scavenging enzymes,3 ,  
10, 11 which deviates from the simplicity of RDRP protocols. To address this, Gody et al. 
demonstrated standard RAFT polymerization using only conventional ingredients used 
for RAFT polymerization, without degassing, in vessels open to air.12 This elegant and 
simple approach takes advantage of the fast propagation of monomers in water a solvent 
known to increase the rate of radical polymerization, which is further accelerated at 
elevated temperatures. This ultrafast RAFT polymerization was generally demonstrated 
with acrylamide-based monomers with 2,2'-azobis[2-(2-imidazolin-2-
yl)propane]dihydrochloride (VA-044) as an initiator (10 hr ½ life = 44 °C) and heating to 
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100 °C, allowing iterative chain extensions to synthesize multiblock copolymers 
(MBCPs) within 3 minutes per block such that monomer is fully consumed before the 
initiator is fully decomposed (approximately 80%).12 
 
MBCPs are macromolecules with defined control over block sequence and that can be 
synthesized from just simple chemical ingredients without complex biologica l 
machineries, and are amenable to industrial scales.13-15 The synthesis of MBCPs has been 
progressed more recently with RDRP, including copper mediated polymerization16-24 and 
RAFT polymerization.25-31 In spite of the inevitable small number of radical termina tion 
events, 21 iterative block extensions have been reliably demonstrated with these 
methods.32 Furthermore, these routes are popular as they allow incorporation of 
monomers of various functional groups33-38  and do not require exhaustively dried 
reagents and environments, required for ionic living polymerization systems.39 Recently, 
work on sulfur- free RAFT polymerization offers the potential for MBCP synthesis 
amenable to industrial scales.32, 40, 41 However, the possible benefits of scaling down 
MBCP synthesis is often overlooked in academic settings. Industry often relies on the 
inexpensive small scale combinatorial reactions or optimisation before larger scale 
synthesis of the preferred choice or optimized conditions. Microscale MBCP synthesis 
could have applicability in high throughput microarrays,42 thus allowing the implicat ions 
in permutations of monomers and block lengths of MBCPs to be rapidly investigated.  
 
Here, it is proposed that the aforementioned ultrafast RAFT protocol could be applicable 
in microliter scale reactions due to the rapid consumption of the monomer without 
deoxygenation. Thereby demonstrating the synthesis of MBCPs at a scale suitable for 
applications such as microarray patterning and combinatorial chemistry with 
conventional ingredients for RAFT polymerization.  
 
7.2 Results and Discussions 
7.2.1 Scaling down 
To counteract the inherent problem of increased air/water interface when scaling down 
the protocol proposed by Gody et al., we used a narrow micro-volume glass inserts (4.6 
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mm diameter, 200 μL capacity) with conical bottoms (cone volume = approximately 20 
μL) that are typically fitted into a standard 2 ml vials for HPLC/GPC analysis for low 
volume analyses. A master mix of the RAFT agent, monomer, solvent and initiator was 
made as “all-in-one” stock solution and added into the insert using a standard micropipe tte 
(scheme 7.1). This mix was made following closely to the published protocol,12 using 
VA0-44 as an initiator (3 x 10-3 M, [CTA]/[I]0 = 40 ) and N-acryloyl morpholine (NAM) 
as suitable acrylamidic monomer ([M]0 = 3 M) in aqueous mixture and 2-(((butylthio)-
carbonothioyl)thio)propanoic acid (PABTC) as a RAFT agent. The inserts were then 
heated in an oil bath at 100 °C for 3 minutes. In contrast to the previous study where the 
temperature of the reaction increase was gradual, taking 80 seconds to reach 96 °C,12 we 
assume the temperature of the reaction to reach equilibrium almost immediate ly. 
Conveniently as the polymerizations were carried in SEC vial inserts, the reaction mixture 
was directly diluted with SEC eluent within the insert, and injected directly for SEC 
analysis (Figure 7.1). A duplicate reaction was carried out to dilute with NMR solvent 
(d6-DMSO) to measure monomer conversion by NMR. 
 
 
Figure 7.1 Figure  Photograph of the inserts in the GPC vials before dilution. 
 
Preliminary experiments were designed to investigate the absolute limit of scale for the 
solution-based polymerization. Initially this was investigated with a targeted degree of 
polymerization (DP) of 25 using 20 % dioxane to aid the solubility of the CTA.  At 10 μL 
(Mn,SEC = 2200; Đ = 1.23), 5 μL (Mn,SEC = 2600; Đ = 1.23), and 2 μL (Mn,SEC = 2600; Đ = 
1.29) we were able to reproducibly obtain PNAM25 as observed by SEC analysis (Figure 
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7.2) with a slight increase in dispersity at the microliter scale, however comparable to 
polymerization carried out in 5.4 ml test tubes (termed macroscale in this paper) (Mn,SEC 
= 2700 g mol-1; Đ = 1.19). At 1 μL (Mn,SEC = 2600 g mol-1; Đ = 1.42) scale polymers were 
obtained, but results were not reproducible. The weight loss due to evaporation was also 
noted (Table 7.1), which suggests that the effect of evaporation was detrimental at 1 µL 
scale. Hence we presume that 2 μL is the lower scale limit achievable with this method.  
 
Figure 7.2: Polymerisation of P[NAM]25 carried out different scale inside microvolume inserts. At 
range of scales: 10  μL, 5  μL, 2  μL and 1 μL. It’s important to note that at 1 μL scale the results 







Table 7.1: The percentage of the weight loss in the microvolume inserts from evaporation. 
Scale Percentage of weight loss  
10  μL 14 % 
5  μL 26 % 
2  μL 43 % 




Figure 7.3: SEC analysis (DRI, CHCl3) of P(NAM)n (n = 25, 100 and 200) in microscale (2 µL) in 
microvolume inserts and normal scale (500 µL) in conventional test tubes (5.4 ml). All the 
polymerization carried out under 3 minutes without stirring, deoxygenation and open to air. 
 
7.2.2 Varying DPn of P(NAM)n at 2 µL scale 
Next, this protocol was applied to synthesise longer polymer chain lengths of P(NAM)n 
(Figure 7.3). Increasing the chain length four-fold (DPn = 100), required a slight 
modification of the master mix (10 % dioxane; [I]0 = 1 x 10-3 M, [CTA]/[I]0 = 30). 
Pleasingly polymerization yielded PNAM100 at 2 μL scale (Mn,SEC = 9200 g mol-1; Đ = 
1.36), in contrast to macroscale the molecular weight distributions was relatively broader 
by SEC analysis (Mn,SEC = 8900 g mol-1; Đ = 1.19). Increasing the length further (DPn = 
200), increased the dispersity at 2 µL scale (PNAM200, Mn,SEC = 26800 g mol-1; Đ = 1.43), 
compared to the macroscale equivalent (Mn,SEC = 15000 g mol-1; Đ = 1.23). SEC analysis 
in all cases revealed slightly higher dispersity due to appearance of low molecular tailing. 
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Also the 1H NMR spectra revealed more residual monomer was present (approximate ly 
2-3 % more). As targeting DP of 25 of NAM yielded relatively narrow dispersity at 2 µL 
scale, we therefore decided to keep this a constant block length for our MBCPs.   
 
7.2.3 Iterative multi-chain extension at 2 µL per block scale 
In order to generate MBCP’s through iterative chain extension with the current protocol, 
it was important to consider the limitation of mixing sequential monomers in the 
polymerization mixture, as stirring during polymerization is unfeasible at the 2 µL scale. 
To maximise the mixing of each monomer aliquot the polymerization reaction mixture 
was cooled prior to addition of new monomer and stirred before heating again at 100 °C 
for successful sequential chain extension. This circumvented the need for continua l 
stirring during the addition of sequential monomers. Thus by adopting this necessary 
measure of cooling and mixing before reheating (Scheme 7.1), successive chain 
extensions were possible within the insert vials to synthesize a homopolymer in five 
successive chain extensions, P(NAM25)5, at 5 µL per block (final Mn,SEC = 10600 g mol-
1; Đ = 1.25) and 2 µL per block (final Mn,SEC = 10000 g mol-1; Đ = 1.31) (Figure 7.2). 
Centrifugation was necessary to collect the new monomer solution into the bottom the 
insert before stirring (see experimental info for full details). It is important to note, that 
the monomer concentration of the chain extension stock solution was kept constant at 3 
M, such that the same DP per chain extension could be targeted by sequentially adding 
the same volume as the original block. It is noteworthy that all the chain extension stock 
solutions had contained the same initiator concentration of 2.2 x 10-3 M. This was 
designed to give an overall macroCTA/initiator ratio of 40 constant per block, whilst 
assuming that 20% of initiator is still remaining from the previous block. This gave a 
good balance of quantitative monomer consumption (>96%, Table 7.1) at each block 
whilst keeping the theoretical livingness of each block high (>98%, see experimental for 
calculation and experimental conditions) to prevent dead chains formed (See table 7.7-




Scheme 7.1: “master mix” (with monomer, CTA, initiator and solvent) is added into the 
microvolume insert using a regular air displacement micropipettes. After 3 mins of heating at 100 
°C in an oil bath polymerisation was complete, the insert was cooled with liquid nitrogen. For 
sequential chain extension, separate monomer master mix is directly added and mixed by stirring 
with a needle and centrifugation, before reheating for further 3 minutes for block extension. This 
cycle was repeated to yield pentablock copolymer. All the polymerisation were carried out without 
deoxygenation and in presence of open air. 
 
The monomer consumption was followed by 1H NMR spectroscopy and succession of 
the sequential chain extension was confirmed by GPC analysis of polymerization at each 
block. To analyze each chain extension, the same number of replicate reactions as the 
number of iterative blocks was prepared (Scheme 7.2), whereby representative vessel at 





Scheme 7.2: the method for analysis of the multiblock copolymers at microscale.Twice as many 
reactions are prepared as number of blocks and polymerised simultaneously. After each block cycle 
a whole insert is taken as a representative sample. Two separate samples per block are required to 
enable both GPC and NMR analysis . 
 
In all cases, a linear increase in Mn,SEC was observed with increasing number of iterative 
block extensions (Figure 7.5, 5 µL per block; Figure 7.6, 2 µL per block,), suggesting 
excellent control in polymerization at the microscale. In comparison the molecular weight 
distributions of P[[NAM]25]5 was only slightly broader at microscale compared to 
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macroscale with our protocol (Figure 7.4, final Mn,SEC = 12600 g mol-1; Đ = 1.23). At the 
macroscale, bimodal distributions were observed, due to back-biting induced β-scission 
and subsequent branching, with successive chain extensions.43 Although this is typically 
characteristic of more labile methine backbone hydrogens of acrylic monomer families, 
as a result of high temperature this was observed here with an acrylamide monomer. This 
was indeed the case in previous work which used similar polymer composition, manifest 
as high molecular weight tailing.12 At the microscale (25 µL and 10 µL), this feature is 
still present despite molecular weight distributions appearing to be unimodal, due to the 
broadening of the molecular weight distribution. We attribute this result to an increased 
interface between air and solution phase when scaling down, subsequently leading to dead 
chains as a result of oxygen related termination events. It’s noteworthy that the weight 
loss for each chain extension is considerably greater at the microscale compared to the 






Figure 7.4 Multichain extension to generate P(NAM25)5 synthesis with Ultrafast RAFT 
polymerization through iterative chain extensions at conventional macroscale = 2.5 ml, 0.5 ml per 
block. Photograph after reaction next to a British penny coin (20.3 mm in diameter) as a reference 
to the size of the scale. SEC chromatograms for successive chain extensions. Evolution of number-
average molar masses and dispersity values with the number of blocks during the preparation of 
the P(NAM25)5. The black line represents the theoretical molar mass calculated from Eqn. A.2. The 
filled squares represents the experimental molar mass and empty squares represents the dispersity 







Figure 7.5 Multichain extension to generate P(NAM25)5 synthesis with Ultrafast RAFT 
polymerization through iterative chain extensions at microscale = 25 µL, 5 µL per block. 
Photograph after reaction next to a British penny coin (20.3 mm in diameter) as a reference to the 
size of the scale. SEC chromatograms for successive chain extensions. Evolution of number-average 
molar masses and dispersity values with the number of blocks during the preparation of the 
P(NAM25)5. The black line represents the theoretical molar mass calculated from Eqn A.2. The 
filled squares represents the experimental molar mass and empty squares represents the dispersity 






Figure 7.6 Multichain extension to generate P(NAM25)5 synthesis with Ultrafast RAFT 
polymerization through iterative chain extensions at microscale = 10 µL, 2 µL block. Photograph 
after reaction next to a British penny coin (20.3 mm in diameter) as a reference to the size of the 
scale. SEC chromatograms for successive chain extensions. Evolution of number-average molar 
masses and dispersity values with the number of blocks during the preparation of the P(NAM25)5. 
The black line represents the theoretical molar mass calculated from equation Eqn A.2. The filled 
squares represents the experimental molar mass and empty squares represents the dispersity 








Table 7.2: The percentage of the weight loss after each block extension during the preparation of 
P(NAM25)5 in the microvolume inserts versus conventional test tube (5.4 ml) from evaporation. 
 Percentage of weight loss (per block) 
 2 µL per block 500 µL per block 
Block 1 43 % 3.7 % 
Block 2 39 % 3.6 % 
Block 3 40 % 3.6 % 
Block 4 44 % 3.3 % 
Block 5 28 % 2.7 % 
 
7.2.4 Synthesis of MBCP at 2 µL per block scale 
To further demonstrate the robustness of this method MBCPs were synthesized with 
blocks of different monomers: dimethylacrylamide (DMAm) and 
hydroxyethylacrylamide (HEAm). Pentablock of P(NAM)25-b-(DMAm)25-b-(NAM)25-b-
(HEAm)25-b-(NAM)25 were prepared in the inserts at the microliter scale (2 µL per block) 
following this protocol, with well-defined molecular weight distribution (Mn,SEC = 14000 
g mol-1; Đ = 1.35) which was comparable to macroscale synthesis (Mn,SEC = 15100 g mol-
1; Đ = 1.32). Note that the theoretical number average molecular (Mn,th) of this pentablock 
gave a good agreement with Mn,SEC owing to the DMF used an eluent for the SEC analysis 















Table 7.3 The range of (micro)scales, monomer conversion, theoretical and experimental number 











 > 97 3600 2700 1.18 
 10 > 98 3600 2200 1.23 
 5 > 98 3600 2600 1.23 
 2 > 98 3600 2600 1.29 
 1e > 96e 3600e 2600e 1.42e 
P(NAM)100 500 > 99 14000 8900 1.19 
 2 > 97 13600 9200 1.36 
P(NAM)200 500 > 98 26800 15000 1.23 
 2 > 98 26800 13000 1.43 
P(NAM)25 -b-(NAM)25 –b-(NAM)25 -b-(NAM)25-b-
(NAM)25 
2500 > 99.9 17200 12600 1.23 
 25 > 99 17200 10600 1.25 
 10 > 99 17200 10000 1.31 
P(NAM)25 -b-(DMAm)25 -b-(NAM)25 -b-(HEAm)25-b-
(NAM)25 
2500 > 96 15400 15100f 1.32f 
 10 > 98 15500 14000f 1.35f 
a All polymerizations are carried out in insert vials unless the scale is above or equal to 500 µL are carried out 
in test tube (5.4 ml). b Determined using equation 1 in supporting information. c As calculated from equation 2 
in supporting information. d Determined by SEC with THF as the eluent with PMMA as a calibrant, unless stated 






Figure 7.7. (a) 1H NMR spectra (DMSO, 400 MHz) showing the monomer conversion for each new 
block P[(NAM)25-b-(DMAm)25-b-(NAM)25-b-(HEAm)25-b-(NAM)25], after 3 mins of iterative RAFT 
polymerisation at conventional scale (scale = 0.5 ml per each block). SEC chromatograms for 
successive chain extensions. Evolution of number-average molar masses and dispersity values with 
the number of blocks during the preparation of the pentablock copolymer. The black line 
represents the theoretical molar mass calculated from equation A.2. The filled squares represents 
the experimental molar mass and empty squares represents the dispersity values, both as 






Figure 7.8 1H NMR spectra (DMSO, 400 MHz) showing the monomer conversion for each new 
block P[(NAM)25-b-(DMAm)25-b-(NAM)25-b-(HEAm)25-b-(NAM)25] after 3 mins of iterative RAFT 
polymerisation inside microvolume inserts (scale = 2 µL per each block). SEC chromatograms for 
successive chain extensions. Evolution of number-average molar masses and dispersity values with 
the number of blocks during the preparation of the pentablock copolymer. The black line 
represents the theoretical molar mass calculated from Eqn A.2. The filled squares represents the 
experimental molar mass and empty squares represents the dispersity values, both as determined 
by DMF SEC. 
 
7.3 Conclusion 
To conclude, we have demonstrated the robustness of oxygen tolerant ultrafast RAFT 
polymerization at microscale of 2 µL. By careful consideration of monomer mixing we 
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generated well-controlled MBCPs (pentablock copolymer) by iterative addition, with an 
overall scale of 10 µL without continual stirring. Currently ongoing investigation(s) are 
in progress to investigate the robustness of the protocol for complex architectures, solvent 




2-((Butylthio)-carbonothioyl) thio propanoic acid (PABTC) was synthesised according to 
the reported literature and recrystallized at least twice in hexane before use.44 N-
Acryloylmorpholine (NAM) N,N-Dimethylacrylamide (DMAm) were filtered through a 
basic aluminium oxide (activated, basic, Brockman I, standard grade) to remove the 
radical inhibitor. 2,2′-azobis[2-(2-imidazolin-2yl)propane] dihydrochloride (VA-044, 
Wako), Dioxane (Sigma-Aldrich, >99%), HEAm (Sigma-Aldrich, > 97 %) and HPCL-
grade H2O (sigma-aldrich, > 99%) were used without further purification. 
7.4.2 Instruments: 
Nuclear  Magnetic  Resonance (NMR) spectroscopy  (1H  NMR  spectra)  were  recorded  
on  a  Bruker HD  400  spectrometer  (400  MHz) at  27  °C using d6-DMSO as solvent 
and the residual proton signal of the solvent (δ H = 2.50 ppm) was used as interna l 
reference. Chemical shift values (δ) are reported in ppm. ACDLABS software was used 
to analyse the data obtained.  
Number-average molar masses (Mn,SEC) and dispersity values (Ð) were determined using 
Size exclusion Chromatography (SEC) with THF or DMF as the eluent, depending on the 
composition of the copolymer. For conventional scale synthesis (for scales greater than 
20 µL) polymer samples diluted with GPC eluent (1.5 ml) were filtered through a nylon 
membrane with 0.22 μm pore size before injection. For microscale synthesis with the 
microvolume inserts, the mixture was diluted with GPC eluent (200 µL) in the reaction 
vessels and were fitted inside a GPC sample vial. These were directly injected (80 µL) in 
to the SEC system. The THF system, Agilent 390-LC MDS instrument equipped with 
differential refractive index (DRI), viscometry (VS), dual angle light scatter (LS) and dual 
wavelength UV detectors. The system was equipped with 2 x PLgel Mixed C columns 
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(300 x 7.5 mm) and a PLgel 5 µm guard column. The eluent is THF with 2 % TEA 
(triethylamine) and 0.01 % BHT (butylated hydroxytoluene) additives. Samples were run 
at 1ml/min at 30 °C. Poly(methyl methacrylate) (PMMA) standards (Agilent EasyVia ls) 
were used for calibration between 955,000 – 550 gmol-1. The DMF system was operating 
on Agilent 390-LC MDS instrument, which was equipped with differential refractive 
index (DRI), viscometry (VS), dual angle light scatter (LS) and UV detectors. The system 
was equipped with 2 x PLgel Mixed D columns (300 x 7.5 mm) and a PLgel 5 µm guard 
column. The DMF eluent had 5 mmol NH4BF4 additive. Samples were run at 1 ml/min at 
50 °C. PMMA were used for calibration. Both instruments were equipped with an 
autosampler. Experimental molar mass (Mn,SEC) and dispersity (Đ) values of synthesized 
polymers were determined based on PMMA calibration using Agilent GPC/SEC 
software. 
 
7.4.3 Determination of monomer conversions  
Monomer conversion (ρ) were calculated from 1H NMR sprectra using the following 
equation from Gody’s protocol:12 











  (Eqn A.1) 
 
Where [M]0 is the initial monomer concentration and [M]t  is the concentrations of the 
monomer at time t. (∫ M5.5-7.00 ppm / (∫ CTACH3) is the corrected integrals for the vinylic 
protons of the monomer, DPtargeted is the degree of the polymeirsation targeted and ∫CTA-
CH3 is the integral of the 3 methyl protons belonging to the Z group of the RAFT agent 
(CH2-CH3) used as an internal reference. Note, the integral range for the vinylic protons 
is slightly wider than previously reported, this is to sufficiently cover all the vinylic 
protons.  
 
7.4.4 Calculation of theoretical number average molar mass Mn,th 











+ 𝑀𝐶𝑇𝐴   (Eq A.2) 
 
Where [M]0, [I]0and [CTA]0 are the initial concentrations of the monomer, initiator and 
chain transfer agent respectively; ρ is the monomer conversion as determined by 1H NMR 
(from Eqn 1), MM and MCTA are the molar molar masses (gmol-1) of the monomer and 
chain transfer agent respectively. The factor “2” accounts for two radicals generated from 
one molecule of azoinitiator with efficiency f (assumed to be 0.5) to react with monomers 
to initiate propagating chains. The decomposition rate constant, kd  is calculated from the 
Arrhenius equation for a given temperature (Eqn 3). Time, t is polymerisation time (in 
seconds). The term (1-fc/2) represents the number of chains produced in a radical-radica l 
termination events. The coupling factor, fc has a value between 1 (100% termination occur 
by bimolecular combination) and 0 (100% termination occurs by disproportionation). For 
simplicity in this study 100 % termination is assumed to be by disproportionation (fc = 
0). 
 




𝑅𝑇⁄    (Eq A.3) 
 
T is the temperature (in Kelvin). R is the molar gas constant (or universal gas constant) 
and has a value of 8.314 Jmol-1. EA is the activation energy, which is 10800 Jmol-1 for 
VA-044 (obtained from wako).45 The Pre-exponential factor, A is determined using Eqn 
4 shown below: 
 






 (Eqn A.4) 
 
Where kd(317K) is the decomposition rate when the initiator has a 10 hr half-life, at the 
specific temperature of the initiator. This temperature is 44 °C or 317 K for VA-044. The 
decomposition rate for a given half-life is a mathematical constant (for 10 hrs, it is 1.92 
x 10-5 s-1). In most cases, where available, the 10 hr half-life temperature and activation 
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energy of commercial thermal initiators can be obtained from the supplier (Wako).45 From 
this the pre-exponential factor of VA-044 has a value of 1.18 x 1013. 
 
7.4.6 Calculation of the theoretical number fraction of living chains (livingness, L)  









   (Eqn A.5) 
 
All side reactions with oxygen is neglected. 
 
7.4.7 General procedure for microscale polymerisation. 
Master mix with CTA, Monomer, initiator and solvent (preparation of the master mix with 
CTA described below) is added into microvolume inserts using regular air displacement 
micropipettes (P10’s for 1 - 10 µL reactions). The insert is heated for 3 mins at 100 °C in 
an oil bath. The insert is either directly diluted with GPC eluent and inserted into a GPC 
vial, directly used for SEC analysis or alternatively diluted with deuterated DMSO for 1H 
NMR analysis. Duplicate reactions are required to achieve both analysis (one for each).  
 
7.4.8 General Procedure for Conventional scale polymerisation (500 µL scale) 
Master mix with CTA, Monomer, initiator and solvent (preparation of the master mix with 
CTA described below) is added into test tube (with or without stirrer) using a regular air 
displacement micropipettes (P1000) to pipette 500 µL. The test tube is heated for 3 mins 
at 100 °C in an oil bath. Approximately 10 µL is used for GPC and NMR analysis. 
 
7.4.9 General procedure preparing the for master mix with CTA (with NAM, 3M, 
DPn = 25) 
The RAFT agent PABTC (67.5 mg, 0.28 mmol, 1 eq), is weighed into a sealable vial. 
NAM is carefully weighed directly into the same vial (1000 mg, 7.1 mmol, 25 eq). 
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Dioxane (294 µL) and water (1061 µL) is added and vortexed until the PABTC is 
completely dissolved. The solution was cooled in fridge or ice until the mixture is 
sufficiently below the room temperature before adding a stock solution of VA-044 (114.5 
µL of 20 mg/ml stock solution) and vortex. Note, the solution may appear cloudy when 
chilled but will return back to clear solution at ambient temperatures.  
In this study, a stock initiator solution is prepared and used to avoid weighing minute 
amount of initiator (2.29 mg). It is important to note that all initiator stock solution and 
master mix’s once the initiator is added to be kept on ice or stored in the fridge to avoid 
decomposition of the initiator.  
 
7.4.10 General procedure for microscale multiblock synthesis 
2 µL of the master mix with CTA (preparation of the CTA master mix described above) 
was added into the insert(s) using a regular air displacement micropipettes (P10’s). After 
3 mins of heating at 100 °C in an oil bath, the insert is cooled with liquid nitrogen until 
the insert is frozen (approximately 30 seconds). For sequential chain extension, 2 µL of a 
separate master mix with monomer (with identical Monomer concentration to previous 
block to target the same DPn), initiator and solvent (no CTA) (preparation of chain 
extension master described below) was directly added using the micropipette. For 
thorough mixing, initially the inserts are placed inside an Eppendorf tube and centrifuged 
at 1.38 x 104 rpm for 1 minute to force the newly added monomer solution to bottom of 
the insert with the previous mixture. The mixtures were then crudely stirred with 23 gauge 
needle until the solution appeared homogenous and re-centrifuged (1.38 x 104 rpm for 1 
minute). The mixture was then heated for 3 minutes 100 °C in an oil bath. This process 
was repeated for additional chain extensions. Tables S6, S7 has detailed conditions for 
specific multiblock described in the paper. For GPC and NMR analysis of each block see 
the Scheme S2 for the analysis of the multiblock copolymers at microscale. 
 
7.4.11 General procedure for conventional scale synthesis (done without a stirrer 
bar) 
For comparison study with the microscale synthesis, conventional scale synthesis was 
carried without stirrer during polymerisation. Procedure follows: 500 µL of the master 
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mix with CTA is added into insert using a regular air displacement micropipet tes 
(P1000’s). After 3 mins of heating at 100 °C in an oil bath, two aliquots of 10 µL of 
samples were taken out using P200’s separately for GPC and NMR analysis. The reaction 
mixture was allowed to be cooled in ice, until the reaction mixture was sufficiently below 
room temperature. 500 µL of separate master mix (chain extension master described 
below) was directly added using the micropipette (P1000’s). The layered mixture was 
carefully mixed thoroughly until the mixture was completely homogenous. Samples taken 
for GPC and NMR increased by additional 10 µL every 2 blocks i.e. 2 x 20 µL were taken 
3rd and 4th block and 2 x 30 µL were taken for 5th (final) block. Multiblock obtained by 
this appeared identical to the multiblock made with stirring. 
 
7.4.12 General procedure for preparing the chain extension master mix (NAM, 3M) 
NAM is carefully weighed directly into the sealable vial (1000 mg, 7.1 mmol). Water 
(1061 µL) is added and then cool the solution in fridge or ice until the mixture is 
sufficiently below the room temperature. A stock solution of VA-044 (91.7 µL of 20 
mg/ml stock solution) was added and vortexed. Note, combined with the initiator stock 
solution makes 3 M monomer concentration. The mixture can be used directly and should 
be stored in the fridge when not in use.  
 
7.4.13 General procedure for preparing the chain extension master mix (DMAm, 
3M) 
DMAm is carefully weighed directly into the sealable vial (702 mg, 7.1 mmol). Water 
(1540 µL) is added and the solution was then cooled in fridge or ice until the mixture is 
sufficiently below the room temperature. A stock solution of VA-044 (91.7 µL of 20 
mg/ml stock solution) was added and vortex. Note, combined with the initiator stock 
solution makes 3 M monomer concentration. The mixture can be used directly and should 




7.4.14 General procedure for preparing the chain extension master mix (HEAm, 
3M) 
HEAm is carefully weighed directly into the sealable vial (816 mg, 7.1 mmol). Water 
(1535 µL) is added and then cool the solution in fridge or ice until the mixture is 
sufficiently below the room temperature. A stock solution of VA-044 (91.7 µL of 20 
mg/ml stock solution) and vortex. Note, combined with the initiator stock solution makes 
3 M monomer concentration. The mixture can be used directly and should be stored in 





Table 7.4 Experimental conditions for the preparation of P(NAM)25 at range of  scales in 
H2O/dioxane at 100 °C with VA-044 as initiator (3 mins per reaction, in presence of air an without 
degassing). 
Scale 500 μL[a] 10 μL[b] 5 μL[b] 2 μL[b] 1 μL[b] 
Monomer NAM NAM NAM NAM NAM 
DPtargeted 25 25 25 25 25 
mmonomer added (mg) 211.7 4.24 2.12 0.848 0.424 
mCTA added (mg) 14.3 0.286 0.143 5.73 x 10-2 2.86 x 10-2 
mVA-044 added (mg) 0.48 9.71 x 10-3 4.86 x 10-3 1.94 x 10-3 9.71 x 10-4 
Vwater added (μL) 249 4.986 2.493 0.997 0.499 
Vdioxane added (μL) 62 1.247 0.623 0.249 0.125 
[VA-044]0 Master mix (moldm-3) [c] 3.00 x 10-3 3.00 x 10-3 3.00 x 10-3 3.00 x 10-3 3.00 x 10-3 
[NAM]0 Master mix (moldm-3) [c] 3.00 3.00 3.00 3.00 3.00 
Water/Dioxane ratio master mix 80:20 100:0 100:0 100:0 100:0 
V master mix added (μL) [d] 500 10 5 2 1 
% H2O 80 % 80 % 80 % 80 % 80 % 
Vtotal (μL) 0.500 0.010 0.005 0.002 0.001 
Overall [VA-044]0 (moldm-3) 3.00 x 10-3 3.00 x 10-3 3.00 x 10-3 3.00 x 10-3 3.00 x 10-3 
Overall [NAM]0 (moldm-3) 3 3 3 3 3 
[CTA]0/[VA-044]0 40 40 40 40 40 
L[e] (%) 98.04 98.04 98.04 98.04 98.04 
[a] Reaction carried out in a conventional X ml test tube. [b] Reaction carried out in a 200 
μL inserts [c] Overall concentration of the master mix (monomer, initiator and solvent), 
CTA added in the cycle 1 master mix. For subsequent chain extensions (cycles = 2, 3, 4 
and 5) the same master mix was used. [d] Volume of the master mix added into the 
reaction vessel using an air displacement micropipette. [e] Theoretical estimation of the 
fraction of living chains per block (e.g. extendable chains having the Z group).  
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Table 7.5 Experimental conditions for the preparation of P(NAM)100 at range of  scales in 
H2O/dioxane at 100 °C with VA-044 as initiator (3 mins per reaction, consuming 80%  of initiator; 
in presence of air and without degassing). 
Scale  500 μL[a] 2 μL[b] 
Monomer  NAM NAM 
DPtargeted  100 100 
mmonomer added (mg)  211.7 0.848 
mCTA added (mg)  35.7 1.43 x 10-2 
mVA-044 added (mg)  0.36 6.5 x 10-4 
Vwater added (μL)  280 1.122 
Vdioxane added (μL)  311 0.125 
[VA-044]0 Master mix (moldm-3) [c]  1.00 x 10-3 1.00 x 10-3 
[NAM]0 Master mix (moldm-3) [c]  3.00 3.00 
Water/Dioxane ratio master mix  90:10 90:10 
V master mix added (μL) [d]  500 2 
% H2O  90 % 90 % 
Vtotal (μL)  500 2 
Overall [VA-044]0 (moldm-3)  1.00 x 10-3 1.00 x 10-3 
Overall [NAM]0 (moldm-3)  3.00 3.00 
[CTA]0/[VA-044]0  30 30 
L[e] (%)  97.40 97.40 
[a] Reaction carried out in a conventional X ml test tube. [b] Reaction carried out in a 200 
μL inserts [c] Overall concentration of the master mix (monomer, initiator and solvent), 
CTA added in the cycle 1 master mix. For subsequent chain extensions (cycles = 2, 3, 4 
and 5) the same master mix was used. [d] Volume of the master mix added into the 
reaction vessel using an air displacement micropipette. [e] Theoretical estimation of the 





Table 7.6 Experimental conditions for the preparation of P(NAM)200 at range of  scales in 
H2O/dioxane at 100 °C with VA-044 as initiator (3 mins per reaction, consuming 80%  of initiator; 
in presence of air and without degassing). 
Scale 500 μL[a] 2 μL[b] 
Monomer NAM NAM 
DPtargeted 200 200 
mmonomer added (mg) 211.7 0.848 
mCTA added (mg) 1.79 7.2 x 10-3 
mVA-044 added (mg) 0.121 4.9 x 10-4 
Vwater added (μL) 296 1.184 
Vdioxane added (μL) 156 0.062 
[VA-044]0 Master mix (moldm-3) [c] 7.50 x 10-4 7.50 x 10-4 
[NAM]0 Master mix (moldm-3) [c] 3.00 3.00 
Water/Dioxane ratio master mix 95:05 95:05 
V master mix added (μL) [d] 500 2 
% H2O 95 % 95 % 
Vtotal (μL) 500 2 
Overall [VA-044]0 (moldm-3) 7.5 x 10-4 7.5 x 10-4 
Overall [NAM]0 (moldm-3) 3.00 3.00 
[CTA]0/[VA-044]0 20 20 
L[e] (%) 96.15 96.15 
[a] Reaction carried out in a conventional X ml test tube. [b] Reaction carried out in a 200 
μL inserts [c] Overall concentration of the master mix (monomer, initiator and solvent), 
CTA added in the cycle 1 master mix. For subsequent chain extensions (cycles = 2, 3, 4 
and 5) the same master mix was used. [d] volume of the master mix added into the reaction 
vessel using an air displacement micropipette. [e] theoretical estimation of the fraction of 





Table 7.7. Experimental conditions for the preparation of multichain extension to generate 
P[(NAM)25]5 at 25 μL scale (5 μL per block) in H2O/dioxane at 100 °C with VA-044 as initiator (3 
mins per block, consuming 80%  of initiator; per block in presence of air an without degassing). 
Cycles 1 2 3 4 5 
Monomer NAM NAM NAM NAM NAM 
DPtargeted 25 25 25 25 25 
mmonomer added (mg) 2.117 2.117 2.117 2.117 2.117 
mCTA added (mg) 0.143 - - - - 
mVA-044 added (mg) 4.85 x 10-3 3.88 x 10-3 3.88 x 10-3 3.88 x 10-3 3.88 x 10-3 
Vwater added (μL) 0.997 1.247 1.247 1.247 1.247 
Vdioxane added (μL) 0.249 - - - - 
[VA-044]0 Master mix (moldm-3) [a] 3.00 x 10-3 2.37 x 10-3 2.37 x 10-3 2.37 x 10-3 2.37 x 10-3 
[NAM]0 Master mix (moldm-3) [a] 3.00 3.00 3.00 3.00 3.00 
Water/Dioxane ratio master mix 80:20 100:0 100:0 100:0 100:0 
V master mix added (μL)  [b] 5.00 5.00 5.00 5.00 5.00 
% H2O 80 % 90 % 93 % 95 % 96 % 
Vtotal[c] (μL) 5.00 10.00 15.00 20.00 25.00 
Overall [VA-044]0 (moldm-3) [d] 3.00 x 10-3 1.50 x 10-3 1.00 x 10-3 7.5 x 10-4 6.0 x 10-4 
Overall [NAM]0 (moldm-3) 3.00 1.50 1.00 0.75 0.60 
[CTA]0/[VA-044]0 40 40 40 40 40 
L[e] (%) 98.04 98.04 98.04 98.04 98.04 
Cumulative L[f] (%) 98.04 96.11 94.23 92.38 90.56 
[a] Overall concentration of the master mix (monomer, initiator and solvent), CTA added 
in the cycle 1 master mix. For subsequent chain extensions (cycles = 2, 3, 4 and 5) the 
same master mix was used. [b] volume of the master mix added into the reaction vessel 
using an air displacement micropipette. [c] the sum of volume of the solvent added + 
volume of monomer + Vtotal previous block. [d] takes into the account the theoretical 
initiator remaining from the previous block (using the Arrhenius equation). [e] theoretical 
estimation of the fraction of living chains per block (e.g. extendable chains having the Z 





Table 7.8 Experimental conditions for the preparation of multichain extension to generate 
P[(NAM)25]5 at 10 μL scale (2 μL per block) in H2O/dioxane at 100 °C with VA-044 as initiator (3 
mins per block, consuming 80%  of initiator; per block in presence of air an without degassing). 
Cycles 1 2 3 4 5 
Monomer NAM NAM NAM NAM NAM 
DPtargeted 25 25 25 25 25 
mmonomer added (mg) 0.847 0.847 0.847 0.847 0.847 
mCTA added (mg) 5.73 x 10-2 - - - - 
mVA-044 added (mg) 1.94 x 10-3 1.55 x 10-3 1.55 x 10-3 1.55 x 10-3 1.55 x 10-3 
Vwater added (μL) 0.996 1.247 1.247 1.247 1.247 
Vdioxane added (μL) 0.249 - - - - 
[VA-044]0 Master mix (moldm-3) [a] 3.00 x 10-3 2.37 x 10-3 2.37 x 10-3 2.37 x 10-3 2.37 x 10-3 
[NAM]0 Master mix (moldm-3) [a] 3.00 3.00 3.00 3.00 3.00 
Water/Dioxane ratio master mix 80:20 100:0 100:0 100:0 100:0 
V master mix added (μL)  [b] 2.00 2.00 2.00 2.00 2.00 
% H2O 80 % 90 % 93 % 95 % 96 % 
Vtotal[c] (μL) 2.00 4.00 6.00 8.00 10.00 
Overall [VA-044]0 (moldm-3) [d] 3.00 x 10-3 1.50 x 10-3 1.00 x 10-3 7.5 x 10-4 6.0 x 10-4 
Overall [NAM]0 (moldm-3) 3.00 1.50 1.00 0.75 0.60 
[CTA]0/[VA-044]0 40 40 40 40 40 
L[e] (%) 98.04 98.04 98.04 98.04 98.04 
Cumulative L[f] (%) 98.04 96.11 94.23 92.38 90.56 
[a] Overall concentration of the master mix (monomer, initiator and solvent), CTA added 
in the cycle 1 master mix. For subsequent chain extensions (cycles = 2, 3, 4 and 5) the 
same master mix was used. [b] volume of the master mix added into the reaction vessel 
using an air displacement micropipette. [c] the sum of volume of the solvent added + 
volume of monomer + Vtotal previous block. [d] takes into the account the theoretical 
initiator remaining from the previous block (using the Arrhenius equation). [e] theoretical 
estimation of the fraction of living chains per block (e.g. extendable chains having the Z 





Table 7.9 Experimental conditions for the preparation of multichain extension to generate 
P[(NAM)25]5 at 2.5 ml scale in H2O/dioxane at 100 °C with VA-044 as initiator (3 mins per block, 
consuming 80%  of initiator; per block in presence of air an without degassing). 
Cycles 1 2 3 4 5 
Monomer NAM NAM NAM NAM NAM 
DPtargeted 25 25 25 25 25 
mmonomer added (mg) 211.7 211.7 211.7 211.7 211.7 
mCTA added (mg) 14.3 - - - - 
mVA-044 added (mg) 0.48 0.39 0.39 0.39 0.39 
Vwater added (μL) 249 311 311 311 311 
Vdioxane added (μL) 62 - - - - 
[VA-044]0 Master mix (moldm-3) [a] 3.00 x 10-3 2.37 x 10-3 2.37 x 10-3 2.37 x 10-3 2.37 x 10-3 
[NAM]0 Master mix (moldm-3) [a] 3.00 3.00 3.00 3.00 3.00 
Water/Dioxane ratio master mix 80:20 100:0 100:0 100:0 100:0 
V master mix added (μL)  [b] 500 500 500 500 500 
% H2O 80 % 90 % 93 % 95 % 96 % 
Vtotal[c] (μL) 500 1000 1500 2000 2500 
Overall [VA-044]0 (moldm-3) [d] 3.00 x 10-3 1.50 x 10-3 1.00 x 10-3 7.5 x 10-4 6.0 x 10-4 
Overall [NAM]0 (moldm-3) 3.00 1.50 1.00 0.75 0.60 
[CTA]0/[VA-044]0 40 40 40 40 40 
L[e] (%) 98.04 98.04 98.04 98.04 98.04 
Cumulative L[f] (%) 98.04 96.11 94.23 92.38 90.56 
[a] Overall concentration of the master mix (monomer, initiator and solvent), CTA added 
in the cycle 1 master mix. For subsequent chain extensions (cycles = 2, 3, 4 and 5) the 
same master mix was used. [b] volume of the master mix added into the reaction vessel 
using an air displacement micropipette. [c] the sum of volume of the solvent added + 
volume of monomer + Vtotal previous block. [d] takes into the account the theoretical 
initiator remaining from the previous block (using the Arrhenius equation). [e] theoretical 
estimation of the fraction of living chains per block (e.g. extendable chains having the Z 





Table 7.10 Experimental conditions for the preparation of the pentablock copolymer P[(NAM)25-b-
(DMAm)25-b-(NAM)25-b-(HEAm)25-b-(NAM)25] at 10 μL scale (2 μL per block)scale in H2O/dioxane 
at 100 °C with VA-044 as initiator (3 mins per block, consuming 80%  of initiator; per block in 
presence of air an without degassing). 
Cycles 1 2 3 4 5 
Monomer NAM DMAm NAM HEAm NAM 
DPtargeted 25 25 25 25 25 
mmonomer added (mg) 0.848 0.595 0.848 0.691 0.848 
mCTA added (mg) 5.72 x 10-2 - - - - 
mVA-044 added (mg) 1.94 x 10-3 1.55 x 10-3 1.55 x 10-3 1.55 x 10-3 1.55 x 10-3 
Vwater added (μL) 0.996 1.382 1.245 1.378 1.245 
Vdioxane added (μL) 0.249 - - - - 
[VA-044]0 Master mix (moldm-3) [a] 3.00 x 10-3 2.37 x 10-3 2.37 x 10-3 2.37 x 10-3 2.37 x 10-3 
[M]0 Master mix (moldm-3) [a] 3.00 3.00 3.00 3.00 3.00 
Water/Dioxane ratio master mix 80:20 100:0 100:0 100:0 100:0 
V master mix added (μL)  [b] 2.00 2.00 2.00 2.00 2.00 
% H2O 80 % 90 % 93 % 95 % 96 % 
Vtotal[c] (μL) 2.00 4.00 6.00 8.00 10.00 
Overall [VA-044]0 (moldm-3) [d] 3.00 x 10-3 1.50 x 10-3 1.00 x 10-3 7.5 x 10-4 6.0 x 10-4 
Overall [M]0 (moldm-3) 3.00 1.50 1.00 0.75 0.60 
[CTA]0/[VA-044]0 40 40 40 40 40 
L[e] (%) 98.04 98.04 98.04 98.04 98.04 
Cumulative L[f] (%) 98.04 96.11 94.23 92.38 90.56 
[a] Overall concentration of the master mix (monomer, initiator and solvent), CTA added 
in the cycle 1 master mix. For subsequent chain extensions (cycles = 2, 3, 4 and 5) the 
same master mix was used. [b] volume of the master mix added into the reaction vessel 
using an air displacement micropipette. [c] the sum of volume of the solvent added + 
volume of monomer + Vtotal previous block. [d] takes into the account the theoretical 
initiator remaining from the previous block (using the Arrhenius equation). [e] theoretical 
estimation of the fraction of living chains per block (e.g. extendable chains having the Z 





Table 7.11 Experimental conditions for the preparation of the pentablock copolymer P[(NAM)25-b-
(DMAm)25-b-(NAM)25-b-(HEAm)25-b-(NAM)25] at 2.5 ml scale (500 μL per block)scale in 
H2O/dioxane at 100 °C with VA-044 as initiator (3 mins per block, consuming 80%  of initiator; per 
block in presence of air an without degassing). 
Cycles 1 2 3 4 5 
Monomer NAM DMAm NAM HEAm NAM 
DPtargeted 25 25 25 25 25 
mmonomer added (mg) 212 149 212 173 212 
mCTA added (mg) 14.3 - - - - 
mVA-044 added (mg) 0.49 0.39 0.39 0.39 0.39 
Vwater added (μL) 249.0 345.5 311.3 344.6 311.3 
Vdioxane added (μL) 62 - - - - 
[VA-044]0 Master mix (moldm-3) [a] 3.00 x 10-3 2.37 x 10-3 2.37 x 10-3 2.37 x 10-3 2.37 x 10-3 
[M]0 Master mix (moldm-3) [a] 3.00 3.00 3.00 3.00 3.00 
Water/Dioxane ratio master mix 80:20 100:0 100:0 100:0 100:0 
V master mix added (μL)  [b] 500 500 500 500 500 
% H2O 80 % 90 % 93 % 95 % 96 % 
Vtotal[c] (μL) 2.00 4.00 6.00 8.00 10.00 
Overall [VA-044]0 (moldm-3) [d] 3.00 x 10-3 1.50 x 10-3 1.00 x 10-3 7.5 x 10-4 6.0 x 10-4 
Overall [M]0 (moldm-3) 3.00 1.50 1.00 0.75 0.60 
[CTA]0/[VA-044]0 40 40 40 40 40 
L[e] (%) 98.04 98.04 98.04 98.04 98.04 
Cumulative L[f] (%) 98.04 96.11 94.23 92.38 90.56 
[a] Overall concentration of the master mix (monomer, initiator and solvent), CTA added in the 
cycle 1 master mix. For subsequent chain extensions (cycles = 2, 3, 4 and 5) the same master mix 
was used. [b] volume of the master mix added into the reaction vessel using an air displacement 
micropipette. [c] the sum of volume of the solvent added + volume of monomer + V total previous 
block. [d] takes into the account the theoretical initiator remaining from the previous block 
(using the Arrhenius equation). [e] theoretical estimation of the fraction of living chains per 
block (e.g. extendable chains having the Z group). [f] Theoretical estimation of the cumulated 
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S2.4: DLS Correlation coefficient, intensity distribution and number distribution as a 













S2.5: DLS Correlation coefficient, intensity distribution and number distribution as a 



















S2.6: DLS Correlation coefficient as a function of temperature for P2.2 (left) and P2.3 




S2.7A: DLS Correlation coefficient, intensity distribution and number distribution as a 





S2.7B: DLS Correlation coefficient, intensity distribution and number distribution as a 






S2.8A: DLS Correlation coefficient and intensity distribution as a function of temperature 




S2.8B: DLS Correlation coefficient and intensity distribution as a function of temperature 
for P2.5 in Figure 2.8 
 
S2.9A DLS Correlation coefficient, intensity distribution and number distribution as a 
function of temperature for P2.2 in Figure 2.9. Temporal changes in the particle size of the 
cross-linked particles of (PEGA20-n-co-As Amn)-b-NIPAM80 (P2.2) after heating in 
hypophos phorous solution (10 mins, 10 mg/ml). DLS cell was heated from 25 – 60 °C over 
120 secs followed by 60 secs equilibration time before being held at 60 °C for 10 – 90 mins. 
Cooling of the cell occurred over 120 secs followed by 60 secs equilibration after which 




S2.9B DLS Correlation coefficient, intensity distribution and number distribution as a 
function of temperature for P2.3 in Figure 2.9. Temporal changes in the particle size of the 
cross-linked particles of (PEGA20-n-co -As Amn)-b -NIPAM80 (P2.3) after heating in 
hypophos phorous solution (10 mins, 10 mg/ml). DLS cell was heated from 25 – 60 °C over 
120 secs followed by 60 secs equilibration time before being held at 60 °C for 10 – 90 mins. 
Cooling of the cell occurred over 120 secs followed by 60 secs equilibration after which 

















S2.10A DLS Correlation coefficient, intensity distribution and number distribution as a 
function of temperature for P2.4 in Figure 2.10. Temporal changes in the particle size of the 
cross-linked particles of PEGA20-b-(NIPAm80-n-co-As Amn) (P2.4) after heating in 
hypophos phorous acid (10 mg/ml). DLS cell was heated from 25 – 60 °C over 120 secs 
followed by 60 secs equilibration time before being held at 60 °C for 30 mins (P2.4) 
respectively. Cooling of the cell occurred over 120 secs followed by 60 secs equilibration 
















S2.10B DLS Correlation coefficient, intensity distribution and number distribution as a 
function of temperature for P2.5 in Figure 2.10. Temporal changes in the particle size of the 
cross-linked particles of PEGA20-b-(NIPAm80-n-co-As Amn)  (P2.5) after heating in 
hypophos phorous acid (10 mg/ml). DLS cell was heated from 25 – 60 °C over 120 secs 
followed by 60 secs equilibration time before being held at 60 °C for 10 mins (P2.5) 
respectively. Cooling of the cell occurred over 120 secs followed by 60 secs equi libration 















S2.12 DLS Correlation coefficient, intensity distribution and number distribution as a 
function of temperature for P2.4 in Figure 2.12. Stability of particles derived from PEGA20-
b-(NIPAM75-co-As Am5) (P2.4) after heating at 60 °C in aqueous hypophos phorous acid for 
10 mins. DLS cell was heated from 25 – 60 °C for 120 secs followed by 60 secs equilibration 
time before being held at 60 °C for 10 mins. Cooling of the cell occurred over 120 secs 
followed by 60 secs equilibration after which measurement of stability commenced (t = 0, 25 









S2.13 DLS Correlation coefficient as a function of temperature for PEGA20-b -(NIPAm70-co -












S2.16 DLS Correlation coefficient and intensity distribution of NPAs-10 (red) and P2.5 (black) 













S2.21 DLS Correlation coefficient of NPAS-10, NPAS-15 and NPAS-20 in Figure 2.21 
 
 
S2.26A DLS Correlation coefficient and intensity distribution for NPAS-10 as a function time 




S2.26B DLS Correlation coefficient and intensity distribution for NPAS-15 as a function time 




S2.26C DLS Correlation coefficient and intensity distribution for NPAS-20 as a function time 




S2.27A DLS Correlation coefficient and intensity distribution for NPAS-10 as a function time 













S2.27B DLS Correlation coefficient and intensity distribution for NPAS-15 as a function time 




S2.27C DLS Correlation coefficient and intensity distribution for NPAS-20 as a function time 
in aqueous GSH solution (5mM) in Figure 2.27 
 
 
S2.28A DLS Correlation coefficient and intensity distribution for NPAS-10 as a function time 
in aqueous hydrogen peroxide solution (5mM) in Figure 2.28 
 
 
S2.28B DLS Correlation coefficient and intensity distribution for NPAS-15 as a function time 




S2.28C DLS Correlation coefficient and intensity distribution for NPAS-20 as a function time 
in aqueous hydrogen peroxide solution (5mM) in Figure 2.28 
 
  
S3.4: DLS Correlation coefficient and intensity distribution as a function of temperature for 
P3.1 in Figure 3.4 
 
 
S3.5: DLS Correlation coefficient and intensity distribution as a function of temperature for 




S3.7A: DLS Correlation coefficient and intensity distribution for NPAS(I) as a function time 
in aqueous GSH solution (5mM) in Figure 3.7 
 
 
S3.7B: DLS Correlation coefficient and intensity distribution for NPAS(I) as a function time 
in aqueous hydrogen peroxide solution (5mM) in Figure 3.7 
 
  
S3.9: DLS Correlation coefficient and intensity distribution of P3.2 after cross -linking with 






S3.10: DLS Correlation coefficient and intensity distribution of P3.1 (black) and NPAs-S4 
(green) in Figure 3.10 
 
 
S3.11: DLS Correlation coefficient and intensity distribution of NPAs-S4 as function of 
temperature in Figure 3.11 
 
 
S3.14: DLS Correlation coefficient and intens ity distribution for NPAs-S4 as a function time 





S3.15: DLS Correlation coefficient and intensity distribution for P3.1 (black ) and NPAs-S4/2 
(green) in Figure 3.15 
 
 
S3.17: DLS Correlation coefficient and intensity distribution of NPAs-S4/2 as function of 
temperature in Figure 3.17 
 
 
S3.19: DLS Correlation coefficient and intensity distribution for NPAs-S4/2 as a function time 





S3.20: DLS Correlation coefficient and intensity distribution for P3.1 (black ) and NPAs-S3 
(red) in Figure 3.20 
 
 
S3.23: DLS Correlation coefficient and intensity distribution for P3.1 (black ) and NPAs-S3/2 
(red) in Figure 3.23 
 
 
S3.26A: DLS Correlation coefficient and intensity distribution for NPAs-S3 as a function time 




S3.26B: DLS Correlation coefficient and intensity distribution for NPAs-S3/2 as a function 
time in aqueous GSH solution (5mM) in Figure 3.26 
 
 
S3.27: DLS Correlation coefficient and intensity distribution of P3.1 with stoichiometric 
HBT cross-linker (black ) and half the stoichiometric HBT cross -linker (red) in Figure 3.27 
 
 
S3.30: DLS Correlation coefficient and intensity distribution for NPAs-S2 as a function time 




S3.31A: DLS Correlation coefficient and intensity distribution for NPAs-S4 as a function time 
in aqueous hydrogen peroxide solution (5mM) in Figure 3.31 
 
 
S3.31B: DLS Correlation coefficient and intensity distribution for NPAs-S4/2 as a function 
time in aqueous hydrogen peroxide solution (5mM) in Figure 3.31 
 
 
S3.31C: DLS Correlation coefficient and intensity distribution for NPAs-S3as a function time 





S3.31D: DLS Correlation coefficient and intensity distribution for NPAs-S3/2 as a function 
time in aqueous hydrogen peroxide solution (5mM) in Figure 3.31 
 
 
S3.31E: DLS Correlation coefficient and intensity distribution for NPAs-S2 as a function time 
in aqueous hydrogen peroxide solution (5mM) in Figure 3.31 
 
 
S4.4A: DLS Correlation coefficient and intensity distribution for P4.1 as function of 




S4.4B: DLS Correlation coefficient and intensity distribution for P4.2 as function of 
temperature in Figure 4.4 
 
 
S4.4C: DLS Correlation coefficient and intensity distribution for P4.3 as function of 
temperature in Figure 4.4 
 
 
S4.4D: DLS Correlation coefficient and intensity distribution for P4.4 as function of 




 S4.5A: DLS Correlation coefficient and intensity distribution for NPAs(I)-4 as function of 
temperature in Figure 4.5 
 
 
S4.5B: DLS Correlation coefficient and intensity distribution for NPAs(I)-11 as function of 












S4.5C: DLS Correlation coefficient and intensity distribution for NPAs(I)-15 as function of 





S4.5D: DLS Correlation coefficient and intensity distribution for NPAs(I)-18 as function of 
temperature in Figure 4.5 
 
 
S4.8A: DLS Correlation coefficient and intensity distribution for NPPgOH-4 as function of 
temperature in Figure 4.8 
 
 
 S4.8B: DLS Correlation coefficient and intensity distribution for NPPgOH-11 as function of 




S4.8C: DLS Correlation coefficient and intensity distribution for NPPgOH-15 as function of 
temperature in Figure 4.8 
 
 
S4.8D: DLS Correlation coefficient and intensity distribution for NPPgOH-18 as function of 
temperature in Figure 4.8 
 
 
S4.10A: DLS Correlation coefficient and intensity distribution for NPPgOH-4 as function of 





S4.10B: DLS Correlation coefficient and intensity distribution for NPPgOH-11 as function of 
time in aqueous GSH (5 mM) in Figure 4.10 
 
 
S4.10C: DLS Correlation coefficient and intensity distribution for NPPgOH-15 as function of 
time in aqueous GSH (5 mM) in Figure 4.10 
 
 
S4.10D: DLS Correlation coefficient and intensity distribution for NPPgOH-18 as function of 




S4.11A: DLS Correlation coefficient and intensity distribution for NPPgOH-4 as function of 
time in aqueous hydrogen peroxide (5 mM) in Figure 4.11 
 
 
S4.11B: DLS Correlation coefficient and intensity distribution for NPPgOH-11 as function of 
time in aqueous hydrogen peroxide (5 mM) in Figure 4.11 
 
 
S4.11C: DLS Correlation coefficient and intensity distribution for NPPgOH-15 as function of 




 S4.11D: DLS Correlation coefficient and intensity distribution for NPPgOH-18 as function of 
time in aqueous hydrogen peroxide (5 mM) in Figure 4.11 
 
 
S4.12A: DLS Correlation coefficient and intensity distribution for NPPgNH-4 as function of 
temperature in Figure 4.12 
 
 
 S4.12B: DLS Correlation coefficient and intensity distribution for NPPgNH-11 as function of 




S4.12C: DLS Correlation coefficient and intensity distribution for NPPgNH-15 as function of 
temperature in Figure 4.12 
 
 
S4.12D: DLS Correlation coefficient and intensity distribution for NPPgNH-18 as function of 




S4.13A: DLS Correlation coefficient and intensity distribution for NPPAc-4 as function of 




S4.13B: DLS Correlation coefficient and intensity distribution for NPPAc-11 as function of 
temperature in Figure 4.13 
 
 
S4.13C: DLS Correlation coefficient and intensity distribution for NPPAc-15 as function of 
temperature in Figure 4.13 
 
 
S4.13D: DLS Correlation coefficient and intensity distribution for NPPAc-18 as function of 




S4.16A: DLS Correlation coefficient and intensity distribution for NPPAc-18 as function of 
time in hydrogen peroxide solution (5 mM) Figure 4.16 
 
 
S4.16B: DLS Correlation coefficient and intensity distribution for NPPAc-4 as function of 
time in hydrogen peroxide solution (5 mM) Figure 4.16 
 
 
S4.16C: DLS Correlation coefficient and intensity distribution for NPPAc-18 as function of 





S4.16D: DLS Correlation coefficient and intensity distribution for NPPAc-4 as function of 
time in GSH solution (5 mM) Figure 4.16 
 
 
S4.17A: DLS Correlation coefficient and intensity distribution for NPPg-NH-18 as function of 
time in hydrogen peroxide solution (5 mM) Figure 4.17 
 
 
S4.17B: DLS Correlation coefficient and intensity distribution for NPPg-NH-4 as function of 




S4.17C: DLS Correlation coefficient and intensity distribution for NPPg-NH-18 as function of 
time in GSH solution (5 mM) Figure 4.17 
 
 
S4.17D: DLS Correlation coefficient and intensity distribution for NPPg-NH-4 as function of 
time in GSH solution (5 mM) Figure 4.17 
 
 
S4.22A: DLS Correlation coefficient and intensity distribution for NPRh-4 as function of 




S4.22B: DLS Correlation coefficient and intensity distribution for NPRh-11 as function of 
temperature Figure 4.22 
 
 
S4.22C: DLS Correlation coefficient and intensity distribution for NPRh-15 as function of 
temperature Figure 4.22 
 
 
S4.22D: DLS Correlation coefficient and intensity distribution for NPRh-18 as function of 




S4.24A: DLS Correlation coefficient and intensity distribution for NPRh-18 as function of 




S4.24B: DLS Correlation coefficient and intensity distribution for NPRh-4 as function of time 
in aqueous hydrogen peroxide solution (5 mM) Figure 4.24 
 
  
S4.24C: DLS Correlation coefficient and intensity distribution for NPRh-18 as function of 




S4.24D: DLS Correlation coefficient and intensity distribution for NPRh-4 as function of time 
in aqueous GSH solution (5 mM) Figure 4.24 
 
  
S5.16A: HPLC chromatogram of arsanilic acid released from arsenohydrogels from P5.1 in 




S5.16B: HPLC chromatogram of arsanilic acid released from arsenohydrogels from P5.2 in 





S5.16C: HPLC chromatogram of arsanilic acid released from arsenohydrogels from P5.3 in 




S5.16D: HPLC chromatogram of arsanilic acid released from arsenohydrogels from P5.4 in 
aqueous solution (left) and under stimulated oxidative stress using stoichiometric H2O2 
(right) 
 
S5.16E: HPLC Calibration curve of arsanilic acid in hypophos phorous acid 
